U.S. patent number 11,214,540 [Application Number 16/613,697] was granted by the patent office on 2022-01-04 for compositions for treating neurodegenerative diseases.
This patent grant is currently assigned to Cognition Therapeutics, Inc.. The grantee listed for this patent is COGNITION THERAPEUTICS, INC.. Invention is credited to Susan M. Catalano, Gary C. Look, Gilbert M. Rishton.
United States Patent |
11,214,540 |
Rishton , et al. |
January 4, 2022 |
Compositions for treating neurodegenerative diseases
Abstract
The present disclosure relates to novel compounds, and
pharmaceutical compositions thereof, useful for treating for
treating neurodegenerative diseases, including Alzheimer's disease
and cognitive decline. Methods for inhibiting synapse number
decline or membrane trafficking abnormalities associated with
exposure of a neuronal cell to Abeta species are also disclosed.
Representative members of these compounds include: ##STR00001##
Inventors: |
Rishton; Gilbert M. (Los
Angeles, CA), Look; Gary C. (Santa Clara, CA), Catalano;
Susan M. (Pittsburgh, PA) |
Applicant: |
Name |
City |
State |
Country |
Type |
COGNITION THERAPEUTICS, INC. |
Pittsburgh |
PA |
US |
|
|
Assignee: |
Cognition Therapeutics, Inc.
(Pittsburgh, PA)
|
Family
ID: |
64274594 |
Appl.
No.: |
16/613,697 |
Filed: |
May 15, 2018 |
PCT
Filed: |
May 15, 2018 |
PCT No.: |
PCT/US2018/032726 |
371(c)(1),(2),(4) Date: |
November 14, 2019 |
PCT
Pub. No.: |
WO2018/213281 |
PCT
Pub. Date: |
November 22, 2018 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20200299234 A1 |
Sep 24, 2020 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
62506226 |
May 15, 2017 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D
265/30 (20130101); C07D 403/06 (20130101); A61P
25/28 (20180101); C07D 241/04 (20130101); C07D
405/02 (20130101); C07C 217/46 (20130101); C07C
309/14 (20130101); C07D 207/08 (20130101); C07D
207/12 (20130101); C07D 211/06 (20130101); C07D
295/185 (20130101); C07D 295/192 (20130101); C07D
205/04 (20130101); C07D 491/107 (20130101); C07D
407/14 (20130101); C07D 211/22 (20130101); C07D
405/04 (20130101); C07D 405/12 (20130101); C07C
211/27 (20130101); C07D 211/30 (20130101); C07D
207/16 (20130101); C07D 211/62 (20130101); C07D
241/08 (20130101); C07D 295/18 (20130101); C07D
403/14 (20130101); C07D 403/04 (20130101); C07D
211/46 (20130101); C07D 211/48 (20130101); C07D
413/04 (20130101); C07D 413/14 (20130101); C07D
207/06 (20130101); C07C 309/04 (20130101); C07D
295/06 (20130101); C07D 401/04 (20130101); C07D
295/08 (20130101) |
Current International
Class: |
C07D
491/107 (20060101); C07D 211/46 (20060101); C07D
211/22 (20060101); C07D 207/08 (20060101); C07D
205/04 (20060101); C07D 211/48 (20060101); C07D
241/04 (20060101); C07D 401/04 (20060101); C07D
403/06 (20060101); C07D 403/14 (20060101); C07D
405/04 (20060101); C07D 405/12 (20060101); C07D
413/14 (20060101); C07D 207/16 (20060101); C07D
241/08 (20060101); C07D 265/30 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
2008314922 |
|
Apr 2009 |
|
AU |
|
1018188 |
|
Sep 1977 |
|
CA |
|
1275934 |
|
Nov 1990 |
|
CA |
|
2073841 |
|
Jan 1993 |
|
CA |
|
101121670 |
|
Feb 2008 |
|
CN |
|
4000610 |
|
Jul 1991 |
|
DE |
|
10320560 |
|
Jan 2004 |
|
DE |
|
0002222 |
|
Jun 1979 |
|
EP |
|
0443606 |
|
Aug 1991 |
|
EP |
|
0613007 |
|
Aug 1994 |
|
EP |
|
0881220 |
|
Dec 1998 |
|
EP |
|
1088550 |
|
Apr 2001 |
|
EP |
|
S62283922 |
|
Dec 1987 |
|
JP |
|
H01180822 |
|
Jul 1989 |
|
JP |
|
01305085 |
|
Aug 1989 |
|
JP |
|
H01305085 |
|
Dec 1989 |
|
JP |
|
H02215789 |
|
Aug 1990 |
|
JP |
|
H045266 |
|
Jan 1992 |
|
JP |
|
H06321781 |
|
Nov 1994 |
|
JP |
|
H09157144 |
|
Jun 1997 |
|
JP |
|
2003113117 |
|
Apr 2003 |
|
JP |
|
2004002517 |
|
Jan 2004 |
|
JP |
|
1982002551 |
|
Aug 1982 |
|
WO |
|
1991009594 |
|
Jul 1991 |
|
WO |
|
199511221 |
|
Apr 1995 |
|
WO |
|
1996012697 |
|
May 1996 |
|
WO |
|
1999025363 |
|
May 1999 |
|
WO |
|
1999029673 |
|
Jun 1999 |
|
WO |
|
2001030335 |
|
May 2001 |
|
WO |
|
2001091558 |
|
Dec 2001 |
|
WO |
|
2003016274 |
|
Feb 2003 |
|
WO |
|
2003051380 |
|
Jun 2003 |
|
WO |
|
2005087212 |
|
Sep 2005 |
|
WO |
|
2006020879 |
|
Feb 2006 |
|
WO |
|
2006138349 |
|
Dec 2006 |
|
WO |
|
2007077543 |
|
Jul 2007 |
|
WO |
|
2008042755 |
|
Apr 2008 |
|
WO |
|
2009059214 |
|
May 2009 |
|
WO |
|
2010062260 |
|
Jun 2010 |
|
WO |
|
2010088450 |
|
Aug 2010 |
|
WO |
|
2010093704 |
|
Aug 2010 |
|
WO |
|
2012027548 |
|
Mar 2012 |
|
WO |
|
2015020523 |
|
Feb 2015 |
|
WO |
|
Other References
Martirosyan, et al., Armyanskii Khimicheskii Zhurnal (1971), 24(9),
798-801. cited by examiner .
International Search Report and Written Opinion dated Jun. 30, 2012
for PCTUS2011026530. cited by applicant .
International Search Report and Written Opinion dated May 31, 2012
for PCTUS2012023483. cited by applicant .
International Search Report and Written Opinion dated Sep. 21, 2018
for PCT/US2018/032726. cited by applicant .
International Search Report and Written Opinion dated Sep. 24, 2010
for PCTUS2010044136. cited by applicant .
Ishikawa et al. "The role of sigma-1 receptors in the
pathophysiology of neuropsychiatric diseases" J. Receptor Ligand
and Channel Res. 2009 retrieved from
http:researchgate.netprofileMasotomo_Ishikawapublication49606718
<http://researchgate.net/profile/Masotomo_Ishikawa/publication/4960671-
8>_the_role_of_signa-1_receptors_in_the_pathophysiology_of_
Neuropsychatric_diseases. cited by applicant .
Jacobsen et al. "GSI-953 is a Protein APP-Selective Gamma-Secretase
Inhibitor for the Treatment of Alzheimer's Disease" Oral 03-06:
Therapeutics and Therapeutic Strategies: Novel Targets 2008 1.
cited by applicant .
Jiang et al. "Metal-Organic Conjugated Microporous Polymers" Agnew.
Chem. Int. Ed. 2011 50:1072-1075. cited by applicant .
Jin et al. "Novel tricyclic pyrone compounds prevent intracellular
APP C99-induced cell death" J Mol Neurosci Aug.-Oct. 2002
191-2:57-61. cited by applicant .
Johansson et al. "Physiochemical characterization of the
Alzheimer's disease-related peptides Abeta1-42Arctic and
Abeta1-42wt" FEBS J. Jun. 2006 27312:2618-2630. cited by applicant
.
Kaech et al. "Culturing hippocampal neurons" Nat Protoc 2006
15:2406-2415. cited by applicant .
Kamal et al. "Total synthesis of R- and S-turmerone and
7S9R-bisacumol by an efficient chemoenzymatic approach"
Tetrahedron: Asymmetry 2009 20:1267-1271. cited by applicant .
Kamenetz et al. "APP processing and synaptic function" Neuron. Mar.
27, 2003 376:925-937. cited by applicant .
Kholodov et al., Clinical pharmacokinetics, Moscow, Medicine, 1985,
pp. 83-98, 134-138, 160, 378-380. cited by applicant .
Kimura "Chemical Structural Requirement in Gingerol Derivatives for
Potentiation of Prostaglandin F2 alpha-induced Contraction in
Isolated Mesenteric Veins of Mice" J. Pharmacobio-Dyn. 1989
12:220-227. cited by applicant .
Klyubin et al. "Amyloid beta Protein Dimer-Containing Human CSF
Disrupts Synaptic Plasticity: Prevention by Systemic Passive
Immunization" J Neurosci. Apr. 16, 2008 2816:4231-4237. cited by
applicant .
Koffie et al. "Oligomeric amyloid beta associates with postsynaptic
densities and correlates with excitatory synapse loss near senile
plaques" Proc Natl Acad Sci USA Mar. 10, 2009 10610:4012-4017.
cited by applicant .
Kornhuber et al. "Cerebrospinal fluid and serum concentrations of
the N-methyl-D-aspartate NMDA receptor antagonist memantine in man"
Neurosci Lett Aug. 4, 1995 1952:137-139. cited by applicant .
Kotilinek et al. "Reversible memory loss in a mouse transgenic
model of Alzheimer's disease" J Neurosci. Aug. 1, 2002
2215:6331-6335. cited by applicant .
Krafft et al. "ADDLs and the signaling web that leads to
Alzheimer's disease" Neuropharmacology 2010 59:230-242. cited by
applicant .
Lacor et al. "Abeta oligomer-induced aberrations in synapse
composition shape and density provide a molecular basis for loss
and connectivity in Alzheimer's disease" J Neurosci. Jan. 24, 2007
274:796-807. cited by applicant .
Lacor et al. "Synaptic targeting by Alzheimer's-related Amyloid
beta oligomers" J Neurosci. Nov. 10, 2004 2445:10191-10200. cited
by applicant .
Lambert et al. "Monoclonal antibodies that target pathological
assemblies of Abeta" J Neurochem Jan. 2007 1001:23-35. cited by
applicant .
Lambert et al. "Diffusible nonfibrillar ligands derived from
Abeta1-42 are potent central nervous system neurotoxins" Proc Natl
Acad Sci USA May 26, 1998 9511:6448-6453. cited by applicant .
Lannfelt et al. "Safety efficacy and biomarker findings of PBT2 in
targeting Abeta as a modifying therapy for Alzheimer's disease: a
phase Iia double-blind randomized placebo-controlled trial" Lancet
Neurol Sep. 2008 79:779-786. cited by applicant .
Lauren et al. "Cellular prion protein mediates impairment of
synaptic plasticity by Amyloid-beta oligomers" Nature Feb. 26, 2009
4577233:1128-1132. cited by applicant .
Leal P. et al. "Functional Properties of Spice Extracts Obtained
via Supercritical Fluid Extraction" J. Agri. Food Chem. 2003
519:2520-2525 Derwent Abstract. cited by applicant .
Lecanu et al. "Identification of naturally occurring spirostenols
preventing beta-amyloid-induced neurotoxicity" Steroids Jan. 2004
691:1-16. cited by applicant .
Lesne et al. "A specific amyloid-beta protein assembly in the brain
impairs memory" Nature Mar. 16, 2006 4407082:352-357. cited by
applicant .
Lesuisse et al. "Long-term culture of mouse cortical neurons as a
model for neuronal development aging and death" J. Neurobiol. 2002
51:9-23. cited by applicant .
Levine "Alzheimer's beta-peptide oligomer formation at physiologic
concentrations" Anal. Biochem. Dec. 1, 2004 3351:81-90. cited by
applicant .
Levine "Biotin-avidin interaction-based screening assay for
Alzheimer's beta-peptide oligomer inhibitors" Analytical
Biochemistry 2006 356:265-272. cited by applicant .
Li et al. "Soluble oligomers of Amyloid beta protein facilitate
hippocampal long-term depression by disrupting neuronal glutamate
uptake" Neuron. Jun. 25, 2009 626:788-801. cited by applicant .
Li et al. "Total asymmetric synthesis of 7S9R-+-bisacumol"
Tetrahedrom: Asymmetry 2003 14:75-78. cited by applicant .
Liu et al. "Amyloid ? peptide alters intracellular trafficking and
cholesterol homeostasis" Proc. Natl. Acad. Sci 1998 95:13266-3271.
cited by applicant .
Liu et al. "Cytotoxic Amyloid Peptides Inhibit Cellular
3-45-Dimethyithiazol-2yl-25-Diphenyitetrazolium Bromide MTT
Reduction by Enhancing MTT Formazan Exocytosis" J Neurochem. Dec.
1997 696:2285-2293. cited by applicant .
Liu et al. "Detecting bioactive Amyloid beta peptide species in
Alzheimer's disease" J Neurochem. Nov. 2004 91:648-656. cited by
applicant .
Liu et al. "Treating Alzheimer's Disease by Inactivating Bioactive
Amyloid beta Peptide" Curr Alzheimer Res Apr. 2006 32:129-135.
cited by applicant .
Lleo et al. "Clinical pathological and biochemical spectrum of
Alzheimer disease associated with PS-1 mutations" Am J Geriatr.
Psychiatry Mar.-Apr. 2004 122:146-156. cited by applicant .
Look et al. "Discovery of ADDL-Targeting Small Molecule Drugs for
Alzheimer's disease" Curr Alzheimer Res. Dec. 2007 45:562-567.
cited by applicant .
Maezawa et al. "A novel tricyclic pyrone compound ameliorates cell
death associated with intracellular Amyloid-beta oligomeric
complexes" J Neurochem. Jul. 2006 981:57-67. cited by applicant
.
Maier et al. "Synthesis and SAR Studies of 3-Substituted
1'-Benzylspiro[[2] benzoxepine1 4'-piperidines]" Euro. J. Org.
Chem. Feb. 2003 20034:714-720. cited by applicant .
Majno "Apoptosis oncosis and necrosis: an overview of cell death"
Am J Pathol. Jan. 1995 1461:3-15. cited by applicant .
Mann et al. "Amyloid angiopathy and variability in Amyloid beta
deposition is determined by mutation position in
presenilin-1-linked Alzheimer's disease" Am J Pathol. Jun. 2001
1586:2165-2175 cited by applicant .
Masaki et al. "A Facile Regio- and Sterio-Specific Allylic
Oxidation of Gem-dimethyl Olefins Via Addition of Benzenesulphenyl
Chloride. Synthesis of Allylic Oxygenated Terpenes" J. Chem. Soc.
Perkin. Trans. | Jul. 4, 1984 4912;1289-1295. cited by applicant
.
Masuda et al. "Antioxidant properties of gingerol related compounds
from ginger" Biofactors 2004 211-4:293-296. cited by applicant
.
Matsubara et al. Soluble Abeta homeostasis in AD and DS: impairment
of anti-amyloidogenic protection by lipoproteins' Neurobiol Aging
Aug. 2004 257:833-84.1 cited by applicant .
Matsuda et al. "Hepatoprotective Constituents from Zedoariae
Rhozoma: Absolute Stereostructures of Three New Carabrane-type
Sesquiterpenes Curcumenolactones A B and C" Bioorganic &
Medicinal Chem. 2001 9:909-916. cited by applicant .
Matsuda et al. "Medicinal foodstuffs. XXVIII. Inhibitors of nitric
oxide production and new sesquiterpenes zedoarofuran
4-epicurcumenol neocumenol gajutsulactones A and B and zedoaroiides
A and B from Sedoariae Rhizoma" Chem. Pharma. Bulletin
Pharmaceutical Society of Japan Dec. 1, 2001 4912:1558-1566. cited
by applicant .
Maurice et al. "The pharmacology of sigma-1 receptors" Pharma. and
Thera. Nov. 2009 1242:195-206. cited by applicant .
Mayer et al. "Discovery of Begacestat a Notch-1-Sparing ?-Secretase
Inhibitor for the Treatment of Alzheimer's Disease" J Med Chem Oct.
3, 2008 51:7348-7351. cited by applicant .
Chin et al. "Fyn kinase induces synaptic and cognitive impairments
in a transgenic mouse model of Alzheimer's disease" J. Neurosci.
Oct. 19, 2005 2542:9694-9703. cited by applicant .
Cirrito et al. "Endocytosis is required for synaptic
activity-dependent release of Amyloid-beta in vivo" Neuron. Apr.
10, 2008 581:42-51. cited by applicant .
Citron "Strategies for Disease Modification in Alzheimer's Disease"
Nat Rev Neurosci. Sep. 2004 59:677-685. cited by applicant .
Citron et al. "Evidence that the 42- and 40-amino acid forms of
amyloid beta protein are generated from the beta-amyloid precursor
protein by different protease activities" Proc. Nat. Acad. Sci. USA
Nov. 1996 93:13170-13175. cited by applicant .
Cleary et al. "Natural oligomers of the Amyloid-beta protein
specifically disrupt cognitive function" Nat Neurosci. Jan. 2005
81:79-84. cited by applicant .
Craig et al. "How to build a central synapse: clues from cell
culture" Trends Neurosci. Jan. 2006 291:8-20. cited by applicant
.
Crawford et al. "Methalation of limonene. Novel method for the
synthesis of bisabolane sesquiterpenes" J. Amer. Chem. Soc. Jun.
14, 1972 9412:4298-4306. cited by applicant .
Dahlgren et al. "Oligomeric and Fibrillar Species of Amyloid-beta
Peptides Differentially Affect Neuronal Viability" J Biol Chem.
Aug. 30, 2002 27735:32046-32053. cited by applicant .
Database CA Chemical Abstracts Service Columbus Ohio Alexander et
al. "Terpenoids. XVIII Facile Elaboration of +-ar-turmerone to
+-nuciferal via +-ar-curcumene" retrieved from STN Database
Accession No. 1971:541008; and Alexander et al. "Terpenoids. XVIII
Facile Elaboration of+-ar-turmerone to +-nuciferal via
+-ar-curcumene" Indian Journal of Chemistry 1971 98:776-9. cited by
applicant .
Database CA Chemical Abstracts Service Columbus Ohio Duchene et al.
"Improved Syntheses of .+-.-ar-turmerone via organotin reagents"
retrieved from STN Database Accession No. 1986:479177; and Duchene
et al. "Improved Syntheses of .+-.-ar-turmerone via organotin
reagents" Synthetic Communications 1985 1510:873-882. cited by
applicant .
Database CA Chemical Abstracts Service Columbus Ohio Marterosyan et
al. "Synthesis and reactions of .beta gamma-unsaturated
amines.X.Condensation of .beta. .gamma-unsaturated amines with
aromatichydrocarbons in the presence of aluminum chloride"
retrieved from STN Database Accession No. 1744, database accession
No. 1972:153257 (abstract) and Marterosyan et al. "Synthesis and
reactions of .beta, .gamma-unsaturated amines.X. Condensation of
.beta, .gamma-unsaturated amines with aromatichydrocarbons in the
presence of aluminum chloride" Martirosyan, et al., Armyanskii
Khimicheskii Zhurnal (1971), 24(9), 798-801. cited by applicant
.
Database CA Chemical Abstracts Service Columbus Ohio MASE, Dec. 8,
1989 "Preparation of pyridylziatholidinecarboxamide derivatives
asplatelet-activating factor (PAF) antagonists" retrieved from STN
Database Accession No. 1749 (abstract). cited by applicant .
Database CA Chemical Abstracts Service Columbus Ohio Park et al.
"Allylic Fluorination" retrieved from STN Database Accession No.
1989:8424; and Park et al. "Allylic Fluorination" Archives of
Pharmacal Research 1987 104 239-44. cited by applicant .
Davigulus et al. 2010, NIH Consensus and State of the Science
Statement, 27(4), 1-30 (abstract attached). cited by applicant
.
De Felice et al. "A Oligomers Induce Neuronal Oxidative Stress
through an N-Methyl-D-aspartate Receptor-dependent Mechanism That
is Blocked by the Alzheimer Drug Memantine" J. Biol. Chem. 2007
282:11590-11601. cited by applicant .
De Felice et al. "Targeting the neurotoxic species in Alzheimer's
disease: inhibitors of Abeta oligomerization" FASEB J. Sep. 2004
1812:1366-1372. cited by applicant .
Dedov et al. "Gingerols: a novel class of vanilloid receptor VR1
agonists" Br. J. Pharm. Nov. 2002 1376:793-798. cited by applicant
.
Denniff "Syntheses of the .+-.-[n]-Gingerois Pungent Principles of
Ginger and Related Compounds through Regioselective Aldol
Condensations: Relative Pungency Assays" J. Chem. Soc. Perkin 1
1981 82-87. cited by applicant .
Dodart et al. "Immunization reverses memory deficits without
reducing brain Abeta burden in Alzheimer's disease model" Nat
Neurosci May 2002 55:452-457. cited by applicant .
Doody et al. "Effect of dimebon on cognition activities of daily
living behavior and global function in patients with
mild-to-moderate Alzheimer's disease: a randomized double-blind
placebo-controlled study" Lancet Jul. 19, 2008 3729634:207-215.
cited by applicant .
European Search Report and Written Opinion for EP 15743281 dated
May 11, 2017. cited by applicant .
European Search Report and Written Opinion for EP 18802363 dated
Nov. 26, 2020. cited by applicant .
Extended European Search Report by the European Patent Office dated
Apr. 15, 2015 for European Patent Application No. 12824979.4. cited
by applicant .
Extended European Search Report for European Patent Application No.
19154222.4 dated Mar. 19, 2019. cited by applicant .
Fenili et al. "Properties of scyllo-inositol as a therapeutic
treatment of AD-like pathology" J Mol Med. Jun. 2007 856:603-611.
cited by applicant .
Flood et al. "FAD mutant PS-1 gene-targeted mice: Increased Abeta42
and Abeta deposition without APP overproduction" Neurobiol Aging
May-Jun. 2002 233:335-348. cited by applicant .
Fujiwara et al. "Acetylcholinesterase Inhibitory Activity of
Volatile Oil from Peltophorum dasyrachis Kurz ex Bakar Yellow Batai
and Bisabolane-Type Sesquiterpenoids" J. Agri. and Food Chem. Jan.
2010 585:2824-2829. cited by applicant .
Fukumoto et al. "Beta-Secretase Activity increases with Aging in
Human Monkey and Mouse Brain" Am. J. Path. Feb. 2004 1642:719-725.
cited by applicant .
Georganopoulou et al. "Nanoparticle-based detection in cerebral
spinal fluid of a soluble pathogenic biomarker for Alzheimer's
disease" PNAS Feb. 15, 2005 1027:2273-2276. cited by applicant
.
Golde "Alzheimer disease therapy: can the Amyloid cascade be
haltered?" J Clin Invest. Jan. 2003 1111:11-18. cited by applicant
.
Gopalan et al. "Supercritical Carbon Dioxide Extraction of Tumeric
Curcuma longa" J. Agric. Food Chem. 2000 48:2189-2192. cited by
applicant .
Greene et al. Protective Groups in Organic Synthesis 3rd Ed. Wiley
& Sons New York 1999. cited by applicant .
Griffith et al., "Elevated brain scyllo-inositol concentrations in
patients with Alzheimer's disease" NMR Biomed Dec. 2007
208:709-716. cited by applicant .
Grzanna et al. "Ginger--An herbal medicinal product with broad
anti-inflammatory actions" J. Medicinal Foods 2005 82:125-132.
cited by applicant .
Gortz et al. "Neuronal network properties of human teratocarcinoma
cell line-derived neurons" Brain Res Aug. 20, 2004 10181:18-25.
cited by applicant .
Hampel et al., Core candidate neurochemical and imaging biomarkers
of Alzheimer's disease, Alzheimers Dement (Jan. 2008), 4(1 ):38-48.
cited by applicant .
Hansson et al. "Reduced Levels of Amyloid-beta-Binding Proteins in
Cerebrospinal Fluid from Alzheimer's Disease Patients" J Alzheimers
Dis 2009 162:389-397. cited by applicant .
Hisashi et al. "Heptatoproctective Constituents from Zedoariae
Rhizoma: Absolute Stereostructures of Three New Carabrane-type
Sesquiterpenes Curcumenolactones A B and C" Bioorganic & Med.
Chem. 2001 9:909-916. cited by applicant .
Hisashi et al. "Medicinal Foodstuffs. XXVIII.1 Inhibitors of Nitric
Oxide Production and New Sesquiterpenes Zedoarofuran
4-Epicurcumenol Neocurcumenol Gajutsulactones A and B y and
Zedoarolides A and B from Zedoariae Rhizoma" Chem. Pharm. Bull.
2001 4912 13-15:1558-1566. cited by applicant .
Ho et al. "Heterogeneity in red wine polyphenolic contents
differentially influences Alzheimer's disease-type neuropathology
and cognitive deterioration" J Alzheimers Dis. 2009 161:59-72.
cited by applicant .
Hong et al. "Candidate anti-Abeta fluorine compounds selected from
analogs of Amyloid imaging agents" Neurobiol Aging. Oct. 2010
3110:1690-1699. cited by applicant .
Hong et al. "Combining the rapid MTT formazan exocytosis assay and
the MC65 protection assay led to the discovery of carbazole analogs
as small molecule inhibitors of Abeta oligomer-induced
cytotoxicity" Brain Res. Jan. 26, 2007 11301:223-234. cited by
applicant .
Hong et al. "Inhibition of Alzheimer's Amyloid toxicity with a
trycyclic pyrone molecule in vitro and in vivo" J Neurochem. Feb.
2009 1084:1097-1108 cited by applicant .
Hsieh et al. "AMPAR removal underlies Abeta-induced synaptic
depression and Dendritic spine loss" Neuron. Dec. 7, 2006
525:831-843. cited by applicant .
International Search Report and Written Opinion dated Apr. 30, 2015
for PCTUS2015013754. cited by applicant .
International Search Report and Written Opinion dated Feb. 25, 2013
for PCTUS2012052572. cited by applicant .
International Search Report and Written Opinion dated Jan. 16, 2019
for PCT/US2018/058789 . cited by applicant .
International Search Report and Written Opinion dated Jan. 18, 2013
for PCTUS2012052578. cited by applicant .
International Search Report and Written Opinion dated Jun. 10, 2010
for PCTUS2010030130. cited by applicant .
International Search Report and Written Opinion dated Jun. 3, 2008
for PCTUS200779850. cited by applicant .
Miklossy et al. "Two novel presenilin-1 mutations Y256S and Q222H
are associated with early-onset Alzheimer's disease" Neurobiol.
Aging Sep. 2003 245:655-662. cited by applicant .
Mori et al. "Synthesis of a Mixture of+-Dehydrojuvabione and its
Stereoisomer" Tetrahedron Letters 1967 48:4853-4856. cited by
applicant .
Morris "Episodic-like memory in animals: psychological criteria
neural mechanisms and the value of episodic-like tasks to
investigate animal models of neurodegenerative disease" Philos
Trans R Soc Lond B Biol Sci. Sep. 29, 2001 3561413:1453-1465. cited
by applicant .
Morris "The Organization of Behavior" Wiley New York 1949 Brain
Research Bulletin May 19 1999 505-6:437-438. cited by applicant
.
Mucke et al. "High-level neuronal expression of Abeta1-42 in
wild-type human Amyloid protein precursor transfenic mice:
synaptotoxicity without plaque formation" J Neurochem. Jun. 1, 2000
2011:4050-4058. cited by applicant .
Mukaiyama et al., "N-Alkylation of Phthalimide, Carboxamide, and
Sulfonamides By Oxidation-Reduction Condensation Using
Di-tert-butyl-1 4-benzoquinone and Alkyl Diphenyiphosphinite,"
Chemistry Letters, vol. 34, No. 2, Apr. 25, 2004, pp. 142-143.
cited by applicant .
Mustafa et al. "Drug Development Report 9: Pharmacology of Ginger
Zingiber Officinale" J. Drug. Dev. 1993 61:25-39. cited by
applicant .
Negron et al. "Study of the asymmetric induction of the 13-dipolar
cycloaddition of chiral azomXethine ylides with unactivated double
bonds" CASREACT 1992 117:26230 Accession No. 1992:426230. cited by
applicant .
Nielsen et al. "Binding and Uptake of Abeta1-42 by Primary Human
Astrocytes In Vitro" GLIA 2009 57:978-988. cited by applicant .
Nikolaev et al. "APP binds DR6 to trigger axon pruning and neuron
death via distrinct caspases" Nature Feb. 19, 2009 4577232:981-989.
cited by applicant .
Nomura et al. "Mechanism of impairment of long-term potentiation by
Amyloid beta is independent of NMDA receptors or voltage-dependent
calcium channels in hippocampal CA1 pyramidal neurons" Neurosci
Lett. Dec. 31, 2005 3911-2:1-6. cited by applicant .
Ono et al. "Effects of grape seed-derived polyphenols on Amyloid
beta-protein self-assembly and cytotoxicity" J Biol Chem. Nov. 12,
2008 28347:32176-32187. cited by applicant .
Plant et al. "The Production of Amyloid ? Peptide Is a Critical
Requirement for the Viability of Central Neurons" The Journal of
Neuroscience Jul. 2003 2313:5531-5535. cited by applicant .
Poling et al., "Oligomers of the Amyloid-beta protein disrupt
working memory: confirmation with two behavioral procedures" Behav
Brain Res. Nov. 21, 2008 1932:230-234. cited by applicant .
Price et al. "Neuron number in the entorhinal cortex and CA1 in
preclinicai Alzheimer disease" Arch Neurol. Sep. 2001
589:1395-1402. cited by applicant .
Priller et al. "Mutant presenilin 1 alters synaptic transmission in
cultured hippocampal neurons" J Biol Chem. Jan. 12, 2007
2822:1119-1127. cited by applicant .
Puzzo et al. "Amyloid-beta Peptide Inhibits Activation of the
Nitric OxidecGMPcAMP-Responsive Element-Binding Protein Pathway
during Hippocampal Synaptic Plasticity" J Neurosci Jul. 20, 2005
2529:6887-6897. cited by applicant .
Puzzo et al. Picomolar Amyloid-beta positively modulates synaptic
plasticity and memory in hippocampus J Neurosci. Dec. 31, 2008
2853:14537-14545. cited by applicant .
Rana et al. "Syntheses of tricyclic pyrones and pyridinones and
protection of Abeta-peptide induced MC65 neuronal cell death"
Bioorg Med Chem Lett Feb. 1, 2009 193:670-674. cited by applicant
.
Remington's Pharmaceutical Sciences Mack Publishing Company Easton
Pennsylvania 1985. cited by applicant .
Rishton "Nonleadlikeness and leadlikeness in biochemical screening"
Drug Discov Today Jan. 15, 2003 82:86-96. cited by applicant .
Rishton "Reactive compounds and in vitro false positives in HTS"
DDT Sep. 9, 1997 29:382-334. cited by applicant .
Rishton et al. "Computational approaches to the prediction of
blood-brain barrier permeability: a comparative analysis of central
nervous system drugs versus secretase inhibitors for Alzheimer's
disease" Curr Opin Drug Discov Devel. May 2006 93:303-313. cited by
applicant .
Rowan et al. "Mechanisms of the inhibitory effects of Amyloid
beta-protein on synaptic plasticity" Exp Gerontol. Nov.-Dec. 2004
3911-12:1661-1667. cited by applicant .
Ronicke et al. "Abeta mediated diminution of MTT reduction-an
artifact of single cell culture?" PloS One Sep. 18, 2008 39:e3236.
cited by applicant .
Sampson et al. "Metal protein attenuating compounds for the
treatment of Alzheimer's disease review" The Cochrane Collaboration
published in The Cochrane Library 2009 Issue 1. cited by applicant
.
Scheff et al. "Hippocampal synaptic loss in early Alzheimer's
disease and mild cognitive impairment" Neurobiol Aging Oct. 2006
2710:1372-1384. cited by applicant .
Scheff et al. "Synaptic alternations in CA1 mild Alzheimer's
disease and mild cognitive impairment" Neurology 2007 68:1501-1508.
cited by applicant .
Sejnowski et al. "The Book of Hebb: Minireview" Neuron Dec. 1999
24:773-776. cited by applicant .
Sergeev, et al. "Concise course in the molecular pharmacology,"
Moscow, (1975), 10-11 (In Russian-English translation not
available). cited by applicant .
Shankar et al. "Amyloid-beta protein dimmers isolated directly from
Alzheimer's brains impair synaptic plasticity and memory" Nat Med.
Aug. 2008 148:837-842. cited by applicant .
Shankar et al. "Natural oligomers of the Alzheimer Amyloid-beta
protein induce reversible synapse loss by modulating an NMDA-type
glutamate receptor-dependent signaling pathway" J Neurosci. Mar.
14, 2007 2711:2866-2875. cited by applicant .
Shin et al. "Zingerone as an Antioxidant against Peroxynitrite" J.
of Agric. & Food Chem. 2005 53:7617-7622. cited by applicant
.
Shrestha et al. Amyloid beta peptide adversely affects spine number
and motility in hippocampal neurons Mol Cell Neurosci Nov. 2006
333:274-282. cited by applicant .
Snyder et al. "Regulation of NMDA receptor trafficking by
Amyloid-beta" Nat Neurosci. Aug. 2005 88:1051-1058. cited by
applicant .
Song et al. "Memantine protects rat cortical cultured neurons
against ?-amyloid-induced toxicity by attenuating tau
phosphorylation" European J. Neuro. 2008 28:1989-2002. cited by
applicant .
Subbarayappa et al."An efficient method for the synthesis of 2,
3-dihydro-1H-isoindoles." Indian Journal of Chemistry 2009
488:545-552. cited by applicant .
Supplementary European Search Report by the European Patent Office
dated Jun. 19, 2017 for European Patent Application No. 15743281.6.
cited by applicant .
Supplementary European Search Report from European Patent Office
dated Sep. 21, 2015 for European Patent Application No. 12825341.6.
cited by applicant .
Surh et al. "Enzymic Reduction of [6]-Gingerol a Major Pungent
Principle of Ginger in the Cell-Free Preparation of Rat Liver" Life
Sci. 1994 5419:321-326. cited by applicant .
Terry "Cell death or synaptic loss in Alzheimer's disease" J
Neuropathol Exp Neurol. Dec. 2000 5912:1118-1119. cited by
applicant .
Ting et al. "Amyloid precursor protein overexpression depresses
excitatory transmission through both presynaptic and postsynaptic
mechanisms" Proc Natl Acad Sci USA Jan. 2, 2007 1041:353-358. cited
by applicant .
Tomiyama et al. "A New Amyloid beta Variant Favoring
oligomerization in Alzheimer's-type dementia" Ann Neurol Mar. 2008
633:377-387. cited by applicant .
Tong et al. "beta-amyloid Peptide at Sublethal Concentrations
Downregulates Brain-Derived Neurotrophic Factor Functions in
Cultured Cortical Neurons" J. Neurosci. Jul. 28, 2004
2430:6799-6809. cited by applicant .
Townsend et al. "Orally available compound prevents deficits in
memory caused by the Alzheimer Amyloid-beta oligomers" Ann Neurol
Dec. 2006 606:668-676. cited by applicant .
Turner et al. "Roles of amyloid precursor protein and its fragments
in regulating neural activity plasticity and memeory" Prog. in
Neurobiol. 2003 70:1-32. cited by applicant .
Uehara et al. "New Bisabolane Sesquiterpenoids from the Rhizomes of
Curuma Xanthorrhiza Zinziberaceae" Chem. and Pharma. Bulletin 1989
371:237-240. cited by applicant .
Verdile et al. "The role of beta amyloid in Alzheimer's disease:
still a cause of everything or the only one who got caught?"
Pharmacol Res Oct. 2004 504:397-409. cited by applicant .
Walsh et al. "Certain inhibitors of synthetic Amyloid beta-peptide
Abeta fibrillogenesis block oligomerization of natural Abeta and
thereby rescue long-term potentiation" J Neurosci. Mar. 9, 2005
2510:2455-2462. cited by applicant .
Walsh et al. "Naturally secreted oligomers of Amyloid beta protein
potently inhibit hippocampal long-term potentiation in vivo" Nature
Apr. 4, 2002 4166880:535-539. cited by applicant .
Wang et al. "A Versatile Catalyst for Reductive Amination by
Transfer Hydogenation" Agnew. Chem. Int. Ed. 2010 49:7548-7552.
cited by applicant .
Wang et al. "Block of Long-Term Potentiation by Naturally Secreted
and Synthetic Amyloid beta-Peptide in Hippocampal Slices is
Mediated Via Activation of the Kinases c-Jun N-Terminal Kinase
Cyolin-Dependent Kinase 5 and p38 Mitogen-Activated Protein Kinase
as well as Metabotropic Glutamate Receptor Type 5" J. Neurosci.
Mar. 31, 2004 2413:3370-3378. cited by applicant .
Wang et al. "Grape-derived polyphenolics prevent Abeta
oligomerization and attenuate cognitive deterioration in a mouse
model of Alzheimer's disease" J Neurosci. Jun. 18, 2008
2825:6388-6392. cited by applicant .
Wang et al. "Moderate consumption of Cabernet Sauvignon attenuates
Abeta neuropathology in a mouse model of Alzheimer's disease" FASEB
J. Nov. 2006 2013:2313-2320. cited by applicant .
Wang et al. "Soluble oligomers of beta Amyloid 1-42 inhibit
long-term potentiation but not long-term depression in rat dentate
gyrus" Brain Res. Jan. 11, 2002 9242:133-140. cited by applicant
.
Weiyan et al. "Research Advances on Chemistry and Pharmacology of
Zingiber officinale" Chinese J. of Ethnomedicine and
Ethnopharmacology 2008 9. cited by applicant .
West et al. "Hippocampal neurons in pre-clinical Alzheimer's
disease" Neurobiol Aging Oct. 2004 259:1205-1212. cited by
applicant .
Whitlock et al. "Learning induces long-term potentiation in the
hippocampus" Science Aug. 25, 2006 3135790:1093-1097. cited by
applicant .
Wolozin "Cholesterol and the Biology of Alzheimer's Disease" Neuron
Jan. 8, 2004 41:7-10. cited by applicant .
Yang et al. "New ELISAs with high specificity for soluble oligomers
of amyloid ?-protein detect natural A? oligomers in human brain but
not CSF" Alzheimers Dement. Mar. 2013 92:99-112. cited by applicant
.
Yao et al. "The Ginkgo biloba extract EGb 761 rescues the PC12
neuronal cells from beta-amyloid-induced cell death by inhibiting
the formation of beta-amyloid-derived diffusible neurotoxic
ligands" Brain Res. Jan. 19, 2001 8891-2:181-190. cited by
applicant .
Yu et al. "Per-6-Substituted beta-Cyclodextrin Libraries Inhibit
Formation of beta-Amyloid-Peptide Abeta-Derived Soluble Oligomers"
J Mol Neurosci Aug.-Oct. 2002 191-2:51-55. cited by applicant .
Zhang et al. "A Simple Statistical Parameter for Use in Evaluation
and Validation of High Throughput Screening Assays" J Biomol Screen
1999 42:67-73. cited by applicant .
Zhang et al. "Chiral Benzyl Centers 1-6 through Asymmetric
Catalysis. A Three-Step Synthesis of R-Alpha-Curcumene via
Asymmetric Hydrovinylation" Organic Letters American Chemical
Society Aug. 3, 2004 618:3159-3161. cited by applicant .
Zhao et al. "Amyloid beta oligomers induce impairment of neuronal
insulin receptors" FASEB J. 2008 22:246-260. cited by applicant
.
Zhao et al. "Identification of antihypertensive drugs which inhibit
Amyloid-beta protein oligomerization" J Alzheimers Dis. 2009
161:49-57. cited by applicant .
Zlokovic "New therapeutic targets in the neurovascular pathway in
Alzheimer's disease" Neurotherapeutics Jul. 2008 53:409-414. cited
by applicant .
Aboul-Enein et al. "Synthesis of certain 1 7 7-trimethylbicyclo
2.2.1 heptane derivatives with anticonfuisant hypoglycemic and
anti-inflammatory potential" 2006 CASREACT 147:10056 Accession No.
2006:599283. cited by applicant .
Adams et al. "The Leaf Essential Oils and Taxonomy of Juniperus
oxycedrus L. subsp. oxycedrus subsp. badia H. Gay Debeaux and
subsp. macrocarpa Sibth. & Sm. Ball." J. Essent. Oil Res.
Mar.Apr. 1999 11:167-172. cited by applicant .
Albright "Diverse Approaches to Alzheimer's Therapies Continue to
Show Progress at ICAD" International Conference on Alzheimer's
Disease 2008 Jul. 26-31, 2008 Chicago Illinois. cited by applicant
.
Arai et al. "Chemically conditioned extracts of ginger oil:
leadlike `alkaloidal` compounds derived from natural extracts via
reductive amination" Gen. Biochem. Biotech. and Pharma.--Poster
Wednesday Jan. 25, 2006 Laguna DoubleTree Hotel. cited by applicant
.
Balaji et al. "Toxicity Prediction of Compounds from Turmeric" Food
and Chemical Toxicology 2010 vol. 48 2951-2959. cited by applicant
.
Banerjee et al. "Chemical Modification of Turmeric Oil to More
Value Added Products" Indian Perfumer 1981 vol. 25 25-30. cited by
applicant .
Barghorn et al. "Globular amyloid beta-peptide1-42 oligomer--a
homogenous and stable neurophathological protein in Alzheimer's
disease" J. Neurochem. Nov. 2005 953:834-847. cited by applicant
.
Batra et al. "Hydrogenolysis of
3-methyl-4-phenylmethyl-52H-isoxazolone derivatives: A
reinvestigation" Indian J. Chem. Jan. 1992 31B:60-62. cited by
applicant .
Beckurts et al. Archiv der Pharmazie und Berichte der Deutschen
Phamazeutischen Gessellschaft 1927 265:15-26. cited by applicant
.
Begum et al., "Curcumin Structure-Function Bioavailability and
Efficacy in Models of Neuroinflammation and Alzheimer's Disease" J.
Pharma. Experimental Thera. Feb. 4, 2008 3261:196-208. cited by
applicant .
Belikov et al. V.G., "Pharmaceutical Chemistry," Moscow, Vyshaya
Shkola Publishing House, (1993), 43-46. cited by applicant .
Blossom et al. "Beyond mild cognitive impairmentl vascular
cognitive impairment, no dementia" Alzheimers Res Ther. 2009; 1(1):
16 pages. cited by applicant .
Bornholdt et al. "Ring Opening of Pymisyl-Protected Aziridines with
Organocuprates" Chem. A European J. 2010 16:12474-12480. cited by
applicant .
Brody et al., "Amyloid-beta Dynamics Correlate with Neurological
Status in the Injured Human Brain" Science Aug. 29, 2008
3215893:1221-1224. cited by applicant .
Bu "Apolipoprotein E and its receptors in Alzheimer's disease:
pathways pathogenesis and therapy" Nat Rev Neurosci. May 2009
105:333-344. cited by applicant .
Calabrese et al. "Rapid concurrent alternations in pre- and
postsynaptic structure induced by naturally-secreted Amyloid-beta
protein" Mol. Cell. Neurosci. Feb. 2, 2007 1-11. cited by applicant
.
Campbell Med. Hypotheses 2001 563:388-391. cited by applicant .
Casagrande et al. "Systhesis of Some Isoindolines and
1234-Tetrahydroisoquinolines and heir Evaluation as ?-Adrenergic
and Adrenergic Neuron Blocking Agents" II Farmaco Edizion
Scientifica 1972 276:445-470. cited by applicant .
Catalano et al. "The role of Amyloid-beta derived diffusible
ligands ADDLs in Alzheimer's disease" Curr Top Med Chem. 2006
66:597-608. cited by applicant .
Chang et al. "AMPA receptor downscaling at the onset of Alzheimer's
disease pathology in double knockin mice" PNAS Feb. 28, 2006
1039:3410-3415. cited by applicant .
Chang et al. "Supercritical carbon dioxide extraction of turmeric
oil from Curcuma longa Linn and purification of turmerones"
Separation and Purification Technology 2006 47:119-125. cited by
applicant .
Chemical Abstracts Registry No. 1099652-84-2. cited by applicant
.
Chemical Abstracts Registry No. 1099652-96-6. cited by applicant
.
Chemical Abstracts Registry No. 1179275-25-2. cited by applicant
.
Chemical Abstracts Registry No. 1179710-89-4. cited by applicant
.
Chemical Abstracts Registry No. 1181691-78-0. cited by applicant
.
Chemical Abstracts Registry No. 1181707-36-7. cited by applicant
.
Chemical Abstracts Registry No. 1181721-34-5. cited by applicant
.
Chemical Abstracts Registry No. 1181772-10-0. cited by applicant
.
Chemical Abstracts Registry No. 1181779-90-7. cited by applicant
.
Chemical Abstracts Registry No. 1181977-85-4. cited by applicant
.
Chemical Abstracts Registry No. 1181984-40-6. cited by applicant
.
Chemical Abstracts Registry No. 1182269-99-3. cited by applicant
.
Chemical Abstracts Registry No. 1184509-73-6. cited by applicant
.
Chemical Abstracts Registry No. 1216315-24-0. cited by applicant
.
Chemical Abstracts Registry No. 1291982-54-1. cited by applicant
.
Chemical Abstracts Registry No. 1292175-79-1. cited by applicant
.
Chemical Abstracts Registry No. 1307058-18-9. cited by applicant
.
Chemical Abstracts Registry No. 1307880-18-7. cited by applicant
.
Chemical Abstracts Registry No. 415960-77-9. cited by applicant
.
Chemical Abstracts Registry No. 415970-72-8. cited by applicant
.
Chemical Abstracts Registry No. 415971-26-5. cited by applicant
.
Chemical Abstracts Registry No. 416863-98-4. cited by applicant
.
Chemical Abstracts Registry No. 416864-44-3. cited by applicant
.
Chemical Abstracts Registry No. 416865-91-3. cited by applicant
.
Chemical Abstracts Registry No. 416866-75-6. cited by applicant
.
Chemical Abstracts Registry No. 416867-24-8. cited by applicant
.
Chemical Abstracts Registry No. 416870-18-3. cited by applicant
.
Chemical Abstracts Registry No. 416870-75-2. cited by applicant
.
Chemical Abstracts Registry No. 864420-46-2. cited by
applicant.
|
Primary Examiner: Murray; Jeffrey H
Attorney, Agent or Firm: Troutman Pepper Hamilton Sanders
LLP
Government Interests
GOVERNMENT INTEREST
This invention was made with support from the U. S. government
under a grant from the National Institute On Aging of the National
Institute of Health, grant number U01AG047059. The U. S. government
has certain rights in this invention.
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national stage filing under 35 U.S.C.
.sctn. 371 of International Application No. PCT/US2018/032726 filed
May 15, 2018 entitled "COMPOSITIONS FOR TREATING NEURODEGENERATIVE
DISEASES", which claims priority under 35 U.S.C. .sctn. 119(e) to
U.S. Provisional Application No. 62/506,226, filed May 15, 2017,
the contents of which is hereby incorporated by reference in its
entirety.
Claims
What is claimed is:
1. A compound of Formula I or pharmaceutically acceptable salt
thereof: ##STR00174## wherein: each of R.sup.a, R.sup.b, R.sup.c,
R.sup.d and R.sup.e is independently selected from the group
consisting of, H, hydroxyl, halo, alkyl, alkoxy, CF.sub.3,
SO.sub.2CH.sub.3, and morpholino; R.sup.1 is selected from the
group consisting of hydrogen, alkyl, phenyl, or
--CH.dbd.C(CH.sub.3).sub.2; and R.sup.2 is an optionally
substituted cyclic amino group; selected from the groups consisting
of: ##STR00175## ##STR00176## ##STR00177## ##STR00178##
##STR00179## ##STR00180## ##STR00181## ##STR00182## ##STR00183##
##STR00184## ##STR00185## ##STR00186## ##STR00187## ##STR00188##
##STR00189## ##STR00190## ##STR00191## ##STR00192## ##STR00193##
##STR00194## ##STR00195## ##STR00196## ##STR00197## ##STR00198##
##STR00199## ##STR00200## ##STR00201## ##STR00202## ##STR00203##
##STR00204## ##STR00205## ##STR00206## ##STR00207## ##STR00208##
##STR00209## ##STR00210## ##STR00211## ##STR00212## ##STR00213##
##STR00214## ##STR00215## ##STR00216## ##STR00217## ##STR00218##
##STR00219## ##STR00220##
2. The compound of claim 1, selected from the group consisting of
##STR00221## or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a therapeutically
effective amount of a compound of claim 1 or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable carrier
or diluent.
4. The pharmaceutical composition of claim 3 wherein the compound
is selected from the group consisting of ##STR00222## or a
pharmaceutically acceptable salt thereof.
5. A method of treating Alzheimer's disease comprising
administering to a subject in need thereof, a therapeutically
effective amount of a pharmaceutical composition according to claim
3.
6. A method for inhibiting cognitive decline in a subject
exhibiting, or at risk of exhibiting, cognitive decline, comprising
administering a therapeutically effective amount of a
pharmaceutical composition according to claim 3.
7. A method of inhibiting amyloid beta effect on a neuronal cell
comprising administering to a subject in need thereof, a
therapeutically effective amount of a pharmaceutical composition
according to claim 3.
8. A method of treating mild cognitive impairment in Alzheimer's
disease in a subject in need thereof, comprising administering to
the subject a therapeutically effective amount of a pharmaceutical
composition according to claim 3.
Description
SUMMARY
Various embodiments provide novel compounds, pharmaceutical
compositions comprising such compounds, and methods for inhibiting
or restoring synapse loss in neuronal cells, modulating a membrane
trafficking change in neuronal cells, and treating cognitive
decline and neurodegenerative diseases and disorders.
Some embodiments of the present disclosure are directed to a
compound of Formula I or pharmaceutically acceptable salt
thereof:
##STR00002## wherein:
each of R.sup.a, R.sup.b, R.sup.c, R.sup.d and R.sup.e is
independently selected from the group consisting of H, hydroxyl,
halo, alkyl, alkoxy, CF.sub.3, SO.sub.2CH.sub.3, and
morpholino;
R.sup.1 is selected from the group consisting of hydrogen, alkyl,
phenyl, or --CH.dbd.C(CH.sub.3).sub.2; and
R.sup.2 is an optionally substituted cyclic amino group.
Some embodiments of the present disclosure are directed to a
compound selected from the group consisting of
##STR00003## ##STR00004## ##STR00005## ##STR00006##
##STR00007##
Embodiments herein describe a pharmaceutical composition
comprising: a compound according to any embodiment described
herein, or a pharmaceutically acceptable salt thereof; and a
pharmaceutically acceptable carrier or diluent
Some embodiments describe a method of treating Alzheimer's disease
(AD) comprising administering to the subject a therapeutically
effective amount of a compound or a pharmaceutical composition
according to any embodiment described herein.
Some embodiments describe a method of inhibiting cognitive decline
in a subject exhibiting, or at risk of exhibiting, cognitive
decline, comprising administering a therapeutically effective
amount of a compound or a pharmaceutical composition according to
any embodiment described herein.
Some embodiments describe a method of inhibiting amyloid beta
effect on a neuronal cell comprising administering to a subject in
need thereof, a therapeutically effective amount of a
pharmaceutical composition according to any embodiment described
herein.
Some embodiments describe a method of treating mild cognitive
impairment in Alzheimer's disease in a subject in need thereof,
comprising administering to the subject a therapeutically effective
amount of a pharmaceutical composition according to any embodiment
described herein.
Some embodiments describe use of a compound according to according
to any embodiment described herein, in the manufacture of a
medicament for the treatment of Alzheimer's disease.
Some embodiments describe a compound according to any embodiment
described herein, for use in the treatment of Alzheimer's
disease.
Some embodiments describe a compound according to any embodiment
described herein, for use in medical therapy.
Some embodiments describe a pharmaceutical composition comprising a
therapeutically effective amount of a compound according to any
embodiment described herein, and pharmaceutically acceptable salt
thereof, and a pharmaceutically acceptable carrier or diluent.
DETAILED DESCRIPTION
This invention is not limited to the particular processes,
compositions, or methodologies described, as these may vary. The
terminology used in the description is for the purpose of
describing the particular versions or embodiments only, and is not
intended to limit the scope of the present invention. Unless
defined otherwise, all technical and scientific terms used herein
have the same meanings as commonly understood by one of ordinary
skill in the art. All publications mentioned herein, are
incorporated by reference in their entirety. Nothing herein is to
be construed as an admission that the invention is not entitled to
antedate such disclosure by virtue of prior invention.
Definitions
Where a range of values is provided, it is intended that each
intervening value between the upper and lower limit of that range
and any other stated or intervening value in that stated range is
encompassed within the disclosure. For example, if a range of 1
.mu.m to 8 .mu.m is stated, it is intended that 2 .mu.m, 3 .mu.m, 4
.mu.m, 5 .mu.m, 6 .mu.m, and 7 .mu.m are also explicitly
disclosed.
At various places in the present specification, substituents of
compounds of the disclosure are disclosed in groups or in ranges.
It is specifically intended that embodiments of the disclosure
include each and every individual subcombination of the members of
such groups and ranges. For example, the term "C.sub.1-6 alkyl" is
specifically intended to individually disclose, e.g. methyl
(C.sub.1 alkyl), ethyl (C.sub.2 alkyl), propyl (C.sub.3 alkyl),
butyl (C.sub.4 alkyl), pentyl (C.sub.5 alkyl), and hexyl (C.sub.6
alkyl) as well as, e.g. C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.3
alkyl, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.3 alkyl,
C.sub.2-C.sub.4 alkyl, C.sub.3-C.sub.6 alkyl, C.sub.4-C.sub.5
alkyl, and C.sub.5-C.sub.6 alkyl.
The articles "a" and "an" as used herein, mean "one or more" or "at
least one," unless otherwise indicated. That is, reference to any
element of the present invention by the indefinite article "a" or
"an" does not exclude the possibility that more than one of the
element is present.
As used herein, the term "about" means plus or minus 10% of the
numerical value of the number with which it is being used.
Therefore, about 50 mL means in the range of 45 mL-55 mL.
"Abeta species" or "A.beta." shall include compositions comprising
soluble amyloid peptide-containing components such as Abeta
monomers, Abeta oligomers, or complexes of Abeta peptide (in
monomeric, dimeric or polymeric form) with other soluble peptides
or proteins as well as other soluble Abeta assemblies, including
any processed product of amyloid precursor protein. Soluble A.beta.
oligomers are known to be neurotoxic. Even A.beta.1-42 dimers are
known to impair synaptic plasticity in mouse hippocampal slices. In
one theory known in the art, native A.beta.1-42 monomers are
considered neuroprotective, and self-association of A.beta.
monomers into soluble Abeta oligomers is required for
neurotoxicity. However, certain A.beta. mutant monomers (arctic
mutation (E22G) are reported to be associated with familial
Alzheimer's Disease.
Unless specifically indicated, the term "active ingredient" is to
be understood as referring to a compound according to any
embodiment describe herein.
"Administering," or "administration" and the like, when used in
conjunction with the compounds of the disclosure refers to
providing the compounds or pharmaceutical compositions according to
any of the embodiments described herein, to a subject in need of
treatment. Preferably the subject is a mammal, more preferably a
human. The present invention comprises administering the
pharmaceutical composition of the invention alone or in conjunction
with another therapeutic agent. When a pharmaceutical composition
of the invention is administered in conjunction with another
therapeutic agent, the pharmaceutical composition of the invention
and the other therapeutic agent. can be administered at the same
time or different times.
The term "agonist" refers to a compound, the presence of which
results in a biological activity of a receptor that is the same as
the biological activity resulting from the presence of a naturally
occurring ligand for the receptor.
The term "alkanoyl" or "alkylcarbonyl" as used herein, is meant to
refer to an alkyl group attached to a carbonyl radical. An example
of an alkanoyl is
##STR00008##
As used herein, the term "alkyl" is meant to refer to a saturated
hydrocarbon group which is straight-chained or branched. Example
alkyl groups include, but are not limited to, methyl (Me), ethyl
(Et), propyl (e.g. n-propyl and isopropyl), butyl (e.g. n-butyl,
isobutyl, t-butyl), pentyl (e.g. n-pentyl, isopentyl, neopentyl),
and the like. An alkyl group can contain from 1 to about 20, from 2
to about 20, from 1 to about 10, from 1 to about 8, from 1 to about
6, from 1 to about 4, or from 1 to about 3 carbon atoms.
"C.sub.1-C.sub.10 alkyl" or "C.sub.1-10alkyl", is intended to
include C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, C.sub.6,
C.sub.7, C.sub.8, C.sub.9, and C.sub.10 alkyl groups. Additionally,
for example, "C.sub.1-C.sub.6 alkyl" or "C.sub.1-6 alkyl" denotes
alkyl having 1 to 6 carbon atoms. The term "alkylene" refers to a
divalent alkyl linking group. An example of alkylene is methylene
(CH.sub.2).
As used herein, "alkenyl" is intended to include hydrocarbon chains
of either straight or branched configuration with one or more,
preferably one to three, carbon-carbon double bonds that may occur
in any stable point along the chain. For example, "C.sub.2-C.sub.6
alkenyl" or "C.sub.2-6 alkenyl" (or alkenylene), is intended to
include C.sub.2, C.sub.3, C.sub.4, C.sub.5, and C.sub.6 alkenyl
groups. Examples of alkenyl include, but are not limited to,
ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl,
3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl,
2-methyl-2-propenyl, and 4-methyl-3-pentenyl.
The term "alkoxy" or "alkyloxy" refers to an --O-alkyl group.
"C.sub.1-C.sub.6 alkoxy" or "C.sub.1-6 alkoxy" (or alkyloxy), is
intended to include C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5,
and C.sub.6, alkoxy groups. Examples of alkoxy groups include, but
are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and
isopropoxy), and t-butoxy.
The term "alkoxyxlkoxy" refers to an alkoxy group attached to an
alkoxy group. An example of an alkoxy group includes
--O--(CH.sub.2).sub.2--OCH.sub.3.
As used herein, "alkynyl" is intended to include hydrocarbon chains
of either straight or branched configuration having one or more,
preferably one to three, carbon-carbon triple bonds that may occur
in any stable point along the chain. For example, "C.sub.2-C.sub.6
alkynyl" is intended to include C.sub.2, C.sub.3, C.sub.4, C.sub.5,
and C.sub.6 alkynyl groups; such as ethynyl, propynyl, butynyl,
pentynyl, and hexynyl.
As used herein, an "amyloid beta effect," for example, a "nonlethal
amyloid beta effect," or "Abeta oligomer effect," refers to an
effect, particularly a nonlethal effect, on a cell that is
contacted with an Abeta species. For example, it has been found
that when a neuronal cell is contacted with a soluble Amyloid-beta
("Abeta") oligomer, the oligomers bind to a subset of synapses on a
subset of neuronal cells in vitro. This binding can be quantified
in an assay measuring Abeta oligomer binding in vitro for example.
Another documented effect of Abeta species is a reduction in
synapse number, which has been reported to be about 18% in the
human hippocampus (Scheff et al, 2007) and can be quantified (for
example, in an assay measuring synapse number). As another example,
it has been found that, when a neuronal cell is contacted with an
Amyloid-beta ("Abeta") oligomer, membrane trafficking is modulated
and alteration of membrane trafficking ensues. This abnormality can
be visualized with many assays, including but not limited to, an
MTT assay. For example, yellow tetrazolium salts are endocytosed by
cells and the salts are reduced to insoluble purple formazan by
enzymes located within vesicles in the endosomal pathway. The level
of purple formazan is a reflection of the number of actively
metabolizing cells in culture, and reduction in the amount of
formazan is taken as a measure of cell death or metabolic toxicity
in culture. When cells that are contacted with a yellow tetrazolium
salt are observed through a microscope, the purple formazan is
first visible in intracellular vesicles that fill the cell. Over
time, the vesicles are exocytosed and the formazan precipitates as
needle-shaped crystals on the outer surface of the plasma membrane
as the insoluble formazan is exposed to the aqueous media
environment. Still other effects of Abeta species include cognitive
decline, such as a decline in the ability to form new memories and
memory loss which can be measured in assays using animal models in
vivo. In some embodiments, an Abeta effect is selected from Abeta
oligomer-induced synaptic dysfunction, for example, as seen in an
in vitro assay, such as a membrane trafficking assay, or a synapse
loss assay, or Abeta oligomer mediated sigma-2 receptor activation
of caspase-3, or Abeta induced neuronal dysfunction, Abeta mediated
decrease in long term potentiation (LTP), or in cognitive decline
in a behavioral assay, or in a patient in need thereof.
In some embodiments, a test compound is said to be effective to
treat cognitive decline or a disease associated therewith when it
can inhibit an effect associated with soluble Abeta oligomer
species on a neuronal cell more than about 10%, preferably more
than 15%, and preferably more than 20% as compared to a negative
control. In some embodiments, a test agent is said to be effective
when it can inhibit a processed product of amyloid precursor
protein-mediated effect more than about 10%, preferably more than
15%, and preferably more than 20% as compared to a positive
control. Although the present specification focuses on inhibition
of nonlethal effects of Abeta species, such as abnormalities in
neuronal metabolism and synapse number reduction, these are shown
to correlate with cognitive function and are furthermore expected,
over time, to result in reduction (compared to untreated subjects)
of downstream measurable symptoms of amyloid pathology, notably
clinical symptoms such as 1) fibril or plaque accumulation measured
by amyloid imaging agents such as fluorbetapir, PittB or any other
imaging agent, 2) synapse loss or cell death as measured by glucose
hypometabolism detected with FDG-PET, 3) changes in protein
expression or metabolite amount in the brain or body detectable by
imaging or protein/metabolite detection in cerebrospinal fluid,
brain biopsies or plasma obtained from patients by ELISA, (such as
changes in levels and or ratios of Abeta 42, phosphorylated tau,
total tau measured by ELISA, or patterns of protein expression
changes detectable in an ELISA panel), 4) cerebral vascular
abnormalities as measured by the presence of vascular edema or
microhemorrhage detectable by MRI and any other symptoms detectable
by imaging techniques, and 5) cognitive loss as measured by any
administered cognitive test such as ADAS-Cog, MMSE, CBIC or any
other cognitive testing instrument.
The term "animal" as used herein, includes, but is not limited to,
humans and non-human vertebrates such as wild, experimental,
domestic and farm animals and pets.
The term "antagonist" refers to an entity, e.g. a compound,
antibody or fragment, the presence of which results in a decrease
in the magnitude of a biological activity of a receptor. In certain
embodiments, the presence of an antagonist results in complete
inhibition of a biological activity of a receptor. As used herein,
the term "sigma-2 receptor antagonist" is used to describe a
compound that acts as a "functional antagonist" at the sigma-2
receptor in that it blocks Abeta effects, for example, Abeta
oligomer-induced synaptic dysfunction, for example, as seen in an
in vitro assay, such as a membrane trafficking assay, or a synapse
loss assay, or Abeta oligomer mediated sigma-2 receptor activation
of caspase-3, or in a behavioral assay, or in a patient in need
thereof. The functional antagonist may act directly by inhibiting
binding of, for example, an Abeta oligomer to a sigma-2 receptor,
or indirectly, by interfering with downstream signaling resultant
from Abeta oligomer binding the sigma-2 receptor.
As used herein, "aryl" refers to monocyclic or polycyclic (e.g.
having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for
example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl,
indenyl, and the like. In some embodiments, aryl groups have from 6
to about 20 carbon atoms. In some embodiments, aryl groups have
from 5 to about 10 carbon atoms.
As used herein, "arylalkyl" refers to an aryl group attached to an
alkyl radical. In preferred embodiments the alkyl is a C.sub.1-6
alkyl.
The term "aroyl" or "arylcarbonyl" as used herein, refers to an
aryl group attached to a carbonyl radical. Examples of aroyl
include but are not limited to benzoyl.
As used herein the term "brain penetrability" refers to the ability
of a drug, antibody or fragment, to cross the blood-brain barrier.
In some embodiments, an animal pharmacokinetic (pK) study, for
example, a mouse pharmacokinetic/blood-brain barrier study can be
used to determine or predict brain penetrability. In some
embodiments various concentrations of a compound or pharmaceutical
composition according to any embodiment described herein, can be
administered, for example at 3, 10 and 30 mg/kg, for example p.o.
for 5 days and various pK properties are measured, e.g., in an
animal model. In some embodiments, dose related plasma and brain
levels are determined. In some embodiments, brain Cmax>100, 300,
600, 1000, 1300, 1600, or 1900 ng/mL. In some embodiments good
brain penetrability is defined as a brain/plasma ratio of >0.1,
>0.3, >0.5, >0.7, >0.8, >0.9, preferably >1, and
more preferably >2, >5, or >10. In other embodiments, good
brain penetrability is defined as greater than about 0.1%, 1%, 5%,
greater than about 10%, and preferably greater than about 15% of an
administered dose crossing the BBB after a predetermined period of
time. In certain embodiments, the dose is administered orally
(p.o.). In other embodiments, the dose is administered
intravenously (i.v.), prior to measuring pK properties.
Pharmacokinetic assays and brain penetrability are described in
Example 7.
As used herein, "cognitive decline" can be any negative change in
an animal's cognitive function. For example cognitive decline,
includes but is not limited to, memory loss (e.g. behavioral memory
loss), failure to acquire new memories, confusion, impaired
judgment, personality changes, disorientation, or any combination
thereof. A compound that is effective to treat cognitive decline
can be thus effective by restoring long term neuronal potentiation
(LTP) or long term neuronal depression (LTD) or a balance of
synaptic plasticity measured electrophysiologically; inhibiting,
treating, and/or abatement of neurodegeneration; inhibiting,
treating, and/or abatement of general amyloidosis; inhibiting,
treating, abatement of one or more of amyloid production, amyloid
assembly, amyloid aggregation, and amyloid oligomer binding;
inhibiting, treating, and/or abatement of a nonlethal effect of one
or more of Abeta species on a neuron cell (such as synapse loss or
dysfunction and abnormal membrane trafficking); and any combination
thereof. Additionally, that compound can also be effective in
treating Abeta related neurodegenerative diseases and disorders
including, but not limited to dementia, including but not limited
to Alzheimer's Disease (AD) including mild Alzheimer's disease,
Down's syndrome, vascular dementia (cerebral amyloid angiopathy and
stroke), dementia with Lewy bodies, HIV dementia, Mild Cognitive
Impairment (MCI); Age-Associated Memory Impairment (AAMI);
Age-Related Cognitive Decline (ARCD), preclinical Alzheimer's
Disease (PCAD); and Cognitive Impairment No Dementia (CIND).
As used herein, the term "contacting" refers to the bringing
together or combining of molecules (or of a molecule with a higher
order structure such as a cell or cell membrane) such that they are
within a distance that allows for intermolecular interactions such
as the non-covalent interaction between two peptides or one protein
and another protein or other molecule, such as a small molecule. In
some embodiments, contacting occurs in a solution in which the
combined or contacted molecules are mixed in a common solvent and
are allowed to freely associate. In some embodiments, the
contacting can occur at or otherwise within a cell or in a
cell-free environment. In some embodiments, the cell-free
environment is the lysate produced from a cell. In some
embodiments, a cell lysate may be a whole-cell lysate, nuclear
lysate, cytoplasm lysate, and combinations thereof. In some
embodiments, the cell-free lysate is lysate obtained from a nuclear
extraction and isolation wherein the nuclei of a cell population
are removed from the cells and then lysed. In some embodiments, the
nuclei are not lysed, but are still considered to be a cell-free
environment. The molecules can be brought together by mixing such
as vortexing, shaking, and the like.
The term "cyclic amino" or "cyclic amino group" as used herein, is
a heterocycloalkyl or heteroaryl group containing a nitrogen
radical, thus allowing bonding through the nitrogen atom. The group
can be represented by the formula:
##STR00009## wherein
##STR00010## is any heterocyclic or heteroaromatic ring containing
0-3 additional heteroatoms selected from nitrogen, sulfur and
oxygen.
The term "cycloalkanoyl" or "cycloalkylcarbonyl" as used herein, is
meant to describe a cycloalkyl group attached to a carbonyl
radical. Examples of cycloalkanoyl include but are not limited
to,
##STR00011##
As used herein, "cycloalkyl" refers to non-aromatic cyclic
hydrocarbons including cyclized alkyl, alkenyl, and alkynyl groups
that contain up to 20 ring-forming carbon atoms. Cycloalkyl groups
can include mono- or polycyclic (e.g. having 2, 3 or 4 fused rings)
ring systems as well as spiro ring systems. A cycloalkyl group can
contain from 3 to about 15, from 3 to about 10, from 3 to about 8,
from 3 to about 6, from 4 to about 6, from 3 to about 5, or from 5
to about 6 ring-forming carbon atoms. Ring-forming carbon atoms of
a cycloalkyl group can be optionally substituted by oxo or sulfido.
Example of cycloalkyl groups include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl,
norbornyl, norpinyl, norcarnyl, adamantyl, and the like. Also
included in the definition of cycloalkyl are moieties that have one
or more aromatic rings fused (i.e. having a bond in common with) to
the cycloalkyl ring, for example, benzo or thienyl derivatives of
cyclopentane, cyclopentene, cyclohexane, and the like (e.g.
2,3-dihydro-1H-indene-1-yl, or 1H-inden-2(3H)-one-1-yl).
Preferably, "cycloalkyl" refers to cyclized alkyl groups that
contain up to 20 ring-forming carbon atoms. Examples of cycloalkyl
preferably include cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, adamantyl, and the like
The term "cycloalkylalkyl" refers to a cycloalkyl group attached to
an alkyl radical. In preferred embodiments the alkyl is a C.sub.1-6
alkyl.
The term "drug-like properties" is used herein, to describe the
pharmacokinetic and stability characteristics of a compound upon
administration; including brain penetrability, metabolic stability
and/or plasma stability.
As used herein, the term "effective amount" refers to an amount
that results in measurable inhibition of at least one symptom or
parameter of a specific disorder or pathological process. For
example, an amount of a disclosure compound according to any
embodiment described herein, that provides a measurably lower
synapse reduction in the presence of Abeta oligomer qualifies as an
effective amount because it reduces a pathological process even if
no clinical symptoms of amyloid pathology are altered, at least
immediately.
As used herein, "halo" or "halogen" includes fluorine, chlorine,
bromine, and iodine.
As used herein, "haloalkoxy" represents a haloalkyl group as
defined herein, with the indicated number of carbon atoms, attached
through an oxygen bridge. For example, "C.sub.1-C.sub.6 haloalkoxy"
or "C.sub.1-6 haloalkoxy", is intended to include C.sub.1, C.sub.2,
C.sub.3, C.sub.4, C.sub.5, and C.sub.6 haloalkoxy groups. An
example haloalkoxy group is OCF.sub.3. As used herein,
"trihalomethoxy" refers to a methoxy group having three halogen
substituents. Examples of trihalomethoxy groups include, but are
not limited to, --OCF.sub.3, --OCClF.sub.2, --OCCl.sub.3, and the
like.
As used herein, "haloalkyl" is intended to include both branched
and straight-chain saturated aliphatic hydrocarbon groups having
the specified number of carbon atoms, substituted with one or more
halogens. Example haloalkyl groups include, but are not limited to,
CF.sub.3, C.sub.2F.sub.5, CHF.sub.2, CCl.sub.3, CHCl.sub.2,
C.sub.2Cl.sub.5, CH.sub.2CF.sub.3, and the like.
As used herein, "heteroaryl" groups refer to an aromatic
heterocycle having up to 20 ring-forming atoms and having at least
one heteroatom ring member (ring-forming atom) such as sulfur,
oxygen, or nitrogen. In some embodiments, the heteroaryl group has
at least one or more heteroatom ring-forming atoms each
independently selected from sulfur, oxygen, and nitrogen.
Heteroaryl groups include monocyclic and polycyclic (e.g. having 2,
3 or 4 fused rings) systems. Examples of heteroaryl groups include
without limitation, pyridyl (a.k.a. pyridinyl), pyrimidinyl,
pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl,
thienyl, imidazolyl, thiazolyl, indolyl, pyrryl (a.k.a. pyrrolyl),
oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl,
pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl,
isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl,
indolinyl, and the like. In some embodiments, the heteroaryl group
has from 1 to about 20 carbon atoms, and in further embodiments
from about 1 to about 5, from about 1 to about 4, from about 1 to
about 3, from about 1 to about 2, carbon atoms as ring-forming
atoms. In some embodiments, the heteroaryl group contains 3 to
about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some
embodiments, the heteroaryl group has 1 to about 4, 1 to about 3,
or 1 to 2 heteroatoms.
The term "heterocycloalkoxy" as used herein, refers to an
--O-heterocycloalkyl group. An example of a heterocycloalkoxy group
is
##STR00012##
As used herein, "heterocycloalkyl" or "heterocyclyl" refers to a
non-aromatic heterocyclyl group having up to 20 ring-forming atoms
including cyclized alkyl, alkenyl, and alkynyl groups where one or
more of the ring-forming carbon atoms is replaced by a heteroatom
such as an O, N, or S atom. Heterocycloalkyl groups can be mono or
polycyclic (e.g. both fused and spiro systems). For example,
"heterocycloalkyl" groups include morpholino, thiomorpholino,
piperazinyl, tetrahydrofuranyl, tetrahydrothienyl,
2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo-1,4-dioxane,
piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl,
pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl,
pyrrolidin-2-one-3-yl, and the like. Ring-forming carbon atoms and
heteroatoms of a heterocycloalkyl group can be optionally
substituted by oxo or sulfido. For example, a ring-forming S atom
can be substituted by 1 or 2 oxo (i.e. form a S(O) or S(O).sub.2).
For example, a ring-forming C atom can be substituted by oxo (i.e.
form carbonyl). Also included in the definition of heterocycloalkyl
are moieties that have one or more aromatic rings fused (i.e.
having a bond in common with) to the nonaromatic heterocyclic ring,
for example pyridinyl, thiophenyl, phthalimidyl, naphthalimidyl,
and benzo derivatives of heterocycles such as indoline,
isoindoline, isoindolin-1-one-3-yl,
4,5,6,7-tetrahydrothieno[2,3-c]pyridine-5-yl,
5,6-dihydrothieno[2,3-c]pyridin-7(4H)-one-5-yl, and
3,4-dihydroisoquinolin-1(2H)-one-3yl groups. Ring-forming carbon
atoms and heteroatoms of the heterocycloalkyl group can be
optionally substituted by oxo or sulfido. In some embodiments, the
heterocycloalkyl group has from 2 to about 20 carbon atoms or 3 to
20 carbon atoms. In some embodiments, the heterocycloalkyl group
contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms.
In some embodiments, the heterocycloalkyl group has 1 to 4
heteroatoms. In some embodiments, the heterocycloalkyl group
contains 0 to 3 double bonds. In some embodiments, the
heterocycloalkyl group contains 0 to 2 triple bonds.
In the present application, the term "high affinity" is intended to
mean a compound which exhibits a K.sub.i value of less than 600 nM,
500 nM, 400 nM, 300 nM, 200 nM, less than 150 nM, less than 100 nM,
less than 80 nM, less than 60 nM, or preferably less than 50 nM in
a sigma receptor binding assay, for example against [3H]-DTG, as
disclosed by Weber et al., Proc. Natl. Acad. Sci (USA) 83:
8784-8788 (1986), incorporated herein by reference, which measures
the binding affinity of compounds toward both the sigma-1 and
sigma-2 receptor sites. Especially preferred compounds exhibit
K.sub.i values of less than about 150 nM, preferably less than 100
nM, less than about 60 nM, less than about 10 nM, or less than
about 1 nM against [3H]-DTG.
The terms "hydroxyl" and "hydroxy" are used interchangeably to mean
an OH group.
The term "improves" is used to convey that the disclosure changes
either the characteristics and/or the physical attributes of the
tissue to which it is being provided, applied or administered. The
term "improves" may also be used in conjunction with a disease
state such that when a disease state is "improved" the symptoms or
physical characteristics associated with the disease state. are
diminished, reduced, eliminated, delayed or averted.
The term "inhibiting" includes the blockade, aversion of a certain
result or process, or the restoration of the converse result or
process. In terms of prophylaxis or treatment by administration of
a compound of the disclosure, "inhibiting" includes protecting
against (partially or wholly) or delaying the onset of symptoms,
alleviating symptoms, or protecting against, diminishing or
eliminating a disease, condition or disorder.
The term "inhibiting trafficking deficits" refers to the ability to
block soluble A.beta. oligomer-induced membrane trafficking
deficits in a cell, preferably a neuronal cell. A compound capable
of inhibiting trafficking deficits has an EC.sub.50<20 .mu.M,
less than 15 .mu.M, less than 10 .mu.M, less than 5 .mu.M, and
preferably less than 1 .mu.M in the membrane trafficking assay, and
further is capable of at least 50%, preferably at least 60%, and
more preferably at least 70% maximum inhibition of the Abeta
oligomer effects of soluble Abeta oligomer-induced membrane
trafficking deficits, for example, as described in Example 6.
The term "log P" refers to the partition coefficient of a compound.
The partition coefficient is the ratio of concentrations of
un-ionized compound in each of two solution phases, for example,
octanol and water. To measure the partition coefficient of
ionizable solute compounds, the pH of the aqueous phase is adjusted
such that the predominant form of the compound is un-ionized. The
logarithm of the ratio of concentrations of the un-ionized solute
compound in the solvents is called log P. The log P is a measure of
lipophilicity. For example, log
P.sub.oct/wat=log([solute].sub.octanol/[solute].sub.un-ionized,water).
As used herein the term "metabolic stability" refers to the ability
of a compound to survive first-pass metabolism (intestinal and
hepatic degradation or conjugation of a drug administered orally).
This can be assessed, for example, in vitro by exposure of the
compounds to mouse or human hepatic microsomes. In some
embodiments, good metabolic stability refers to a t.sub.1/2>5
min, >10 min, >15 minutes, >20 minutes, and preferably
>30 min upon exposure of a compound to mouse or human hepatic
microsomes. In some embodiments, good metabolic stability refers to
an Intrinsic Clearance Rate (Cl.sub.int) of <300 uL/min/mg,
preferably .ltoreq.200 uL/min/mg, and more preferably .ltoreq.100
uL/min/mg.
The term "n-membered" where n is an integer typically describes the
number of ring-forming atoms in a moiety where the number of
ring-forming atoms is n. For example, pyridine is an example of a
6-membered heteroaryl ring and thiophene is an example of a
5-membered heteroaryl group.
As used herein, the term "natural ligand" refers to a ligand
present in a subject that can bind to a protein, receptor, membrane
lipid or other binding partner in vivo or that is replicated in
vitro. The natural ligand can be synthetic in origin, but must also
be present naturally and without human intervention in the subject.
For example, Abeta oligomers are known to exist in human subjects.
Therefore the Abeta oligomers found in a subject would be
considered natural ligands. The binding of Abeta oligomers to a
binding partner can be replicated in vitro using recombinant or
synthetic techniques, but the Abeta oligomer would still be
considered a natural ligand regardless of how the Abeta oligomer is
prepared or manufactured. A synthetic small molecule that can also
bind to the same binding partner is not a natural ligand if it does
not exist in a subject. For example, compounds which are described
herein, are not normally present in a subject, and, therefore,
would not be considered natural ligands.
As used herein, the term "a neuronal cell" can be used to refer to
a single cell or to a population of cells. In some embodiments, the
neuronal cell is a primary neuronal cell. In some embodiments, the
neuronal cell is an immortalized or transformed neuronal cell or a
stem cell. A primary neuronal cell is a neuronal cell that cannot
differentiate into other types of neuronal cells, such as glia
cells. A stem cell is one that can differentiate into neurons and
other types of neuronal cells such as glia. In some embodiments,
assays utilize a composition comprising at least one neuronal cell
is free of glia cells. In some embodiments, the composition
comprises less than about 30%, 25%, 20%, 15%, 10%, 5%, or 1% of
glia cells, which are known to internalize and accumulate Abeta.
The primary neuronal cell can be derived from any area of the brain
of an animal. In some embodiments, the neuronal cell is a
hippocampal or cortical cell. The presence of glia cells can be
determined by any method. In some embodiments, glia cells are
detected by the presence of GFAP and neurons can be detected by
staining positively with antibodies directed against MAP2.
As used herein, the term "optionally substituted" means that
substitution is optional and therefore includes both unsubstituted
and substituted atoms and moieties. A "substituted" atom or moiety
indicates that any hydrogen on the designated atom or moiety can be
replaced with a selection from the indicated substituent group,
provided that the normal valence of the designated atom or moiety
is not exceeded, and that the substitution results in a stable
compound. For example, if a methyl group (i.e. CH.sub.3) is
optionally substituted, then up to 3 hydrogen atoms on the carbon
atom can be replaced with substituent groups. Substituent groups
include, but are not limited to, alkanoyl, alkoxy, alkoxyalkyl,
(alkoxy)alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy, aryloyl,
cycloalkanoyl, substituted or unsubstituted C.sub.3-C.sub.10
cycloalkyl, --OC(O)NCH(CH.sub.3).sub.2,
(N,N-dimethylamino)pyridinyl, (N,N-dimethylamino)sulfonyl, halo,
heterocyclyl, (heterocyclyl)alkoxyalkyl, heterocycloalkyl,
hydroxyl, hydroxyalkyl, methylpiperidinyl, methylsulfonyl,
methylsulfonylphenyl, morpholinylpyridinyl, optionally substituted
C.sub.1-C.sub.10 alkyl, optionally substituted C.sub.5-C.sub.10
aryl, optionally substituted C.sub.3-C.sub.10 heteroaryl,
perfluoroalkyl, phenyl, piperidinyl, pyrrolidinylpyridinyl,
tetrahydropyranyl, CF.sub.3. A substituted alkyl group for example
indicates that one or more hydrogen atoms on the alkyl group is
replaced with a substituent group, selected from but not limited
to, halo, hydroxyl, alkoxy, heterocycloalkoxy, alkoxyalkoxy,
C(O)OMe, and C(O)OEt. A substituted aryl group for example,
indicates that one or more hydrogen atoms on the aryl group is
replaced with a substituent group, selected from but not limited
to, --SO.sub.2Me or phenyl group. A substituted heteroaryl group
for example, indicates that one or more hydrogen atoms on the
heteroaryl group is replaced with a substituent group, selected
from, but not limited to, heterocycloalkyl, heteroaryl,
N,N-dimethylamino. A substituted heterocycloalkyl group for
example, indicates that one or more hydrogen atoms on the
heterocycloalkyl group is replaced with a substituent group,
selected from, but not limited to, heterocyclalkyl, heteroaryl,
N,N-dimethylamino, hydroxyl, alkoxy, alkoxycarbonyl, alkyl, aryl,
sulfonyl, dimethylaminosulfonyl, aroyl, cycloalkanoyl, alkanoyl and
--OC(O)NCH(CH.sub.3).sub.2. In some instances two hydrogen atoms on
the same carbon of, for example, a heterocyclyl or alkyl group are
replaced with a group to form a spiro compound selected from but
not limited to, for example,
##STR00013##
The term "partial agonist" refers to a compound the presence of
which results in a biological activity of a receptor that is of the
same type as that resulting from the presence of a naturally
occurring ligand for the receptor, but of a lower magnitude.
The phrase "pharmaceutically acceptable" refers to molecular
entities and compositions that are generally regarded as safe and
nontoxic. In particular, pharmaceutically acceptable carriers,
diluents or other excipients used in the pharmaceutical
compositions of this disclosure are physiologically tolerable,
compatible with other ingredients, and do not typically produce an
allergic or similar untoward reaction (for example, gastric upset,
dizziness and the like) when administered to a patient. Preferably,
as used herein, the term "pharmaceutically acceptable" means
approved by a regulatory agency of the Federal or a state
government or listed in the U.S. Pharmacopoeia or other generally
recognized pharmacopoeia for use in animals, and more particularly
in humans.
The phrase "pharmaceutically acceptable salt(s)", as used herein,
includes those salts of compounds of the disclosure that are safe
and effective for use in mammals and that possess the desired
biological activity. Pharmaceutically acceptable salts include
salts of acidic or basic groups present in compounds of the
disclosure or in compounds identified pursuant to the methods of
the disclosure. Pharmaceutically acceptable acid addition salts
include, but are not limited to, hydrochloride, hydrobromide,
hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid
phosphate, isonicotinate, acetate, lactate, salicylate, citrate,
tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate,
gentisinate, fumarate, gluconate, glucaronate, saccharate, formate,
benzoate, glutamate, methanesulfonate, ethanesulfonate,
benzensulfonate, p-toluenesulfonate and pamoate (i.e.,
1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Certain
compounds of the disclosure can form pharmaceutically acceptable
salts with various amino acids. Suitable base salts include, but
are not limited to, aluminum, calcium, lithium, magnesium,
potassium, sodium, zinc, iron and diethanolamine salts.
Pharmaceutically acceptable base addition salts are also formed
with amines, such as organic amines. Examples of suitable amines
are N,N'-dibenzylethylenediamine, chloroprocaine, choline,
diethanolamine, dicyclohexylamine, ethylenediamine,
N-methylglucamine, and procaine.
As used herein, the term "pharmaceutically acceptable carrier"
includes any of the standard pharmaceutical carriers, such as a
phosphate buffered saline solution, water, emulsions such as an
oil/water or water/oil emulsion, and various types of wetting
agents. The term also encompasses any of the agents approved by a
regulatory agency of the US Federal government or listed in the US
Pharmacopeia for use in animals, including humans.
The term "selectivity" or "selective" refers to a difference in the
binding affinity of a compound (K.sub.i) for a sigma receptor, for
example, a sigma-2 receptor, compared to a non-sigma receptor. The
compound possess high selectivity for a sigma receptor in synaptic
neurons. The K.sub.i for a sigma-2 receptor or both a sigma-2 and a
sigma-1 receptor is compared to the K.sub.i for a non-sigma
receptor. In some embodiments, the compound is a selective sigma-2
receptor antagonist, or sigma-1 receptor ligand, and has at least
10-fold, 20-fold, 30-fold, 50-fold, 70-fold, 100-fold, or 500-fold
higher affinity, or more, for binding to a sigma receptor compared
to a non-sigma receptor as assessed by a comparison of binding
dissociation constant K.sub.i values, or IC.sub.50 values, or
binding constant, at different receptors. Any known assay protocol
can be used to assess the K.sub.i or IC.sub.50 values at different
receptors, for example, by monitoring the competitive displacement
from receptors of a radiolabeled compound with a known dissociation
constant, for example, by the method of Cheng and Prusoff (1973)
(Biochem. Pharmacol. 22, 3099-3108), or specifically as provided
herein.
As used herein the term "plasma stability" refers to the
degradation of compounds in plasma, for example, by enzymes such as
hydrolases and esterases. Any of a variety of in vitro assays can
be employed. Test compounds are incubated in plasma over various
time periods. The percent parent compound (analyte) remaining at
each time point reflects plasma stability. Poor stability
characteristics can tend to have low bioavailability. Good plasma
stability can be defined as greater than 50% analyte remaining
after 30 min, greater than 50% analyte remaining after 45 minutes,
and preferably greater than 50% analyte remaining after 60
minutes.
"Sigma-2 ligand" refers to a compound that binds to a sigma-2
receptor and includes agonists, antagonists, partial agonists,
inverse agonists and simply competitors for other ligands of this
receptor or protein.
The term "sigma-2 receptor antagonist compound" refers to a
compound that binds to a sigma-2 receptor in a measurable amount
and acts as a functional antagonist with respect to Abeta effects
oligomer induced synaptic dysfunction resultant from sigma-2
receptor binding.
The terms "subject," "individual" or "patient" are used
interchangeably and as used herein, are intended to include human
and non-human animals. Non-human animals includes all vertebrates,
e.g. mammals and non-mammals, such as non-human primates, sheep,
dogs, cats, cows, horses, chickens, amphibians, and reptiles,
although mammals are preferred, such as non-human primates, sheep,
dogs, cats, cows and horses. Preferred subjects include human
patients. The methods are particularly suitable for treating human
patients having a disease or disorder described herein.
A "test compound" is a compound according to any embodiment
described herein that is being tested in any test. Tests include
any in vivo or in vitro test, computer model or simulation, virtual
drug trial, stem cell and genetic testing methods, non-invasive
imaging techniques and the like.
As used herein, the term "therapeutic" means an agent utilized to
treat, combat, ameliorate, protect against or improve an unwanted
condition or disease of a subject.
A "therapeutically effective amount" of a compound,
pharmaceutically acceptable salt thereof or pharmaceutical
composition according to any embodiment described herein, is an
amount sufficient to produce a selected effect on at least one
symptom or parameter of a specific disease or disorder. The
therapeutic effect may be objective (i.e., measurable by some test
or marker) or subjective (i.e., subject gives an indication of or
feels an effect or physician observes a change). A therapeutically
effective amount of a compound, according to any embodiment
described herein, may broadly range from 0.01 mg/kg to about 500
mg/kg, about 0.01 to about 250 mg/kg, about 0.01 to about 25 mg/kg,
about 0.05 mg/kg to about 20 mg/kg, about 0.1 mg/kg to about 400
mg/kg, about 0.1 mg/kg to about 200 mg/kg, about 0.1 mg/kg to about
25 mg/kg, about 0.1 to about 10 mg/kg, about 0.2 to about 5 mg/kg,
about 1 mg/kg to about 300 mg/kg, about 10 mg/kg to about 100
mg/kg, body weight. The effect contemplated herein, includes both
medical therapeutic and/or prophylactic treatment, as appropriate.
The specific dose of a compound administered according to this
disclosure to obtain therapeutic and/or prophylactic effects is
determined by the particular circumstances surrounding the case,
including, for example, the compound administered, the route of
administration, the co-administration of other active ingredients,
the condition being treated, the activity of the specific compound
employed, the specific composition employed, the age, body weight,
general health, sex and diet of the patient; the time of
administration, route of administration, and rate of excretion of
the specific compound employed and the duration of the treatment.
The therapeutically effective amount administered will be
determined by the physician in the light of the foregoing relevant
circumstances and the exercise of sound medical judgment. A
therapeutically effective amount of a compound, according to any
embodiment described herein, is typically an amount such that when
it is administered in a physiologically tolerable excipient
composition, it is sufficient to achieve an effective systemic
concentration or local concentration in the tissue. The total daily
dose of the compounds according to any embodiment described herein
administered to a human or other animal in single or in divided
doses can be in amounts, for example, from about 0.01 mg/kg to
about 500 mg/kg, about 0.01 to about 250 mg/kg, about 0.01 to about
25 mg/kg, about 0.05 mg/kg to about 20 mg/kg, about 0.1 mg/kg to
about 400 mg/kg, about 0.1 mg/kg to about 200 mg/kg, about 0.1
mg/kg to about 25 mg/kg, about 0.1 to about 10 mg/kg, about 0.2 to
about 5 mg/kg, about 1 mg/kg to about 300 mg/kg, about 10 mg/kg to
about 100 mg/kg, body weight per day. Single dose pharmaceutical
compositions of any embodiment described herein, may contain such
amounts or submultiples thereof to make up the daily dose. For
example, the compounds according to any embodiment described
herein, may be administered on a regimen of 1 to 4 times per day,
such as once, twice, three times or four times per day. In some
embodiments, the therapeutically effective amount of a compound
according to any embodiment disclosed herein, can range between
about 0.01 and about 25 mg/kg/day. In some embodiments the
therapeutically effective amount is between a lower limit of about
0.01 mg/kg of body weight, about 0.1 mg/kg of body weight, about
0.2 mg/kg of body weight, about 0.3 mg/kg of body weight, about 0.4
mg/kg of body weight, about 0.5 mg/kg of body weight, about 0.60
mg/kg of body weight, about 0.70 mg/kg of body weight, about 0.80
mg/kg of body weight, about 0.90 mg/kg of body weight, about 1
mg/kg of body weight, about 2.5 mg/kg of body weight, about 5 mg/kg
of body weight, about 7.5 mg/kg of body weight, about 10 mg/kg of
body weight, about 12.5 mg/kg of body weight, about 15 mg/kg of
body weight, about 17.5 mg/kg of body weight, about 20 mg/kg of
body weight, about 22.5 mg/kg of body weight, and about 25 mg/kg of
body weight; and an upper limit of 25 mg/kg of body weight, about
22.5 mg/kg of body weight, about 20 mg/kg of body weight, about
17.5 mg/kg of body weight, about 15 mg/kg of body weight, about
12.5 mg/kg of body weight, about 10 mg/kg of body weight, about 7.5
mg/kg of body weight, about 5 mg/kg of body weight, about 2.5 mg/kg
of body weight, about 1 mg/kg of body weight, about 0.9 mg/kg of
body weight, about 0.8 mg/kg of body weight, about 0.7 mg/kg of
body weight, about 0.6 mg/kg of body weight, about 0.5 mg/kg of
body weight, about 0.4 mg/kg of body weight, about 0.3 mg/kg of
body weight, about 0.2 mg/kg of body weight, about 0.1 mg/kg of
body weight, and about 0.01 mg/kg of body weight. In some
embodiments, the therapeutically effective amount is about 0.1
mg/kg/day to about 10 mg/kg/day; in some embodiments the
therapeutically effective amount is about 0.2 and about 5
mg/kg/day. In some embodiments, treatment regimens according to the
disclosure comprise administration to a patient in need of such
treatment will usually include from about 1 mg to about 5000 mg,
about 10 mg to about 2000 mg, about 10 mg to about 200 mg, about 20
to about 1000 mg, about 20 to about 500 mg, about 20 to about 400
mg, about 40 to about 800 mg, about 50 mg to about 500 mg, about 80
to about 1600 mg and about 50 mg, of a compound according to any
embodiment disclosed herein, or a pharmaceutically acceptable salt
thereof, per day in single or multiple doses. In some embodiments
the therapeutically effective amount is a total daily dose of 50 mg
to 500 mg. In some embodiments, the daily dose is between a lower
limit of about 50 mg, about 55 mg, about 60 mg, about 65 mg, about
70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95
mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg; about
120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg,
about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165
mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about
190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg,
about 215 mg; about 220 mg, about 225 mg, about 230 mg, about 235
mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about
260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg,
about 285 mg, about 290 mg, about 295 mg, 300 mg, about 305 mg,
about 310 mg, about 315 mg; about 320 mg, about 325 mg, about 330
mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about
355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg,
about 380 mg, about 385 mg, about 390 mg, about 395, about 400 mg,
about 405 mg, about 410 mg, about 415 mg; about 420 mg, about 425
mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about
450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg,
about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495
mg, and about 500 mg and an upper limit of about 500 mg, about 495
mg, about 490 mg, about 485 mg, about 480 mg, about 475 mg, about
470 mg, about 465 mg, about 460 mg, about 455 mg, about 450 mg,
about 445 mg, about 440 mg, about 435 mg, about 430 mg, about 425
mg, about 420 mg, about 415 mg, about 410 mg, about 405 mg, about
400 mg, about 395 mg, about 390 mg, about 385 mg, about 380 mg,
about 375 mg, about 370 mg, about 365 mg, about 360 mg, about 355
mg, about 350 mg, about 345 mg, about 340 mg, about 335 mg, about
330 mg, about 325 mg, about 320 mg, about 315 mg, about 310 mg,
about 305 mg about 300 mg, about 295 mg, about 290 mg, about 285
mg, about 280 mg, about 275 mg, about 270 mg, about 265 mg, about
260 mg, about 255 mg, about 250 mg, about 245 mg, about 240 mg,
about 235 mg, about 230 mg, about 225 mg, about 220 mg, about 215
mg, about 210 mg, about 205 mg 200 mg, about 195 mg, about 190 mg,
about 185 mg, about 180 mg, about 175 mg, about 170 mg, about 165
mg, about 160 mg, about 155 mg, about 150 mg, about 145 mg, about
140 mg, about 135 mg, about 130 mg, about 125 mg, about 120 mg,
about 115 mg, about 110 mg, about 105 mg, about 100 mg, about 95
mg, about 90 mg; about 85 mg, about 80 mg, about 75 mg, about 70
mg, about 65 mg, about 60 mg, about 55 mg, and about 50 mg of a
compound according to any embodiment herein. In some embodiments,
the total daily dose is about 50 mg to 150 mg. In some embodiments,
the total daily dose is about 50 mg to 250 mg. In some embodiments,
the total daily dose is about 50 mg to 350 mg. In some embodiments,
the total daily dose is about 50 mg to 450 mg. In some embodiments,
the total daily dose is about 50 mg. It will be understood that the
pharmaceutical formulations of the disclosure need not necessarily
contain the entire amount of the compound that is effective in
treating the disorder, as such effective amounts can be reached by
administration of a plurality of divided doses of such
pharmaceutical formulations. The compounds may be administered on a
regimen of 1 to 4 times per day, such as once, twice, three times
or four times per day.
The term "therapeutic phenotype" is used to describe a pattern of
activity for compounds in the in vitro assays that is predictive of
behavioral efficacy. A compound that (1) selectively binds with
high affinity to a sigma-2 receptor, and (2) acts as a functional
antagonist with respect to Abeta oligomer-induced effects in a
neuron, is said to have the "therapeutic phenotype" if (i) it
blocks or reduces A.beta.-induced membrane trafficking deficits;
(ii) it blocks or reduces A.beta.-induced synapse loss and (iii) it
does not affect trafficking or synapse number in the absence of
Abeta oligomer. This pattern of activity in the in vitro assays is
termed the "therapeutic phenotype" and is predictive of behavioral
efficacy.
The term "therapeutic profile" is used to describe a compound that
meets the therapeutic phenotype, and also has good brain
penetrability (the ability to cross the blood brain barrier), good
plasma stability and good metabolic stability.
The term "tissue" refers to any aggregation of similarly
specialized cells which are united in the performance of a
particular function.
The terms "treat," "treated," or "treating" as used herein, refers
to both therapeutic treatment and prophylactic or preventative
measures, wherein the object is to protect against (partially or
wholly) or slow down (e.g., lessen or postpone the onset of) an
undesired physiological condition, disorder or disease, or to
obtain beneficial or desired clinical results such as partial or
total restoration or inhibition in decline of a parameter, value,
function or result that had or would become abnormal. For the
purposes of this disclosure, beneficial or desired clinical results
include, but are not limited to, alleviation of symptoms;
diminishment of the extent or vigor or rate of development of the
condition, disorder or disease; stabilization (i.e., not worsening)
of the state of the condition, disorder or disease; delay in onset
or slowing of the progression of the condition, disorder or
disease; amelioration of the condition, disorder or disease state;
and remission (whether partial or total), whether or not it
translates to immediate lessening of actual clinical symptoms, or
enhancement or improvement of the condition, disorder or disease.
Treatment seeks to elicit a clinically significant response without
excessive levels of side effects. Treatment also includes
prolonging survival as compared to expected survival if not
receiving treatment.
Human Amyloid Beta and Sigma-2 Antagonists
Overproduction and accumulation of amyloid beta is a pathologic
feature of Alzheimer's disease. Human amyloid beta (Abeta) is the
main component of insoluble amyloid plaques-deposits found in the
brain of patients with Alzheimer's disease. The plaques are
composed of fibrillar aggregates of Abeta. Amyloid beta fibrils
have been associated with the advanced stages of Alzheimer's
disease.
The cognitive hallmark of early Alzheimer's disease is an
extraordinary inability to form new memories. Early memory loss is
considered a synapse failure caused by soluble A.beta. oligomers.
These oligomers block long-term potentiation, a classic
experimental paradigm for synaptic plasticity, and they are
strikingly elevated in AD brain tissue and transgenic AD models. It
has been hypothesized that early memory loss stems from synapse
failure before neuron death and that synapse failure derives from
actions of soluble A.beta. oligomers rather than fibrils. Lacor et
al., Synaptic targeting by Alzheimer's-related amyloid .beta.
oligomers, J. Neurosci. 2004, 24(45):10191-10200.
Abeta is a cleavage product of an integral membrane protein,
amyloid precursor protein (APP), found concentrated in the synapses
of neurons. Soluble forms of Abeta are present in the brains and
tissues of Alzheimer's patients, and their presence correlates with
disease progression. Yu et al., 2009, Structural characterization
of a soluble amyloid beta-peptide oligomer, Biochemistry,
48(9):1870-1877. Soluble amyloid .beta. oligomers have been
demonstrated to induce changes in neuronal synapses that block
learning and memory.
Smaller, soluble A.beta. oligomers interfere with a number of
signaling pathways critical for normal synaptic plasticity,
ultimately resulting in spine and synapse loss. Selkoe et al.,
2008, Soluble oligomers of the amyloid beta-protein impair synaptic
plasticity and behavior, Behav Brain Res 192(1): 106-113.
Alzheimer's begins and persists as a synaptic plasticity
disease.
The presence of soluble A.beta. oligomers is believed to be to be
responsible for early cognitive decline in the pre-Alzheimer's
diseased brain. It is known that amyloid beta oligomers bind at
neuronal synapses and that sigma-2 receptors are present in
significant amounts in neurons and glia.
Sigma receptors are multifunctional adapter/chaperone proteins that
participate in several distinct protein signaling complexes in a
tissue and state-related manner. The sigma-2 receptor is expressed
in brain and various peripheral tissues at low levels. (Walker et
al., 1990 Sigma receptors: biology and function. Pharmacol. Rev.
42:355-402). Sigma-2 receptors are present in human hippocampus and
cortex. The sigma-2 receptor was also previously validated as a
biomarker for tumor cell proliferation. (Mach et al., Sigma-2
receptors as potential biomarkers of proliferation in breast
cancer. Cancer Res. 57:156-161, 1997).
Sigma-2 receptors are implicated in many signaling pathways such as
heme binding, Cytochrome P450 metabolism, cholesterol synthesis,
progesterone signaling, apoptosis and membrane trafficking. Only a
subset of sigma receptor binding sites/signaling pathways are
relevant to oligomer signaling in AD. No sigma-2 receptor
knock-outs are currently available and human mutations in sigma-2
sequence have not been studied in a neurodegeneration context.
A sigma-2 receptor was recently identified as the progesterone
receptor membrane component 1 (PGRMC1) in rat liver by use of a
photoaffinity probe WC-21, which irreversibly labels sigma-2
receptors in rat liver. Xu et al. Identification of the PGRMC1
protein complex as the putative sigma-2 receptor binding site.
Nature Communications 2, article number 380, Jul. 5, 2011,
incorporated herein by reference. PGRMC1 (progesterone receptor
membrane component 1) was identified as the critical 25 kDa
component of sigma-2 receptor activity in August 2011 by Xu et al.
PGRMC1 is a single transmembrane protein with no homology to
sigma-1 protein; family members include PGRMC2 and neudesin. PGRMC1
contains a cytochrome b5 heme-binding domain. PGRMC1 is a single
transmembrane protein with no homology to S1 protein; family
members include PGRMC2 and neudesin. PGRMC1 contains a cytochrome
b5 heme-binding domain. Endogenous PGRMC ligands include
progesterone/steroids, cholesterol metabolites, glucocorticoids,
and heme. PGRMC1 functions as chaperone/adapter associated with
different protein complexes in different subcellular locations
(Cahill 2007. Progesterone receptor membrane component 1: an
integrative review. J. Steroid Biochem. Mol. Biol. 105:16-36).
PGRMC1 binds heme with reducing activity, complexes with CYP450
proteins (regulated redox reactions), associates with PAIRBP1 and
mediates progesterone block of apoptosis, and associates with
Insig-1 and SCAP to induce SRE-related gene transcription in
response to low cholesterol. The C. elegans homolog VEM1 associates
with UNC-40/DCC to mediate axon guidance. PGRMC1 contains two SH2
target sequences, an SH3 target sequence, a tyrosine kinase site,
two acidophilic kinase sites (CK2), and consensus binding sites for
ERK1 and PDK1. PGRMC1 contains several ITAM sequences involved in
membrane trafficking (vesicle transport, clathrin-dependent
endocytosis of calveolin-containing pits).
While not being bound by theory, it is proposed that the sigma-2
receptor is a receptor for Abeta oligomer in neurons. Various
receptors have been proposed in the literature for soluble Abeta
oligomers including prion protein, insulin receptor, beta
adrenergic receptor and RAGE (receptor for advanced glycation end
products). Lauren, J. et al, 2009, Nature, 457(7233): 1128-1132;
Townsend, M. et al, J. Biol. Chem. 2007, 282:33305-33312;
Sturchler, E. et al, 2008, J. Neurosci. 28(20):5149-5158. Indeed
many investigators believe that Abeta oligomer may bind to more
than one receptor protein. Without being bound by theory, the
present inventors postulate an additional receptor for Abeta
oligomer located (not necessarily exclusively) in neurons.
Without being bound by theory, Abeta oligomers are sigma receptor
agonists that bind to sigma protein complexes and cause aberrant
trafficking and synapse loss. It is demonstrated herein, that
compounds described herein that antagonize this interaction and/or
sigma receptor function in neurons will compete or otherwise
interfere with Abeta oligomers and return neuronal responses to
normal. Such compounds are considered functional sigma-2 receptor
antagonists.
In some embodiments, a compound of any embodiment described herein,
may act as a functional antagonist in a neuronal cell with respect
to inhibiting soluble A.beta. oligomer induced synapse loss, and
inhibiting soluble A.beta. oligomer induced deficits in a membrane
trafficking assay; exhibiting high affinity at a sigma-2 receptor;
as well as having high selectivity for one or more sigma receptors
compared to any other non-sigma receptor; and exhibiting good
drug-like properties.
In some embodiments, a compound according to any embodiment
described herein, that acts as functional antagonist meeting
certain in vitro assay criteria detailed herein, will exhibit
behavioral efficacy, or be predicted to have behavioral efficacy,
in one or more relevant animal behavioral models. In some
embodiments, behavioral efficacy is determined at 10 mg/kg p.o., or
less.
In vitro assay platforms predictive of behavioral efficacy useful
in the invention described herein, are known in the art, in
particular, in U.S. Pat. No. 9,796,672, herein incorporated by
reference in its entirety. In accordance with the in vitro assay
platform, a compounds of any embodiment described herein, may bind
with high affinity to a sigma-2 receptor; acts as a functional
antagonist with respect to Abeta oligomer-induced effects in a
neuron; inhibits Abeta oligomer-induced synapse loss in a central
neuron or reduces Abeta oligomer binding to neurons to inhibit
synapse loss; and does not affect trafficking or synapse number in
the absence of Abeta oligomer. This pattern of activity in the in
vitro assays is termed the "therapeutic phenotype". The ability of
a compound according to any embodiment described herein, to block
Abeta oligomer effects in mature neurons without affecting normal
function in the absence of Abeta oligomers meets the criteria for
the therapeutic phenotype. A compounds of any embodiment described
herein, having a therapeutic phenotype, can block Abeta
oligomer-induced synaptic dysfunction.
In some embodiments, a compound according to any embodiment
described herein, exhibits sigma-2 antagonist activity, high
affinity for the sigma-2 receptor, and the ability to block soluble
Abeta oligomer binding or Abeta oligomer-induced synaptic
dysfunction.
In some embodiments, a compound according to any embodiment
described herein, is designed to enhance the ability to cross the
blood-brain barrier.
In some embodiments, a compound according to any embodiment
described herein, blocks binding between soluble Abeta oligomers
and a sigma-2 receptor.
In some embodiments, a compound according to any embodiment
described herein, exhibits high affinity for the sigma-2
receptor.
Embodiments of the invention are directed to compounds according to
any embodiment described herein, useful for treating
neurodegenerative disease and cognitive decline, pharmaceutical
compositions containing such compounds and pharmaceutically
acceptable carries, excipients, or diluents, and methods for
treating neurodegenerative disease and cognitive decline by
administering such compounds and pharmaceutical compositions in a
pharmaceutically acceptable amount.
Compounds of the Invention
Various embodiments are directed to a compound of Formula I:
##STR00014## or a pharmaceutically acceptable salt thereof.
Each of substituents R.sup.a, R.sup.b, R.sup.c, R.sup.d and R.sup.e
of Formula I is independently selected from the group consisting
of, H, hydroxyl, halo, alkyl, alkoxy, CF.sub.3, SO.sub.2CH.sub.3,
and morpholino.
Substituent R.sup.1 of Formula I is selected from the group
consisting of hydrogen, alkyl, phenyl, or
--CH.dbd.C(CH.sub.3).sub.2.
Substituent R.sup.2 of Formula I is an optionally substituted
cyclic amino group.
In some embodiments, each of substituents R.sup.a, R.sup.b,
R.sup.c, R.sup.d and R.sup.e of Formula I is independently selected
from the group consisting of, H, hydroxyl, C.sub.1, F, methyl,
--OCH.sub.3, --OC(CH.sub.3).sub.3, O--CH(CH.sub.3).sub.2, CF.sub.3,
SO.sub.2CH.sub.3, and morpholino.
In some embodiments, each of substituents R.sup.a, R.sup.b,
R.sup.c, R.sup.d and R.sup.e of Formula I is independently selected
from the group consisting of, H, Cl, F, and CF.sub.3.
In some embodiments, each of substituents R.sup.a, R.sup.b, R.sup.d
and R.sup.e of Formula I is independently H and R.sup.c, is
selected from the group consisting of H, hydroxyl, halo, alkyl,
alkoxy, CF.sub.3, SO.sub.2CH.sub.3, and morpholino.
In some embodiments, each of substituents R.sup.a, R.sup.b, R.sup.d
and R.sup.e of Formula I is independently H and R.sup.c, is
selected from the group consisting of H, hydroxyl, Cl, F, methyl,
--OCH.sub.3, --OC(CH.sub.3).sub.3, O--CH(CH.sub.3).sub.2, CF.sub.3,
SO.sub.2CH.sub.3, and morpholino.
In some embodiments, each of substituents R.sup.a, R.sup.b, R.sup.d
and R.sup.e of Formula I is independently H and R.sup.c, is
selected from the group consisting of H, Cl, F, and CF.sub.3.
In various embodiments, R.sup.2 is any heterocycloalkyl or
heteroaryl containing a nitrogen in the ring that is bound to the
aliphatic chain of Formula I through the nitrogen atom. In some
embodiments, for example, R.sup.2 is an optionally substituted
cyclic amino group selected from:
##STR00015## and the like, wherein each nitrogen containing
heterocycloalkyl or heteroaryl can be optionally substituted with
one or more substituents selected from, hydroxyl, halo, CF.sub.3,
alkoxy, aryloxy, optionally substituted C.sub.1-C.sub.10 alkyl,
optionally substituted C.sub.5-C.sub.10 aryl, optionally
substituted C.sub.3-C.sub.10 heteroaryl, substituted or
unsubstituted C.sub.3-C.sub.10 cycloalkyl or heterocycloalkyl.
In various embodiments, R.sup.2 is selected from the group
consisting of optionally substituted aziridinyl, optionally
substituted pyrrolidinyl, optionally substituted imidizolidinyl,
optionally substituted piperidinyl, optionally substituted
piperazinyl, optionally substituted oxopiperazinyl, and optionally
substituted morpholinyl.
In some embodiments, when R.sup.2 is a substituted cyclic amino,
one or more of the hydrogen atoms in the cyclic amino group is
replaced with a group selected from alkanoyl, alkoxy, alkoxyalkyl,
(alkoxy)alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy, aryloyl,
cycloalkanoyl, --OC(O)NCH(CH.sub.3).sub.2,
(N,N-dimethylamino)pyridinyl, (N,N-dimethylamino)sulfonyl, halo,
heterocyclyl, (heterocyclyl)alkoxyalkyl, hydroxyl, hydroxyalkyl,
methylpiperidinyl, methylsulfonyl, methylsulfonylphenyl,
morpholinylpyridinyl, perfluoroalkyl, phenyl, piperidinyl,
pyrrolidinylpyridinyl, tetrahydropyranyl, and CF.sub.3. In some
embodiments two hydrogen atoms on the same carbon of the cyclic
amino group are replaced with a compound selected from
##STR00016## and to form a spiro compound.
In some embodiments, R.sup.2 is a pyrrolidinyl or a substituted
pyrrolidinyl substituted with one or more substituents selected
from the group consisting of alkoxyalkyl, alkoxycarbonyl, alkyl,
hydroxyl, and hydroxyalkyl. In some embodiments R.sup.2 is a
substituted pyrrolidinyl substituted with a single substituent
selected from the group consisting of alkoxyalkyl, alkoxycarbonyl,
alkyl, hydroxyl, and hydroxyalkyl. In some embodiments R.sup.2 is a
substituted pyrrolidinyl substituted with a single substituent
selected from the group consisting of hydroxyl, hydroxymethyl,
methoxymethyl, methoxycarbonyl and methyl.
In some embodiments, R.sup.2 is a piperidinyl or a substituted
piperidinyl substituted with one or more substituents selected from
the group consisting of alkoxy, alkoxyalkyl, (alkoxy)alkoxyalkyl,
alkoxycarbonyl, alkyl, aryloxy, --OC(O)NCH(CH.sub.3).sub.2,
(N,N-dimethylamino)pyridinyl, halo, heterocyclyl,
(heterocyclyl)alkoxyalkyl, hydroxy, hydroxyalkyl,
methylpiperidinyl, methylsulfonylphenyl, morpholinylpyridinyl,
perfluoroalkyl, phenyl, piperidinyl, pyrrolidinylpyridinyl,
tetrahydropyranyl, and CF.sub.3. In some embodiments, R.sup.2 is a
piperidinyl or a substituted piperidinyl substituted with a single
substituent selected from the group consisting of alkoxy,
alkoxyalkyl, (alkoxy)alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy,
--OC(O)NCH(CH.sub.3).sub.2, (N,N-dimethylamino)pyridinyl, halo,
heterocyclyl, (heterocyclyl)alkoxyalkyl, hydroxyl, hydroxyalkyl,
methylpiperidinyl, methylsulfonylphenyl, morpholinylpyridinyl,
perfluoroalkyl, phenyl, piperidinyl, pyrrolidinylpyridinyl,
tetrahydropyranyl, and CF.sub.3. In some embodiments, R.sup.2 is a
piperidinyl or a substituted piperidinyl substituted with a single
substituent selected from the group consisting of alkoxy,
alkoxyalkyl, (alkoxy)alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy,
--OC(O)NCH(CH.sub.3).sub.2, (N,N-dimethylamino)pyridinyl, halo,
heterocyclyl, (heterocyclyl)alkoxyalkyl, hydroxyl, hydroxyalkyl,
methylpiperidinyl, methylsulfonylphenyl, morpholinylpyridinyl,
perfluoroalkyl, phenyl, piperidinyl, pyrrolidinylpyridinyl,
tetrahydropyranyl, and CF.sub.3. In some embodiments, R.sup.2 is a
piperidinyl or a substituted piperidinyl substituted with a single
substituent selected from the group consisting of methyl,
isopropyl, isobutyl, CF.sub.3, hydroxymethyl, hydroxyethyl,
(isopropyloxy)ethyl, --(CH.sub.2).sub.2O(CH.sub.2).sub.2OCH.sub.3,
--(CH.sub.2).sub.3OCH.sub.3, --C(O)OMe, --C(O)OEt, hydroxyl,
methoxy, isopropyloxy, phenyloxy, F, ethoxy, phenyl,
##STR00017##
In some embodiments, R.sup.2 is a piperidinyl or a substituted
piperidinyl substituted at the 4 position of the piperidinyl with a
single substituent selected from the group consisting of alkoxy,
alkoxyalkyl, (alkoxy)alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy,
--OC(O)NCH(CH.sub.3).sub.2, (N,N-dimethylamino)pyridinyl, halo,
heterocyclyl, (heterocyclyl)alkoxyalkyl, hydroxyl, hydroxyalkyl,
methylpiperidinyl, methylsulfonylphenyl, morpholinylpyridinyl,
perfluoroalkyl, phenyl, piperidinyl, pyrrolidinylpyridinyl,
tetrahydropyranyl, and CF.sub.3. In some embodiments, R.sup.2 is a
piperidinyl or a substituted piperidinyl substituted at the 4
position of the piperidinyl with a single substituent selected from
the group consisting of methyl, isopropyl, isobutyl, CF.sub.3,
hydroxymethyl, hydroxyethyl, (isopropyloxy)ethyl,
--(CH.sub.2).sub.2O(CH.sub.2).sub.2OCH.sub.3,
--(CH.sub.2).sub.3OCH.sub.3, --C(O)OMe, --C(O)OEt, hydroxyl,
methoxy, isopropyloxy, phenyloxy, F, ethoxy, phenyl,
##STR00018##
In some embodiments, R.sup.2 is a piperidinyl or a substituted
piperidinyl substituted with two substituent groups on the same
carbon of the piperidinyl independently selected from the group
consisting of alkoxyalkyl, alkyl, --OC(O)NCH(CH.sub.3).sub.2,
hydroxyl, and phenyl. In some embodiments, R.sup.2 is a piperidinyl
or a substituted piperidinyl substituted with two substituent
groups at the 4 position of the piperidinyl independently selected
from the group consisting of alkoxyalkyl, alkyl,
--OC(O)NCH(CH.sub.3).sub.2, hydroxyl, and phenyl. In some
embodiments R.sup.2 is a piperidinyl or a substituted piperidinyl
substituted with two substituent groups at the 4 position selected
from the group consisting of hydroxyl and methyl; hydroxyl and
ethyl; hydroxyl and --(CH.sub.2).sub.2OCH.sub.3; hydroxyl and
phenyl; methyl and phenyl; methyl and --OC(O)NCH(CH.sub.3).sub.2;
and butyl and --OC(O)NCH(CH.sub.3).sub.2. In some embodiments two
hydrogen atoms on the same carbon of the piperidinyl are replaced
with a compound selected from
##STR00019## to form a spiro compound. In some embodiments two
hydrogen atoms at the 4 position of the piperidinyl are replaced
with a compound selected from
##STR00020## to form a spiro compound.
In some embodiments, R.sup.2 is a piperazinyl or a substituted
piperazinyl substituted with one or more substituents selected from
the group consisting of alkanoyl, alkoxycarbonyl, aryloyl,
cycloalkanoyl, (N,N-dimethylamino)sulfonyl, heterocyclyl,
methylsulfonyl, and phenyl. In some embodiments, R.sup.2 is a
substituted piperazinyl substituted with a single substituent
selected from the group consisting of alkanoyl, alkoxycarbonyl,
aryloyl, cycloalkanoyl, (N,N-dimethylamino)sulfonyl, heterocyclyl,
methylsulfonyl, and phenyl. In some embodiments, R.sup.2 is a
substituted piperazinyl substituted with a single substituent
selected from the group consisting of --C(O)OC(CH.sub.3).sub.3,
--C(O)OCH.sub.2CH(CH.sub.3).sub.2, --C(O)OCH.sub.2CH.sub.3,
--C(O)OCH.sub.3, phenyl, --C(O)CH.sub.3, --C(O)Ph, --SO.sub.2Me,
--SO.sub.2N(CH.sub.3).sub.2,
##STR00021## In some embodiments, R.sup.2 is a substituted
piperazinyl substituted with a single substituent at the 4 position
selected from the group consisting of --C(O)OC(CH.sub.3).sub.3,
--C(O)OCH.sub.2CH(CH.sub.3).sub.2, --C(O)OCH.sub.2CH.sub.3,
--C(O)OCH.sub.3, phenyl, --C(O)CH.sub.3, --C(O)Ph, --SO.sub.2Me,
--SO.sub.2N(CH.sub.3).sub.2,
##STR00022##
In certain embodiments, R.sup.2 is a substituted piperdinyl of
formula:
##STR00023## wherein, R.sup.3 is hydrogen or C.sub.1-C.sub.8 alkyl,
and R.sup.4 is hydrogen, hydroxyl, halogen, CF.sub.3, alkoxy,
aryloxy, optionally substituted C.sub.1-C.sub.10 alkyl, optionally
substituted C.sub.5-C.sub.10 aryl, optionally substituted
C.sub.3-C.sub.10 heteroaryl, optionally substituted
C.sub.3-C.sub.10 cycloalkyl or optionally substituted
C.sub.3-C.sub.10 heterocycloalkyl.
In some embodiments, R.sup.2 is
##STR00024## wherein each of R.sup.5 and R.sup.6 is independently,
hydrogen, hydroxyl, sulfonyl, dialkylamino, optionally substituted
C.sub.1-C.sub.10 alkyl, optionally substituted C.sub.5-C.sub.10
aryl optionally substituted C.sub.3-C.sub.10 heteroaryl, optionally
substituted C.sub.3-C.sub.10 cycloalkyl or optionally substituted
C.sub.3-C.sub.10 heterocycloalkyl. In some embodiments R.sup.5 is
hydrogen, dialkylamino, or C.sub.3-C.sub.10 heterocycloalkyl. In
some embodiments R.sup.5 is hydrogen, dialkylamino, pyrrolidinyl or
morpholinyl. In some embodiments, R.sup.6 is sulfonyl. In some
embodiments, R.sup.6 is methylsulfonyl.
In some embodiments, R.sup.2 is:
##STR00025## ##STR00026## ##STR00027## wherein R.sup.3a selected
from the group consisting of hydrogen and C.sub.1-C.sub.8 alkyl;
and n is an integer selected from 0, 1 and 2.
In some embodiments R.sup.2 is
##STR00028##
In some embodiments, R.sup.2 is optionally substituted morpholinyl.
In some embodiments, R.sup.2 is morpholinyl.
In some embodiments R.sup.2 or is optionally substituted
piperazinyl of the formula
##STR00029## wherein R.sup.7 is hydrogen, hydroxyl, sulfonyl,
dialkylaminosulfonyl, alkoxycarbonyl, acyl, benzoyl,
cycloalkylcarbonyl, optionally substituted C.sub.1-C.sub.10 alkyl,
optionally substituted C.sub.5-C.sub.10 aryl optionally substituted
C.sub.3-C.sub.10 heteroaryl, optionally substituted
C.sub.3-C.sub.10 cycloalkyl or optionally substituted
C.sub.3-C.sub.10 heterocycloalkyl. In some embodiments R.sup.7 is
sulfonyl, dialkylaminosulfonyl, alkoxycarbonyl, acyl, benzoyl,
cycloalkylcarbonyl, C.sub.5-C.sub.10 aryl or optionally substituted
C.sub.3-C.sub.10 heterocycloalkyl.
In some embodiments R.sup.2 is
##STR00030##
In various embodiments, R.sup.2 is optionally substituted
pyrrolidinyl:
##STR00031## where R.sup.8 is hydrogen, hydroxyl, sulfonyl,
optionally substituted C.sub.1-C.sub.10 alkyl, optionally
substituted C.sub.5-C.sub.10 aryl, optionally substituted
C.sub.3-C.sub.10 heteroaryl, optionally substituted
C.sub.3-C.sub.10 cycloalkyl or optionally substituted
C.sub.3-C.sub.10 heterocycloalkyl. In some embodiments, R.sup.8 is
hydrogen, hydroxyl or optionally substituted C.sub.1-C.sub.10
alkyl.
In some embodiments, R.sup.2 is:
##STR00032##
In some embodiments, R.sup.2 is an optionally substituted bicyclic
ring or an optionally substituted fused ring. For example, in some
embodiments, R.sup.2 is selected from the group consisting of:
##STR00033## where R.sup.9 is hydrogen, hydroxyl, sulfonyl,
optionally substituted C.sub.1-C.sub.10 alkyl, optionally
substituted C.sub.5-C.sub.10 aryl, optionally substituted
C.sub.3-C.sub.10 heteroaryl, optionally substituted
C.sub.3-C.sub.10 cycloalkyl or optionally substituted
C.sub.3-C.sub.10 heterocycloalkyl.
In some embodiments, R.sup.2 is
##STR00034## wherein each of R.sup.11a, R.sup.11b, R.sup.11c, and
R.sup.11d, is, independently selected from, hydrogen, hydroxy,
sulfonyl, optionally substituted C.sub.1-C.sub.10 alkyl, optionally
substituted C.sub.5-C.sub.10 aryl, optionally substituted
C.sub.3-C.sub.10 heteroaryl, optionally substituted
C.sub.3-C.sub.10 cycloalkyl or optionally substituted
C.sub.3-C.sub.10 heterocycloalkyl. In particular embodiments,
R.sup.2 is
##STR00035## ##STR00036##
Some embodiments disclosed herein describe a compound wherein each
R.sup.a, R.sup.b, R.sup.c, R.sup.d and R.sup.e is selected from any
embodiment disclosed herein for each of R.sup.a, R.sup.b, R.sup.c,
R.sup.d and R.sup.e; R.sup.1 is selected from any embodiment
disclosed herein for R.sup.1; and R.sup.2 is selected from any
embodiment disclosed herein for R.sup.2.
Some embodiments are directed to a compound selected from
##STR00037## ##STR00038## ##STR00039## ##STR00040## ##STR00041##
##STR00042## ##STR00043## ##STR00044## ##STR00045## ##STR00046##
##STR00047## ##STR00048## ##STR00049## ##STR00050## ##STR00051##
##STR00052## ##STR00053## ##STR00054## ##STR00055## ##STR00056##
##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061##
##STR00062## ##STR00063## ##STR00064## ##STR00065## ##STR00066##
##STR00067## ##STR00068## ##STR00069## ##STR00070## ##STR00071##
##STR00072## ##STR00073## ##STR00074## ##STR00075## ##STR00076##
##STR00077## ##STR00078## ##STR00079## ##STR00080## ##STR00081##
##STR00082## ##STR00083## ##STR00084## ##STR00085## ##STR00086##
##STR00087## ##STR00088## ##STR00089## ##STR00090## ##STR00091##
##STR00092## ##STR00093##
##STR00094## ##STR00095## ##STR00096## ##STR00097## ##STR00098##
##STR00099## ##STR00100## ##STR00101## ##STR00102## ##STR00103##
##STR00104## ##STR00105## ##STR00106## ##STR00107##
Some embodiments are directed to a compound selected from the group
consisting of
##STR00108## ##STR00109##
Further embodiments are directed to compounds of Formula II or
pharmaceutically acceptable salt thereof:
##STR00110##
Each of substituents R.sup.f, R.sup.g, R.sup.h, R.sup.i and R.sup.j
of Formula II is independently selected from the group consisting
of, H, hydroxyl, halo, alkyl, alkoxy, CF.sub.3, SO.sub.2CH.sub.3,
and morpholino.
Substituent R.sup.10 of Formula II is an optionally substituted
cyclic amino group and m is an integer from 0 to 3.
In some embodiments each of substituents R.sup.f, R.sup.g, R.sup.h,
R.sup.i and R.sup.j of Formula II is independently selected from
the group consisting of, H, hydroxyl, and alkoxy. In some
embodiments each of substituents R.sup.f, R.sup.g, R.sup.h, R.sup.i
and R.sup.j of Formula II is independently selected from the group
consisting of, H, hydroxyl, and methoxy. In some embodiments each
of substituents R.sup.f, R.sup.g, and R.sup.j is H and each of
R.sup.g, and R.sup.h is independently selected from the hydroxyl,
or methoxy.
In some embodiments, R.sup.10 is an optionally substituted
aziridinyl, optionally substituted pyrolidinyl, optionally
substituted imidizolidinyl, optionally substituted piperidinyl,
optionally substituted piperazinyl, optionally substituted
oxopiperazinyl, or optionally substituted morpholinyl, and any of
the individual substituted or unsubstituted piperdinyl, substituted
or unsubstituted morpholinyl, substituted or unsubstituted
piperazinyl, substituted or unsubstituted pyrrolidinyl, substituted
or unsubstituted bicyclic, or substituted or unsubstituted fused
rings described above in relation to Formula I.
In some embodiments, R.sup.10 is an optionally substituted fused
ring, such as:
##STR00111## wherein each of R.sup.11e, R.sup.11f, R.sup.11g, and
R.sup.11h is independently selected from, hydrogen, hydroxy,
sulfonyl, optionally substituted C.sub.1-C.sub.10 alkyl, optionally
substituted C.sub.5-C.sub.10 aryl optionally substituted
C.sub.3-C.sub.10 heteroaryl, optionally substituted
C.sub.3-C.sub.10 cycloalkyl or optionally substituted
C.sub.3-C.sub.10 heterocycloalkyl. In certain embodiments R.sup.10
is not
##STR00112## when m is 2.
In some embodiments, R.sup.10 is
##STR00113## ##STR00114## ##STR00115## ##STR00116##
Some embodiments describe a compound of Formula IIa:
##STR00117##
Each of substituents R.sup.k and R.sup.l is independently selected
from the group consisting of H, hydroxyl, halo, alkyl, alkoxy,
CF.sub.3, SO.sub.2CH.sub.3, and morpholino.
Substituent R.sup.12 is selected from the group consisting of
aryloxy, alkenyloxy, alkoxy, aminoalkyl, N,N-dimethylaminoalkyl,
pyrrolidinyl, n-methylpyrrolidinyl, N-acylpyrrolidinyl,
carboxyaminoalkyl, hydroxyalkyl,
--O(CH.sub.2).sub.2OC(O)CH.sub.3,
##STR00118##
In some embodiments each of substituents R.sup.k and R.sup.l is
independently selected from the group consisting of H, hydroxyl and
methoxy. In some embodiments R.sup.l is methoxy and R.sup.k is
hydroxyl.
In some embodiments substituent R.sup.12 is selected from the group
consisting of phenyloxy, --OCH.sub.2CH.dbd.CH.sub.2, methoxy,
--CH.sub.2NH.sub.2, --CH(NH.sub.2)CH.sub.3, --CH.sub.2N(Me).sub.2,
--CH(CH.sub.3)N(Me).sub.2, --CH.sub.2NHC(O)CH.sub.3,
--CH(OH)CH.sub.3, --O(CH.sub.2).sub.2OC(O)CH.sub.3,
##STR00119##
Some embodiments describe a compound selected from the group
consisting of
##STR00120## ##STR00121## ##STR00122## ##STR00123##
##STR00124##
Some embodiments describe a compound selected from the group
consisting of
##STR00125## ##STR00126## ##STR00127## ##STR00128## ##STR00129##
##STR00130## ##STR00131## ##STR00132## ##STR00133## ##STR00134##
##STR00135## ##STR00136##
Additional embodiments include salts, solvates, stereoisomers,
prodrugs, and active metabolites of the compounds according to any
embodiment described herein.
Some embodiments are directed to free base forms of the compounds
according to any embodiment described herein. Other embodiments
include salts of such compounds including, for example,
pharmaceutically acceptable acid addition salts or pharmaceutically
acceptable addition salts of free bases. Examples of
pharmaceutically acceptable acid addition salts include, but are
not limited to, salts derived from nitric, phosphoric, sulfuric, or
hydrobromic, hydroiodic, hydrofluoric, phosphorous, as well as
salts derived from nontoxic organic acids such as aliphatic mono-
and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyl
alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and
aromatic sulfonic acids, and acetic, maleic, succinic, or citric
acids. Non-limiting examples of such salts include napadisylate,
besylate, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite,
nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate,
metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate,
trifluoroacetate, propionate, caprylate, isobutyrate, oxalate,
malonate, succinate, suberate, sebacate, fumarate, maleate,
mandelate, benzoate, chlorobenzoate, methylbenzoate,
dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate,
phenylacetate, citrate, lactate, maleate, tartrate,
methanesulfonate, and the like. Additional salt forms of the
compounds described above include salts of amino acids such as
arginate and the like and gluconate, galacturonate (see e.g.,
Berge, et al. "Pharmaceutical Salts," J. Pharma. Sci. 1977;
66:1).
Pharmaceutically acceptable base addition salts are formed with
metals or amines, such as alkali and alkaline earth metals or
organic amines. Examples of metals used as cations are sodium,
potassium, magnesium, calcium, and the like. Examples of suitable
amines include N,N'-dibenzylethylenediamine, chloroprocaine,
choline, diethanolamine, dicyclohexylamine, ethylenediamine,
N-methylglucamine, and procaine. The base addition salts of said
acidic compounds are prepared by contacting the free acid form with
a sufficient amount of the desired base to produce the salt in the
conventional manner. The free acid form may be regenerated by
contacting the salt form with an acid and isolating the free
acid.
Various embodiments include total and partial salts, i.e. salts
with 1, 2 or 3, preferably 2, equivalents of base per mole of acid
of a compound or salt described above, with 1, 2 or 3 equivalents,
preferably 1 equivalent, of acid per mole of base of a compound of
according to any embodiment described herein. Typically, a
pharmaceutically acceptable salt of a compound according to any
embodiment described herein, may be readily prepared by using a
desired acid or base as appropriate. The salt may precipitate from
solution and be collected by filtration or may be recovered by
evaporation of the solvent. For example, an aqueous solution of an
acid such as hydrochloric acid may be added to an aqueous
suspension of a compound according to any embodiment described
herein, and the resulting mixture evaporated to dryness
(lyophilized) to obtain the acid addition salt as a solid.
Alternatively, a compound according to any embodiment described
herein, may be dissolved in a suitable solvent, for example an
alcohol such as isopropanol, and the acid may be added in the same
solvent or another suitable solvent. The resulting acid addition
salt may then be precipitated directly, or by addition of a less
polar solvent such as diisopropyl ether or hexane, and isolated by
filtration.
Many organic compounds can form complexes with solvents in which
they are reacted or from which they are precipitated or
crystallized. These complexes are known as "solvates." For example,
a complex with water is known as a "hydrate." Various embodiments
include solvates of a compound according to any embodiment
described herein. In some embodiments, salts of these compounds can
form solvates.
Further embodiments include N-oxides of the compounds according to
any embodiment described herein. N-oxides include heterocycles
containing an otherwise unsubstituted sp.sup.2 N atom. Examples of
such N-oxides include pyridyl N-oxides, pyrimidyl N-oxides,
pyrazinyl N-oxides and pyrazolyl N-oxides.
Compounds according to any embodiment described herein, may have
one or more chiral centers and, depending on the nature of
individual substituents, they can also have geometrical isomers.
Thus, embodiments include stereoisomers, diastereomers, and
enantiomers of the compounds according to any embodiment described
herein. A chiral compound can exist as either an individual
enantiomer or as a mixture of enantiomers. A mixture containing
equal proportions of the enantiomers is called a "racemic mixture."
A mixture containing unequal portions of the enantiomers is
described as having an "enantiomeric excess" (ee) of either the R
or S compound. The excess of one enantiomer in a mixture is often
described with a % enantiomeric excess. The ratio of enantiomers
can also be defined by "optical purity" wherein the degree at which
the mixture of enantiomers rotates plane polarized light is
compared to the individual optically pure R and S compounds. The
compounds can also be a substantially pure (+) or (-) enantiomer of
the compounds described herein. In some embodiments, a composition
can include a substantially pure enantiomer that is at least 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of one enantiomer.
In certain embodiments, a composition may include a substantially
pure enantiomer that is at least 99.5% one enantiomer.
The description above encompasses all individual isomers of the
compounds according to any embodiment described herein, and the
description or naming of a particular compound in the specification
and claims is intended to include both individual enantiomers and
mixtures thereof. Methods for the determination of stereochemistry
and the resolution or stereotactic synthesis of stereoisomers are
well-known in the art. Diastereomers differ in both physical
properties and chemical reactivity. A mixture of diastereomers can
be separated into enantiomeric pairs based on solubility,
fractional crystallization or chromatographic properties, e.g.,
thin layer chromatography, column chromatography or HPLC.
Purification of complex mixtures of diastereomers into enantiomers
typically requires two steps. In a first step, the mixture of
diastereomers is resolved into enantiomeric pairs, as described
above. In a second step, enantiomeric pairs are further purified
into compositions enriched for one or the other enantiomer or, more
preferably resolved into compositions comprising pure enantiomers.
Resolution of enantiomers typically requires reaction or molecular
interaction with a chiral agent, e.g. solvent or column matrix.
Resolution may be achieved, for example, by converting the mixture
of enantiomers, e.g., a racemic mixture, into a mixture of
diastereomers by reaction with a pure enantiomer of a second agent,
i.e., a resolving agent. The two resulting diastereomeric products
can then be separated. The separated diastereomers are then
reconverted to the pure enantiomers by reversing the initial
chemical transformation.
Resolution of enantiomers can also be accomplished by differences
in their non-covalent binding to a chiral substance, e.g., by
chromatography on homochiral adsorbants. The noncovalent binding
between enantiomers and the chromatographic adsorbant establishes
diastereomeric complexes, leading to differential partitioning in
the mobile and bound states in the chromatographic system. The two
enantiomers therefore move through the chromatographic system, e.g.
column, at different rates, allowing for their separation
Further embodiments include prodrugs of the compounds according to
any embodiment described herein, i.e. compounds which release an
active compound according to any of the embodiments described
herein, in vivo when administered to a mammalian subject. A prodrug
is a pharmacologically active or more typically an inactive
compound that is converted into a pharmacologically active agent by
a metabolic transformation. Prodrugs of a compound according to any
embodiment described herein, are prepared by modifying functional
groups present in the compound according to any embodiment
described herein, in such a way that the modifications may be
cleaved in vivo to release the parent compound. In vivo, a prodrug
readily undergoes chemical changes under physiological conditions
(e.g. are hydrolyzed or acted on by naturally occurring enzyme(s))
resulting in liberation of the pharmacologically active agent.
Prodrugs include compounds according to any embodiment described
herein, wherein a hydroxyl, amino, or carboxy group is bonded to
any group that may be cleaved in vivo to regenerate the free
hydroxyl, amino or carboxy group, respectively. Examples of
prodrugs include, but are not limited to esters (e.g., acetate,
formate, and benzoate derivatives) of compounds according to any
embodiment described herein, or any other derivative which upon
being brought to the physiological pH or through enzyme action is
converted to the active parent drug. Conventional procedures for
the selection and preparation of suitable prodrug derivatives are
described in the art (see, for example, Bundgaard. Design of
Prodrugs. Elsevier, 1985).
The invention also embraces isolated compounds. An isolated
compound refers to a compound which represents at least 10%,
preferably at least 20%, more preferably at least 50% and most
preferably at least 80% of the compound present in a mixture.
In some embodiments, one or more hydrogen atoms of a compound
according to any embodiment described herein, is replaced by a
deuterium. It is well established that deuteration of
physiologically active compounds offer the advantage of retaining
the pharmacological profile of their hydrogen counterparts while
positively impacting their metabolic outcome. Selective replacement
of one or more hydrogen with deuterium, in a compound according to
any embodiment described herein, could improve the safety,
tolerability and efficacy of the compound when compared to its all
hydrogen counterpart.
Methods for incorporation of deuterium into compounds is well
established. Using metabolic studies establish in the art, a
compound according to any embodiment described herein, can be
tested to identify sites for selective placement of a deuterium
isotope, wherein the isotope will not be metabolized. Moreover
these studies identify sites of metabolism as the location where a
deuterium atom would be placed.
Pharmaceutical Compositions
Some embodiments describe a pharmaceutical composition comprising:
a compound according to any embodiment described herein, a
pharmaceutically acceptable salt thereof, a solvate thereof, a
stereoisomer thereof, a prodrug thereof, or an active metabolites
thereof; and a pharmaceutically acceptable carrier or diluent. The
pharmaceutical compositions can be prepared in a manner well known
in the pharmaceutical art, and can be administered by a variety of
routes, depending upon whether local or systemic treatment is
desired and upon the area to be treated.
While it is possible that a compound as described in any embodiment
herein, may be administered as the bulk substance, it is preferable
to present the compound in a pharmaceutical formulation, e.g.,
wherein the active agent is in an admixture with a pharmaceutically
acceptable carrier selected with regard to the intended route of
administration and standard pharmaceutical practice.
In particular, the disclosure provides a pharmaceutical composition
comprising a therapeutically effective amount of at least one
compound according to any embodiment described herein, and
optionally, a pharmaceutically acceptable carrier.
Combinations
For the pharmaceutical compositions and methods of the disclosure,
a compound according to any embodiment described herein, may be
used in combination with other therapies and/or active agents.
In some embodiments, the compound according to any embodiment
described herein, can be combined with one or more of a
cholinesterase inhibitor, an N-methyl-D-aspartate (NMDA) glutamate
receptor antagonist, a beta-amyloid specific antibody, a
beta-secretase 1 (BACE1, beta-site amyloid precursor protein
cleaving enzyme 1) inhibitor, a tumor necrosis factor alpha (TNF
alpha) modulator, an intravenous immunoglobulin (IVIG), or a prion
protein antagonist. In some embodiments the compound is combined
with a cholinesterase inhibitor selected from tacrine (COGNEX.RTM.;
Sciele), donepezil (ARICEPT.RTM.; Pfizer), rivastigmine
(EXELON.RTM.; Novartis), or galantamine (RAZADYNE.RTM.;
Ortho-McNeil-Janssen). In some embodiments, the compound is
combined with a TNFalpha modulator that is perispinal etanercept
(ENBREL.RTM., Amgen/Pfizer). In some embodiments, the compound is
combined with a beta-amyloid specific antibody selected from
bapineuzumab (Pfizer), solanezumab (Lilly), PF-04360365 (Pfizer),
GSK933776(GlaxoSmithKline), Gammagard (Baxter) or Octagam
(Octapharma). In some embodiments, the compound is combined with an
NMDA receptor antagonist that is memantine (NAMENDA.RTM.; Forest).
In some embodiments, the BACE1 inhibitor is MK-8931 (Merck). In
some embodiments, the compound is combined with IVIG as described
in Magga et al., J Neuroinflam 2010, 7:90, Human intravenous
immunoglobulin provides protection against Ab toxicity by multiple
mechanisms in a mouse model of Alzheimer's disease, and Whaley et
al., 2011, Human Vaccines 7:3, 349-356, Emerging antibody products
and Nicotiana manufacturing; each of which is incorporated herein
by reference. In some embodiments, the compound is combined with a
prion protein antagonist as disclosed in Strittmatter et al., US
2010/0291090, which is incorporated herein by reference.
Accordingly, the disclosure provides, in a further aspect, a
pharmaceutical composition comprising at least one compound
according to any embodiment described herein, or pharmaceutically
acceptable derivative thereof; a second active agent; and,
optionally a pharmaceutically acceptable carrier.
When combined in the same formulation it will be appreciated that
the two or more compounds must be stable and compatible with each
other and the other components of the formulation. When formulated
separately they may be provided in any convenient formulation, in
such manner as are known for such compounds in the art.
Preservatives, stabilizers, dyes and flavoring agents may be
provided in any pharmaceutical composition described herein.
Examples of preservatives include sodium benzoate, ascorbic acid
and esters of p-hydroxybenzoic acid. Antioxidants and suspending
agents may be also used.
With respect to combinations including biologics such as monoclonal
antibodies or fragments, suitable excipients will be employed to
prevent aggregation and stabilize the antibody or fragment in
solution with low endotoxin, generally for parenteral
administration, for example, intravenous, administration. For
example, see Formulation and Delivery Issues for Monoclonal
Antibody Therapeutics, Daugherty et al., in Current Trends in
Monoclonal Antibody Development and Manufacturing, Part 4, 2010,
Springer, New York pp 103-129.
The compounds according to any embodiment described herein, may be
milled using known milling procedures such as wet milling to obtain
a particle size appropriate for tablet formation and for other
formulation types. Finely divided (nanoparticulate) preparations of
the compounds may be prepared by processes known in the art, for
example see WO 02/00196 (SmithKline Beecham).
Compounds according to any embodiment described herein, or
pharmaceutically acceptable salts thereof, a solvate thereof, a
stereoisomer thereof, a prodrug thereof, or an active metabolites
thereof, can be formulated for any route of administration.
Routes of Administration and Unit Dosage Forms
The routes for administration (delivery) include, but are not
limited to, one or more of: oral (e.g., as a tablet, capsule, or as
an ingestible solution), topical, mucosal (e.g., as a nasal spray
or aerosol for inhalation), parenteral (e.g., by an injectable
form), gastrointestinal, intraspinal, intraperitoneal,
intramuscular, intravenous, intracerebroventricular, or other depot
administration etc.
Therefore, the pharmaceutical compositions according to any
embodiment described herein, include those in a form especially
formulated for the mode of administration. In certain embodiments,
the pharmaceutical compositions of the disclosure are formulated in
a form that is suitable for oral delivery. In some embodiments, the
compound is an orally bioavailable compound, suitable for oral
delivery. In other embodiments, the pharmaceutical compositions of
the disclosure are formulated in a form that is suitable for
parenteral delivery.
The compounds according to any embodiment described herein, may be
formulated for administration in any convenient way for use in
human or veterinary medicine and the disclosure therefore includes
within its scope pharmaceutical compositions comprising a compound
according to any embodiment described herein, adapted for use in
human or veterinary medicine. Such pharmaceutical compositions may
be presented for use in a conventional manner with the aid of one
or more suitable carriers. Acceptable carriers for therapeutic use
are well-known in the pharmaceutical art, and are described, for
example, in Remington's Pharmaceutical Sciences, Mack Publishing
Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical
carrier can be selected with regard to the intended route of
administration and standard pharmaceutical practice. The
pharmaceutical compositions may comprise as, in addition to, the
carrier any suitable binder(s), lubricant(s), suspending agent(s),
coating agent(s), and/or solubilizing agent(s).
There may be different pharmaceutical composition/formulation
requirements depending on the different delivery systems. It is to
be understood that not all of the compounds need to be administered
by the same route. Likewise, if the pharmaceutical composition
comprises more than one active component, then those components may
be administered by different routes. By way of example, the
pharmaceutical composition of the disclosure may be formulated to
be delivered using a mini-pump or by a mucosal route, for example,
as a nasal spray or aerosol for inhalation or ingestible solution,
or parenterally in which the pharmaceutical composition is
formulated by an injectable form, for delivery by, for example, an
intravenous, intramuscular or subcutaneous route. Alternatively,
the formulation may be designed to be delivered by multiple
routes.
The combination of a compound according to any embodiment described
herein, and an antibody or antibody fragment molecule can be
formulated and administered by any of a number of routes and are
administered at a concentration that is therapeutically effective
in the indication or for the purpose sought. To accomplish this
goal, the antibodies may be formulated using a variety of
acceptable excipients known in the art. Typically, the antibodies
are administered by injection, for example, intravenous injection.
Methods to accomplish this administration are known to those of
ordinary skill in the art. For example, Gokarn et al., 2008, J
Pharm Sci 97(8):3051-3066, incorporated herein by reference,
describe various high concentration antibody self buffered
formulations. For example, monoclonal antibodies in self buffered
formulation at e.g., 50 mg/mL mAb in 5.25% sorbitol, pH 5.0; or 60
mg/mL mAb in 5% sorbitol, 0.01% polysorbate 20, pH 5.2; or
conventional buffered formulations, for example, 50 mg/mL mAb1 in
5.25% sorbitol, 25 or 50 mM acetate, glutamate or succinate, at pH
5.0; or 60 mg/mL in 10 mM acetate or glutamate, 5.25% sorbitol,
0.01% polysorbate 20, pH 5.2; other lower concentration
formulations can be employed as known in the art.
Because some compounds of the disclosure cross the blood brain
barrier they can be administered by a variety of methods including
for example systemic (e.g., by iv, SC, oral, mucosal, transdermal
route) or localized methods (e.g., intracranially). Where the
compound according to any embodiment described herein, is to be
delivered mucosally through the gastrointestinal mucosa, it should
be able to remain stable during transit though the gastrointestinal
tract; for example, it should be resistant to proteolytic
degradation, stable at acid pH and resistant to the detergent
effects of bile. For example, compounds according to any embodiment
described herein, prepared for oral administration may be coated
with an enteric coating layer. The enteric coating layer material
may be dispersed or dissolved in either water or in a suitable
organic solvent. As enteric coating layer polymers, one or more,
separately or in combination, of the following can be used; e.g.,
solutions or dispersions of methacrylic acid copolymers, cellulose
acetate phthalate, cellulose acetate butyrate, hydroxypropyl
methylcellulose phthalate, hydroxypropyl methylcellulose acetate
succinate, polyvinyl acetate phthalate, cellulose acetate
trimellitate, carboxymethylethylcellulose, shellac or other
suitable enteric coating layer polymer(s). In some embodiments, the
aqueous enteric coating layer is a methacrylic acid copolymer.
Where appropriate, the pharmaceutical compositions according to any
embodiment described herein, can be administered by inhalation, by
use of a skin patch, orally in the form of tablets containing
excipients such as starch or lactose, or in capsules or ovules
either alone or in admixture with excipients, or in the form of
elixirs, solutions or suspensions containing flavoring or coloring
agents, or they can be injected parenterally, for example
intravenously, intramuscularly or subcutaneously. For buccal or
sublingual administration the pharmaceutical compositions according
to any embodiment described herein, may be administered in the form
of tablets or lozenges, which can be formulated in a conventional
manner.
Where the pharmaceutical composition according to any embodiment
described herein, is to be administered parenterally, such
administration includes without limitation: intravenously,
intraarterially, intrathecally, intraventricularly, intracranially,
intramuscularly or subcutaneously administering the compound of the
disclosure; and/or by using infusion techniques. Antibodies or
fragments are typically administered parenterally, for example,
intravenously.
Pharmaceutical compositions according to any embodiment described
herein, suitable for injection or infusion may be in the form of a
sterile aqueous solution, a dispersion or a sterile powder that
contains the active ingredient, adjusted, if necessary, for
preparation of such a sterile solution or dispersion suitable for
infusion or injection. This preparation may optionally be
encapsulated into liposomes. In all cases, the final preparation
must be sterile, liquid, and stable under production and storage
conditions. To improve storage stability, such preparations may
also contain a preservative to prevent the growth of
microorganisms. Prevention of the action of micro-organisms can be
achieved by the addition of various antibacterial and antifungal
agents, e.g., paraben, chlorobutanol, or acsorbic acid. In many
cases isotonic substances are recommended, e.g., sugars, buffers
and sodium chloride to assure osmotic pressure similar to those of
body fluids, particularly blood. Prolonged absorption of such
injectable mixtures can be achieved by introduction of
absorption-delaying agents, such as aluminum monostearate or
gelatin.
Dispersions can be prepared in a liquid carrier or intermediate,
such as glycerin, liquid polyethylene glycols, triacetin oils, and
mixtures thereof. The liquid carrier or intermediate can be a
solvent or liquid dispersive medium that contains, for example,
water, ethanol, a polyol (e.g., glycerol, propylene glycol or the
like), vegetable oils, non-toxic glycerine esters and suitable
mixtures thereof. Suitable flowability may be maintained, by
generation of liposomes, administration of a suitable particle size
in the case of dispersions, or by the addition of surfactants.
For parenteral administration, the compound according to any
embodiment described herein, is best used in the form of a sterile
aqueous solution which may contain other substances, for example,
enough salts or glucose to make the solution isotonic with blood.
The aqueous solutions should be suitably buffered (preferably to a
pH of from 3 to 9), if necessary. The preparation of suitable
parenteral formulations under sterile conditions is readily
accomplished by standard pharmaceutical techniques well-known to
those skilled in the art.
Sterile injectable solutions can be prepared by mixing a compound
according to any embodiment described herein, with an appropriate
solvent and one or more of the aforementioned carriers, followed by
sterile filtering. In the case of sterile powders suitable for use
in the preparation of sterile injectable solutions, preferable
preparation methods include drying in vacuum and lyophilization,
which provide powdery mixtures of the compounds and desired
excipients for subsequent preparation of sterile solutions.
The compounds according to any embodiment described herein, may be
formulated for use in human or veterinary medicine by injection
(e.g., by intravenous bolus injection or infusion or via
intramuscular, subcutaneous or intrathecal routes) and may be
presented in unit dose form, in ampoules, or other unit-dose
containers, or in multi-dose containers, if necessary with an added
preservative. The pharmaceutical compositions for injection may be
in the form of suspensions, solutions, or emulsions, in oily or
aqueous vehicles, and may contain formulatory agents such as
suspending, stabilizing, solubilizing and/or dispersing agents.
Alternatively the active ingredient may be in sterile powder form
for reconstitution with a suitable vehicle, e.g., sterile,
pyrogen-free water, before use.
The compounds according to any embodiment described herein, can be
administered in the form of tablets, capsules, troches, ovules,
elixirs, solutions or suspensions, for immediate-, delayed-,
modified-, sustained-, pulsed- or controlled-release
applications.
The compounds according to any embodiment described herein, may
also be presented for human or veterinary use in a form suitable
for oral or buccal administration, for example in the form of
solutions, gels, syrups, or suspensions, or a dry powder for
reconstitution with water or other suitable vehicle before use.
Solid pharmaceutical compositions such as tablets, capsules,
lozenges, troches, pastilles, pills, boluses, powder, pastes,
granules, bullets or premix preparations may also be used. Solid
and liquid pharmaceutical compositions for oral use may be prepared
according to methods well-known in the art. Such pharmaceutical
compositions may also contain one or more pharmaceutically
acceptable carriers and excipients which may be in solid or liquid
form.
The tablets may contain excipients such as microcrystalline
cellulose, lactose, sodium citrate, calcium carbonate, dibasic
calcium phosphate and glycine, disintegrants such as starch
(preferably corn, potato or tapioca starch), sodium starch
glycolate, croscarmellose sodium and certain complex silicates, and
granulation binders such as polyvinylpyrrolidone,
hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC),
sucrose, gelatin and acacia.
Additionally, lubricating agents such as magnesium stearate,
stearic acid, glyceryl behenate and talc may be included.
The pharmaceutical compositions according to any embodiment
described herein, may be administered orally, in the form of rapid
or controlled release tablets, microparticles, mini tablets,
capsules, sachets, and oral solutions or suspensions, or powders
for the preparation thereof. Oral preparations may optionally
include various standard pharmaceutical carriers and excipients,
such as binders, fillers, buffers, lubricants, glidants, dyes,
disintegrants, odorants, sweeteners, surfactants, mold release
agents, antiadhesive agents and coatings. Some excipients may have
multiple roles in the pharmaceutical compositions, e.g., act as
both binders and disintegrants.
Examples of pharmaceutically acceptable disintegrants for oral
pharmaceutical compositions according to any embodiment described
herein, include, but are not limited to, starch, pre-gelatinized
starch, sodium starch glycolate, sodium carboxymethylcellulose,
croscarmellose sodium, microcrystalline cellulose, alginates,
resins, surfactants, effervescent compositions, aqueous aluminum
silicates and cross-linked polyvinylpyrrolidone.
Examples of pharmaceutically acceptable binders for oral
pharmaceutical compositions according to any embodiment described
herein, include, but are not limited to, acacia; cellulose
derivatives, such as methylcellulose, carboxymethylcellulose,
hydroxypropylmethylcellulose, hydroxypropylcellulose or
hydroxyethylcellulose; gelatin, glucose, dextrose, xylitol,
polymethacrylates, polyvinylpyrrolidone, sorbitol, starch,
pre-gelatinized starch, tragacanth, xanthine resin, alginates,
magnesium.quadrature.aluminum silicate, polyethylene glycol or
bentonite.
Examples of pharmaceutically acceptable fillers for oral
pharmaceutical compositions according to any embodiment described
herein, include, but are not limited to, lactose, anhydrolactose,
lactose monohydrate, sucrose, dextrose, mannitol, sorbitol, starch,
cellulose (particularly microcrystalline cellulose), dihydro- or
anhydro-calcium phosphate, calcium carbonate and calcium
sulphate.
Examples of pharmaceutically acceptable lubricants useful in the
pharmaceutical compositions according to any embodiment described
herein, include, but are not limited to, magnesium stearate, talc,
polyethylene glycol, polymers of ethylene oxide, sodium lauryl
sulphate, magnesium lauryl sulphate, sodium oleate, sodium stearyl
fumarate, and colloidal silicon dioxide.
Examples of suitable pharmaceutically acceptable odorants for the
oral pharmaceutical compositions according to any embodiment
described herein, include, but are not limited to, synthetic aromas
and natural aromatic oils such as extracts of oils, flowers, fruits
(e.g., banana, apple, sour cherry, peach) and combinations thereof,
and similar aromas. Their use depends on many factors, the most
important being the organoleptic acceptability for the population
that will be taking the pharmaceutical compositions.
Examples of suitable pharmaceutically acceptable dyes for the oral
pharmaceutical compositions according to any embodiment described
herein, include, but are not limited to, synthetic and natural dyes
such as titanium dioxide, beta-carotene and extracts of grapefruit
peel.
Examples of useful pharmaceutically acceptable coatings for the
oral pharmaceutical compositions according to any embodiment
described herein, typically used to facilitate swallowing, modify
the release properties, improve the appearance, and/or mask the
taste of the pharmaceutical compositions include, but are not
limited to, hydroxypropylmethylcellulose, hydroxypropylcellulose
and acrylate-methacrylate copolymers.
Suitable examples of pharmaceutically acceptable sweeteners for the
oral pharmaceutical compositions according to any embodiment
described herein, include, but are not limited to, aspartame,
saccharin, saccharin sodium, sodium cyclamate, xylitol, mannitol,
sorbitol, lactose and sucrose.
Suitable examples of pharmaceutically acceptable buffers include,
but are not limited to, citric acid, sodium citrate, sodium
bicarbonate, dibasic sodium phosphate, magnesium oxide, calcium
carbonate and magnesium hydroxide.
Suitable examples of pharmaceutically acceptable surfactants
include, but are not limited to, sodium lauryl sulphate and
polysorbates.
Solid compositions of a similar type may also be employed as
fillers in gelatin capsules. Preferred excipients in this regard
include lactose, starch, a cellulose, milk sugar or high molecular
weight polyethylene glycols. For aqueous suspensions and/or
elixirs, the agent may be combined with various sweetening or
flavoring agents, coloring matter or dyes, with emulsifying and/or
suspending agents and with diluents such as water, ethanol,
propylene glycol and glycerin, and combinations thereof.
As indicated, a compounds according to any embodiment described
herein, can be administered intranasally or by inhalation and is
conveniently delivered in the form of a dry powder inhaler or an
aerosol spray presentation from a pressurized container, pump,
spray or nebulizer with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, a hydrofluoroalkane such as
1,1,1,2-tetrafluoroethane (HFA 134AT) or
1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA), carbon dioxide or
other suitable gas. In the case of a pressurized aerosol, the
dosage unit may be determined by providing a valve to deliver a
metered amount. The pressurized container, pump, spray or nebulizer
may contain a solution or suspension of the active compound, e.g.,
using a mixture of ethanol and the propellant as the solvent, which
may additionally contain a lubricant, e.g., sorbitan trioleate.
Capsules and cartridges (made, for example, from gelatin) for use
in an inhaler or insufflator may be formulated to contain a powder
mix of a compound according to any embodiment described herein, and
a suitable powder base such as lactose or starch.
For topical administration by inhalation a compounds according to
any embodiment described herein, may be delivered for use in human
or veterinary medicine via a nebulizer.
The pharmaceutical compositions of the disclosure may contain from
0.01 to 99% weight per volume of the active material. For topical
administration, for example, the pharmaceutical composition will
generally contain from 0.01-10%, more preferably 0.01-1% of the
active material.
A compound according to any embodiment described herein, can also
be administered in the form of liposome delivery systems, such as
small unilamellar vesicles, large unilamellar vesicles and
multilamellar vesicles. Liposomes can be formed from a variety of
phospholipids, such as cholesterol, stearylamine or
phosphatidylcholines.
The pharmaceutical composition or unit dosage form, according to
any embodiment described herein, may be administered according to a
dosage and administration regimen defined by routine testing in the
light of the guidelines given above in order to obtain optimal
activity while minimizing toxicity or side effects for a particular
patient. The dosage of the compounds or unit dosage form may vary
according to a variety of factors such as underlying disease
conditions, the individual's condition, weight, sex and age, and
the mode of administration. The exact amount to be administered to
a patient will vary depending on the state and severity of the
disorder and the physical condition of the patient. A measurable
amelioration of any symptom or parameter can be determined by a
person skilled in the art or reported by the patient to the
physician. It will be understood that any clinically or
statistically significant attenuation or amelioration of any
symptom or parameter is within the scope of the disclosure.
Clinically significant attenuation or amelioration means
perceptible to the patient and/or to the physician.
In some embodiments, the amount of the compound to be administered
can range between about 0.01 and about 25 mg/kg/day. Generally,
dosage levels of between 0.01 to 25 mg/kg of body weight daily are
administered to the patient, e.g., humans. In some embodiments the
therapeutically effective amount is between a lower limit of about
0.01 mg/kg of body weight, about 0.1 mg/kg of body weight, about
0.2 mg/kg of body weight, about 0.3 mg/kg of body weight, about 0.4
mg/kg of body weight, about 0.5 mg/kg of body weight, about 0.60
mg/kg of body weight, about 0.70 mg/kg of body weight, about 0.80
mg/kg of body weight, about 0.90 mg/kg of body weight, about 1
mg/kg of body weight, about 2.5 mg/kg of body weight, about 5 mg/kg
of body weight, about 7.5 mg/kg of body weight, about 10 mg/kg of
body weight, about 12.5 mg/kg of body weight, about 15 mg/kg of
body weight, about 17.5 mg/kg of body weight, about 20 mg/kg of
body weight, about 22.5 mg/kg of body weight, and about 25 mg/kg of
body weight; and an upper limit of 25 mg/kg of body weight, about
22.5 mg/kg of body weight, about 20 mg/kg of body weight, about
17.5 mg/kg of body weight, about 15 mg/kg of body weight, about
12.5 mg/kg of body weight, about 10 mg/kg of body weight, about 7.5
mg/kg of body weight, about 5 mg/kg of body weight, about 2.5 mg/kg
of body weight, about 1 mg/kg of body weight, about 0.9 mg/kg of
body weight, about 0.8 mg/kg of body weight, about 0.7 mg/kg of
body weight, about 0.6 mg/kg of body weight, about 0.5 mg/kg of
body weight, about 0.4 mg/kg of body weight, about 0.3 mg/kg of
body weight, about 0.2 mg/kg of body weight, about 0.1 mg/kg of
body weight, and about 0.01 mg/kg of body weight. In some
embodiments, the therapeutically effective amount is about 0.1
mg/kg/day to about 10 mg/kg/day; in some embodiments the
therapeutically effective amount is about 0.2 and about 5
mg/kg/day. It will be understood that the pharmaceutical
formulations of the disclosure need not necessarily contain the
entire amount of the compound that is effective in treating the
disorder, as such effective amounts can be reached by
administration of a plurality of divided doses of such
pharmaceutical formulations. The compounds may be administered on a
regimen of 1 to 4 times per day, such as once, twice, three times
or four times per day.
In some embodiments of the disclosure, a compound according to any
embodiment described herein, is formulated in capsules or tablets,
usually containing about 10 to about 200 mg of the compounds. In
some embodiments the capsule or tablet contains between a lower
limit of about 10 mg, about 15 mg, about 20 mg, about 25 mg, about
30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55
mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80
mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105
mg, about 110 mg, about 115 mg; about 120 mg, about 125 mg, about
130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg,
about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175
mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, and
about 200 mg, and an upper limit of about 200 mg, about 195 mg,
about 190 mg, about 185 mg, about 180 mg, about 175 mg, about 170
mg, about 165 mg, about 160 mg, about 155 mg, about 150 mg, about
145 mg, about 140 mg, about 135 mg, about 130 mg, about 125 mg,
about 120 mg, about 115 mg, about 110 mg, about 105 mg, about 100
mg, about 95 mg, about 90 mg; about 85 mg, about 80 mg, about 75
mg, about 70 mg, about 65 mg, about 60 mg, about 55 mg, about 50
mg, about 45 mg, about 40 mg, about 35 mg, about 30 mg, about 25
mg, about 20 mg, about 15 mg, and about 10 mg of a compound
according to any embodiment herein.
In some embodiments, a compound according to any embodiment herein
is administered to a patient at a total daily dose of 50 mg to 500
mg. In some embodiments, the daily dose is between a lower limit of
about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg,
about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg,
about 100 mg, about 105 mg, about 110 mg, about 115 mg; about 120
mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about
145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg,
about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190
mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about
215 mg; about 220 mg, about 225 mg, about 230 mg, about 235 mg,
about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260
mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about
285 mg, about 290 mg, about 295 mg, 300 mg, about 305 mg, about 310
mg, about 315 mg; about 320 mg, about 325 mg, about 330 mg, about
335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg,
about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380
mg, about 385 mg, about 390 mg, about 395, about 400 mg, about 405
mg, about 410 mg, about 415 mg; about 420 mg, about 425 mg, about
430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg,
about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475
mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, and
about 500 mg and an upper limit of about 500 mg, about 495 mg,
about 490 mg, about 485 mg, about 480 mg, about 475 mg, about 470
mg, about 465 mg, about 460 mg, about 455 mg, about 450 mg, about
445 mg, about 440 mg, about 435 mg, about 430 mg, about 425 mg,
about 420 mg, about 415 mg, about 410 mg, about 405 mg, about 400
mg, about 395 mg, about 390 mg, about 385 mg, about 380 mg, about
375 mg, about 370 mg, about 365 mg, about 360 mg, about 355 mg,
about 350 mg, about 345 mg, about 340 mg, about 335 mg, about 330
mg, about 325 mg, about 320 mg, about 315 mg, about 310 mg, about
305 mg about 300 mg, about 295 mg, about 290 mg, about 285 mg,
about 280 mg, about 275 mg, about 270 mg, about 265 mg, about 260
mg, about 255 mg, about 250 mg, about 245 mg, about 240 mg, about
235 mg, about 230 mg, about 225 mg, about 220 mg, about 215 mg,
about 210 mg, about 205 mg 200 mg, about 195 mg, about 190 mg,
about 185 mg, about 180 mg, about 175 mg, about 170 mg, about 165
mg, about 160 mg, about 155 mg, about 150 mg, about 145 mg, about
140 mg, about 135 mg, about 130 mg, about 125 mg, about 120 mg,
about 115 mg, about 110 mg, about 105 mg, about 100 mg, about 95
mg, about 90 mg; about 85 mg, about 80 mg, about 75 mg, about 70
mg, about 65 mg, about 60 mg, about 55 mg, and about 50 mg of a
compound according to any embodiment herein. In some embodiments,
the total daily dose is about 50 mg to 150 mg. In some embodiments,
the total daily dose is about 50 mg to 250 mg. In some embodiments,
the total daily dose is about 50 mg to 350 mg. In some embodiments,
the total daily dose is about 50 mg to 450 mg. In some embodiments,
the total daily dose is about 50 mg.
A pharmaceutical composition for parenteral administration contains
from about 0.01% to about 100% by weight of the active compound
according to any embodiment described herein, based upon 100%
weight of total pharmaceutical composition.
Generally, transdermal dosage forms contain from about 0.01% to
about 100% by weight of the active compound according to any
embodiment described herein, versus 100% total weight of the dosage
form.
The pharmaceutical composition or unit dosage form may be
administered in a single daily dose, or the total daily dosage may
be administered in divided doses. In addition, co administration or
sequential administration of another compound for the treatment of
the disorder may be desirable. To this purpose, the combined active
principles are formulated into a simple dosage unit.
Compounds according to any embodiment described herein, may be
prepared by the general methods outlined in, for example,
WO2013/029057, incorporated herein by reference, or as described
hereinafter, said methods constituting a further aspect of the
disclosure.
Compounds according to any embodiment disclosed herein can be
synthesized in accordance with general methods provided herein and
specific synthetic examples.
It will be appreciated by those skilled in the art that it may be
desirable to use protected derivatives of intermediates used in the
preparation of the compounds according to any embodiment described
herein. Protection and deprotection of functional groups may be
performed by methods known in the art (see, for example, Green and
Wuts Protective Groups in Organic Synthesis. John Wiley and Sons,
New York, 1999.). Hydroxy or amino groups may be protected with any
hydroxy or amino protecting group. The amino protecting groups may
be removed by conventional techniques. For example, acyl groups,
such as alkanoyl, alkoxycarbonyl and aroyl groups, may be removed
by solvolysis, e.g., by hydrolysis under acidic or basic
conditions. Arylmethoxycarbonyl groups (e.g., benzyloxycarbonyl)
may be cleaved by hydrogenolysis in the presence of a catalyst such
as palladium-on-charcoal.
The synthesis of the target compounds is completed by removing any
protecting groups which may be present in the penultimate
intermediates using standard techniques, which are well-known to
those skilled in the art. The deprotected final products are then
purified, as necessary, using standard techniques such as silica
gel chromatography, HPLC on silica gel and the like, or by
recrystallization.
Methods of Use
In some embodiments, the disclosure provides methods of inhibiting
synapse number decline or membrane trafficking abnormalities
associated with exposure of a neuronal cell to Abeta species by
administration of a compound according to any embodiment described
herein.
In some embodiments the disclosure also provides methods for
treating cognitive decline and/or a neurodegenerative disease, e.g.
Alzheimer's disease or mild cognitive impairment (MCI) in a patient
comprising administering to the patient a compound according to any
embodiment described herein.
In some embodiments, the neurodegenerative disease is selected from
Age-Associated Memory Impairment (AAMI), Age-Related Cognitive
Decline (ARCD), agitation synucleinopathies, Alzheimer's disease
(AD), Amyotrophic lateral sclerosis (ALS) dementia,
autosomal-dominant Parkinson's disease, Cognitive Impairment No
Dementia (CIND), dementia, Diffuse Lewy Body Disease (DLBD) also
known as Dementia with Lewy Bodies (DLB), disorders or conditions
characterized by the presence of Lewy bodies, Down syndrome,
dyskinesia, HIV dementia, Huntington's disease, Incidental LBD,
Inherited LBD, Lewy body dysphagia, Mild Cognitive Impairment
(MCI), multiple sclerosis, multiple system atrophy (MSA),
Olivopontocerebellar Atrophy, Parkinson's disease (PD), preclinical
Alzheimer's Disease (PCAD), Psychosis, Pure Autonomic Failure,
Shy-Drager Syndrome, Striatonigral Degeneration, synucleinopathies,
combined Alzheimer's and Parkinson disease and/or MSA, vascular
dementia, diseases, disorders or conditions associated with
abnormal expression, stability, activities and/or cellular
processing of .alpha.-synuclein, diseases, disorders or conditions
characterized by the presence of Lewy bodies, and combinations
thereof.
In some embodiments, the method of inhibiting, or treating,
cognitive decline and/or a neurodegenerative disease, e.g.
Alzheimer's disease, comprises inhibiting, or treating one or more
symptoms of cognitive decline selected from the group consisting of
memory loss, confusion, impaired judgment, personality changes,
disorientation, and loss of language skills. In some embodiments,
the method comprises inhibiting, or treating, diseases or disorders
or conditions mediated by or associated with Abeta oligomers.
In some embodiments, the method of inhibiting, or treating,
cognitive decline and/or a neurodegenerative disease, e.g.
Alzheimer's disease, comprises one or more of: (i) restoration of
long term potentiation (LTP), long term depression (LTD) or
synaptic plasticity detectable by electrophysiological measurements
or any of the other negative changes in cognitive function as
mentioned in the definition of the term above; and/or (ii)
inhibiting, or treating, neurodegeneration; and/or (iii)
inhibiting, or treating, general amyloidosis; and/or (iv)
inhibiting, or treating, one or more of amyloid production, amyloid
assembly, amyloid aggregation, and amyloid oligomer binding, and
amyloid deposition; and/or (v) inhibiting, treating, and/or abating
an effect, notably a nonlethal effect, of one or more of Abeta
oligomers on a neuron cell.
In some embodiments, the method of inhibiting, treating, and/or
abating cognitive decline and/or a neurodegenerative disease, e.g.
Alzheimer's disease, comprises inhibiting, treating, and/or abating
one or more of amyloid production, amyloid assembly, the
activity/effect of one or more of Abeta oligomers on a neuron cell,
amyloid aggregation, amyloid binding, and amyloid deposition.
In some embodiments, the method of inhibiting, treating, and/or
abating cognitive decline and/or a neurodegenerative disease, e.g.
Alzheimer's disease, comprises inhibiting, treating, and/or abating
one or more of the activity/effect of one or more of Abeta
oligomers on a neuron cell.
In some embodiments, the activity/effect of one or more of Abeta
oligomers on a neuron cell, amyloid aggregation and amyloid binding
is the effect of Abeta oligomers on membrane trafficking or synapse
number. In some embodiments, a compound according to any embodiment
described herein, inhibits the Abeta oligomer effect on membrane
trafficking or synapse number or Abeta oligomer binding.
In some embodiments, the disclosure provides methods of treating a
proteopathic disease associated with Abeta oligomer toxicity,
specifically nonlethal Abeta oligomer effects. In some embodiments,
the method comprises contacting a subject with such a proteopathic
disease with a compound according to any embodiment described
herein, or a pharmaceutical composition containing the same that
binds the sigma-2 receptor.
In some embodiments, the proteopathic disease is a CNS proteopathy,
characterized by an increase in Abeta protein, such as MCI, Down's
Syndrome, macular degeneration or Alzheimer's disease, and the
like.
In some embodiments, the disclosure provides methods of treating
one or more mild cognitive impairment (MCI), or dementia by
administering a compound according to any embodiment described
herein. In some embodiments, the disclosure provides methods of
treating MCI, and dementia.
In some embodiments, the disclosure provides methods of treating
Alzheimer's Disease by administering a compound according to any
embodiment described herein.
In some embodiments, the disclosure provides methods of treating an
individual with a compound according to any embodiment described
herein, to restore, partially or totally, the subject's cells to a
normal phenotype in terms of functions affected adversely by Abeta
species, such as Abeta oligomers. Examples are synaptic number
reduction and membrane trafficking abnormalities, which can be
measured by various methods including assays described herein. The
normal phenotype can be, for example, normal membrane trafficking.
In some embodiments, the normal phenotype is normal cognitive
ability. The "normal" phenotype can be determined by comparing a
subject's results with a sample of normal subjects. The sample may
be as small as 1 subject or 1 sample or may be more than 10 samples
or subjects and the norm is an average that is calculated based
upon a plurality of subjects.
In some embodiments, a compound according to any embodiment
described herein, generally inhibits the Abeta effect on neurons.
In some embodiments, the compounds describe above have an IC.sub.50
for inhibition of Abeta effect of less than about 100 .mu.M, about
50 .mu.M, about 20 .mu.M, about 15 .mu.M, about 10 .mu.M, about 5
.mu.M, about 1 .mu.M, about 500 nM, about 100 nM, about 50 nM, or
about 10 nM on neurons (such as neurons in the brain), amyloid
assembly or disruption thereof, and amyloid (including amyloid
oligomer) binding, and amyloid deposition. In some embodiments, a
compound according to any embodiment described herein, may have an
IC.sub.50 for inhibition of the activity/effect of Abeta species
such as oligomers of less than about 100 .mu.M, about 50 .mu.M,
about 20 .mu.M, about 15 .mu.M, about 10 .mu.M, about 5 .mu.M,
about 1 .mu.M, about 500 nM, about 100 nM, about 50 nM, or about 10
nM on neurons (such as central nervous system neurons).
A compound according to any embodiment described herein, may
inhibit the Abeta effect by specifically binding to a sigma-2
receptor. A compound can be said to be "specific" for a sigma-2
receptor when it binds with a binding affinity that is at least 10%
greater than to the sigma-1 receptor, even though the compound is
capable of binding both sigma-1 and sigma-2 receptor. The compounds
of such embodiments may exhibit a specificity of at least 10%, 20%,
30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, or
1000% greater for sigma-2 receptor than sigma-1 receptor.
In some embodiments, percentage inhibition by a compound according
to any embodiment described herein, of one or more of the effects
of Abeta species such as oligomers on neurons (such as neurons in
the brain), such as amyloid (including amyloid oligomer) binding to
synapses, and abnormalities in membrane trafficking mediated by
Abeta oligomer can be about 1% to about 20%, about 20% to about
50%, about 1% to about 50%, or about 1% to about 80% as measured at
a concentration of from 10 nM to 10 .mu.M. Inhibition can be
assessed for example by quantifying synapse number of a neuron
prior to and after exposure to an amyloid beta species or
quantifying the number of synapses in the presence of both of the
compound according to any embodiment described herein, and the
Abeta species wherein the compound according to any embodiment
described herein, is simultaneous with, or precedes or follows,
Abeta species exposure. As another example, inhibition can be
assessed by determining membrane trafficking and comparing one or
more parameters that measure exocytosis rate and extent,
endocytosis rate and extent, or other indicators of cell metabolism
in the presence and absence of an Abeta species and in the presence
and absence of a compound according to any embodiment described
herein.
In some embodiments, the disclosure provides methods of measuring
beta-amyloid-associated cognitive decline in an animal using a
labeled compound according to any embodiment described herein. In
some embodiments, the method comprises contacting the animal with a
labeled compound according to any embodiment described herein, and
measuring sigma-2 activity or expression. In some embodiments, the
method comprises comparing the sigma-2 activity or expression in
the animal with an animal known to have beta-amyloid induced
cognitive decline. If the activity or expression is the same as the
animal known to have beta-amyloid induced cognitive decline the
animal is said to have the same level of cognitive decline. The
animals can be ranked according the similarities in known activity
or expression of various stages of beta amyloid induced cognitive
decline. Any of the a compound according to any embodiment
described herein, can be labeled so that the labeled compound can
be used in vivo.
In some embodiments, an assay is used to determine if a compound
according to any embodiment described herein, can bind to a sigma-2
receptor. In some embodiments, the method further comprises
determining whether the compound that binds to a sigma-2 receptor
acts as a functional antagonist at a sigma-2 receptor by inhibiting
soluble A.beta. oligomer induced neurotoxicity with respect to
inhibiting soluble A.beta. oligomer induced synapse loss, and
inhibiting soluble A.beta. oligomer induced deficits in a membrane
trafficking assay.
Any form of amyloid .beta. may be used in the practice of the
screening methods and of the assays according to the disclosure,
including amyloid .beta. monomers, oligomers, fibrils, as well as
amyloid .beta. associated with proteins ("protein complexes") and
more generally amyloid .beta. assemblies. For example, screening
methods can employ various forms of soluble amyloid .beta.
oligomers as disclosed, for example, in U.S. patent application
Ser. No. 13/021,872; U.S. Patent Publication 2010/0240868;
International Patent Application WO/2004/067561; International
Patent Application WO/2010/011947; U.S. Patent Publication
20070098721; U.S. Patent Publication 20100209346; International
Patent Application WO/2007/005359; U.S. Patent Publication
20080044356; U.S. Patent Publication 20070218491; WO/2007/126473;
U.S. Patent Publication 20050074763; International Patent
Application WO/2007/126473, International Patent Application
WO/2009/048631, and U.S. Patent Publication 20080044406, U.S. Pat.
Nos. 7,902,328 and 6,218,506, each of which is incorporated herein
by reference.
Amyloid .beta. forms, including monomers or oligomers of amyloid
.beta. may be obtained from any source. For example, in some
embodiments, commercially available amyloid .beta. monomers and/or
amyloid .beta. oligomers may be used in the aqueous solution, and
in other embodiments, amyloid .beta. monomers and/or amyloid .beta.
oligomers that are used in the aqueous protein solution can be
isolated and purified by the skilled artisan using any number of
known techniques. In general, the amyloid .beta. monomers and/or
amyloid .beta. oligomers used in the preparation of the aqueous
solution of proteins and amyloid .beta. of various embodiments may
be soluble in the aqueous solution. Therefore, both the proteins of
the aqueous solution and the amyloid .beta. may be soluble.
The amyloid .beta. added may be of any isoform. For example, in
some embodiments, the amyloid .beta. monomers may be amyloid .beta.
1-42, and in other embodiments the amyloid .beta. monomers may be
amyloid .beta. 1-40. In still other embodiments, the amyloid .beta.
may be amyloid .beta. 1-39 or amyloid .beta. 1-41. Hence, the
amyloid .beta. of various embodiments may encompass any C-terminal
isoform of amyloid .beta.. Yet other embodiments include amyloid
.beta. in which the N-terminus has been frayed, and in some
embodiments, the N-terminus of any of amyloid .beta. C-terminal
isomers described above may be amino acid 2, 3, 4, 5, or 6. For
example, amyloid .beta. 1-42 may encompass amyloid .beta. 2-42,
amyloid .beta. 3-42, amyloid .beta. 4-42, or amyloid .beta. 5-42
and mixtures thereof, and similarly, amyloid .beta. 1-40 may
encompass amyloid .beta. 2-40, amyloid .beta. 3-40, amyloid .beta.
4-40, or amyloid .beta. 5-40.
The amyloid .beta. forms used in various embodiments may be wild
type, i.e. having an amino acid sequence that is identical to the
amino acid sequence of amyloid .beta. synthesized in vivo by the
majority of the population, or in some embodiments, the amyloid
.beta. may be a mutant amyloid .beta.. Embodiments are not limited
to any particular variety of mutant amyloid .beta.. For example, in
some embodiments, the amyloid .beta. introduced into the aqueous
solution may include a known mutation, such as, for example,
amyloid .beta. having the "Dutch" (E22Q) mutation or the "Arctic"
(E22G) mutation. Such mutated monomers may include naturally
occurring mutations such as, for example, forms of amyloid .beta.
isolated from populations of individuals that are predisposed to,
for example, Alzheimer's disease, familial forms of amyloid .beta..
In other embodiments, mutant amyloid .beta. monomers may be
synthetically produced by using molecular techniques to produce an
amyloid .beta. mutant with a specific mutation. In still other
embodiments, mutant amyloid .beta. monomers may include previously
unidentified mutations such as, for example, those mutants found in
randomly generated amyloid .beta. mutants. The term "amyloid
.beta." as used herein, is meant to encompass both wild type forms
of amyloid .beta. as well as any of the mutant forms of amyloid
.beta..
In some embodiments, the amyloid .beta. in the aqueous protein
solution may be of a single isoform. In other embodiments, various
C-terminal isoforms of amyloid .beta. and/or various N-terminal
isoforms of amyloid .beta. may be combined to form amyloid .beta.
mixtures that can be provided in the aqueous protein solution. In
yet other embodiments, the amyloid .beta. may be derived from
amyloid precursor protein (APP) that is added to the protein
containing aqueous solution and is cleaved in situ, and such
embodiments, various isoforms of amyloid .beta. may be contained
within the solution. Fraying of the N-terminus and/or removal of
C-terminal amino acids may occur within the aqueous solution after
amyloid .beta. has been added. Therefore, aqueous solutions
prepared as described herein, may include a variety of amyloid
.beta. isoforms even when a single isoform is initially added to
the solution.
The amyloid .beta. monomers added to the aqueous solution may be
isolated from a natural source such as living tissue, and in other
embodiments, the amyloid .beta. may be derived from a synthetic
source such as transgenic mice or cultured cells. In some
embodiments, the amyloid .beta. forms, including monomers,
oligomers, or combinations thereof are isolated from normal
subjects and/or patients that have been diagnosed with cognitive
decline or diseases associated therewith, such as, but not limited
to, Alzheimer's disease. In some embodiments, the amyloid .beta.
monomers, oligomers, or combinations thereof are Abeta assemblies
that have been isolated from normal subjects or diseased patients.
In some embodiments, the Abeta assemblies are high molecular
weight, e.g. greater than 100 KDa. In some embodiments, the Abeta
assemblies are intermediate molecular weight, e.g. 10 to 100 KDa.
In some embodiments, the Abeta assemblies are less than 10 kDa.
The amyloid .beta. oligomers of some embodiments may be composed of
any number of amyloid .beta. monomers consistent with the commonly
used definition of "oligomer." For example, in some embodiments,
amyloid .beta. oligomers may include from about 2 to about 300,
about 2 to about 250, about 2 to about 200 amyloid .beta. monomers,
and in other embodiments, amyloid .beta. oligomers may be composed
from about 2 to about 150, about 2 to about 100, about 2 to about
50, or about 2 to about 25, amyloid .beta. monomers. In some
embodiments, the amyloid .beta. oligomers may include 2 or more
monomers. The amyloid .beta. oligomers of various embodiments may
be distinguished from amyloid .beta. fibrils and amyloid .beta.
protofibrils based on the confirmation of the monomers. In
particular, the amyloid .beta. monomers of amyloid .beta. oligomers
are generally globular consisting of .beta.-pleated sheets whereas
secondary structure of the amyloid .beta. monomers of fibrils and
protofibrils is parallel .beta.-sheets.
EXAMPLES
Examples 1 and 2 describe Abeta oligomer preparations that could be
used for experiments described below. The particular preparations
used in the membrane trafficking and oligomer bindin/synapse
reduction assays as well as those used in the in vivo assays
described below are each described in the example to which they
pertain.
Example 1: Preparation of Amyloid .beta. Oligomers
The conditions in which amyloid .beta. may oligomerize in nervous
tissue, a milieu of aqueous-soluble proteins with which it may
associate, were re-created to identify the more disease-relevant
structural state of amyloid .beta. oligomers and fibrils. Aqueous
soluble proteins were prepared from rat brain by
ultracentrifugation. Specifically, 5 volumes of TBS buffer (20 mM
Tris-HCL, pH 7.5, 34 mM NaCl and a complete protease inhibitor
cocktail (Santa Cruz) per gram of brain tissue was added to the rat
brain tissue on ice. Dounce homogenization was then carried out
with a tight-fitting pestle. The homogenized brain tissues were
then centrifuged at 150,000.times.g for 1 hour at 4.degree. C.
(40,000 rpm Ty65). The infranatant (between floating myelin and a
half cm above the pellet) was then removed and aliquots were frozen
at -75.degree. C. The pellets were then resuspended in TBS to the
original volume and frozen in aliquots at -75.degree. C. Synthetic,
monomeric human amyloid .beta. 1-42 was added to this mixture to
provide a final concentration of 1.5 uM amyloid .beta., and the
solution was incubated for 24 hours at 4.degree. C. Centrifugation
of the mixture at 5,800 g for 10 minutes was performed to remove
fibrillar assemblies and then Immunoprecipitation was performed
using 6E10 conjugated agarose spin columns (Pierce Chemical
Company) for 24 hours at 4.degree. C. The eluted amyloid .beta.
oligomers were then subject to MALDI-Tof mass spectroscopic
analysis to identify the contents of the sample.
The amyloid .beta. self-associated in the protein containing
solution to form subunit assemblies of 22,599 Da, 5 subunit
pentamers and 31,950 Da, 7 subunit, 7mers. Another peak at 49,291
Da may represent 12 subunit, 12mers, although this would not appear
to be an accurate molecular weight for amyloid .beta. 12mers.
Notably, no peaks are observed at either 4518 Da or 9036 Da which
would represent amyloid .beta. monomers and dimers. However, peaks
at 9,882 Da and 14,731 Da could represent amyloid .beta. dimers
associated with a 786 Da (or 2.times.393 Da) lipids or proteins and
amyloid .beta. trimers associated with 3.times.393 Da lipids or
proteins, respectively. In addition, the presence of a peak at
19,686 Da is indicative of an assembly state possibly involving a
trimer complex and a rat amyloid .beta. fragment of 4954 Da.
Accordingly these data may reflect the association of small lipids
or proteins with dimers and trimers of amyloid .beta. which may
direct the assembly of conformational states unique to
physiological systems.
Example 2 Preparation of Beta-Amyloid Oligomers
A solution of 1.5 uM monomeric human amyloid .beta. 1-42 in a
mixture of rat brain soluble proteins was incubated for 24 hours at
4.degree. C. as described in Example 1. This solution was then
treated with tri-fluoro ethanol (TFE) prior to taking the spectra.
In TFE, assembled protein structures and non-covalently bound
protein complexes dissociate into denatured proteins, and the peaks
associated with assembled oligomers are expected to disappear. The
majority of protein peaks observed in Example 1 disappeared
including the 9822 Da, 14,731 Da, 31,950 Da, and 49,291 Da peaks
identified above. However, an abundant peak is observed at 4518 Da
which represents amyloid .beta. monomer peak. A peak at 4954.7 is
apparent which may represent a longer abeta fragment similar to
amyloid .beta. 1-46. An additional peak is observed at 7086 Da
which was not present in the preparation described in Example 1,
which may represent amyloid .beta. monomers associated with a 2550
Da covalently bound protein.
Example 3: Isolation of Beta-Amyloid Oligomers from Human AD Brain
Tissue
TBS soluble extracts: Samples of post-mortem brain tissue from
human patients characterized via histopathological analysis as
Braak Stage V/VI Alzheimer's disease (AD) were obtained from a
hospital brain tissue bank. Age and gender matched AD and normal
tissue specimens were diluted to 0.15 gm tissue/ml in 20 mM
Tris-HCL, 137 mM NaCl, pH 7.6 containing ImM EDTA and 1 mg/ml
complete protease inhibitor cocktail (Sigma P8340) and homogenized.
Ultracentrifugation of the tissue homogenates was performed at
105,000 g for 1 hour in a Beckman Optima XL-80K Ultracentrifuge.
The resulting TBS soluble fractions were immunodepleted using
protein-A and protein-G agarose columns (Pierce Chemical) and then
size fractionated with Amicon Ultra 3, 10 & 100 kDa NMWCO
filters (Millipore Corporation).
Immunoprecipitation: Size fractionated and immunodepleted TBS
soluble extracts were concentrated to approximately 200 ul in the
appropriate NMWCO Amicon Ultra filters. The concentrated TBS
soluble extracts were diluted up to 400 ul with TBS sample buffer
(Pierce Chemical) and centrifuged for 10 minutes at 5,800 g to
remove fibrils. The resulting supernatant was then
immunoprecipitated with 6E10-conjugated agarose beads overnight at
4.degree. C. followed by antigen elution using high osmotic
strength Gentle elution buffers (Pierce Chemical) to isolate Abeta
containing protein species.
MALDI-mass spectrometry: Immunoisolated beta amyloid was subjected
to mass spectroscopic analysis using an Applied Biosystems (ABI)
Voyager DE-Pro MALDI-Tof instrument. Samples were analyzed using
various matrix types such as .alpha.-Cyano-4-hydroxycinnamic acid
(CHCA), Sinapic acid (SA), or 6-Aza-2-thiothymine (ATT) depending
on the target molecular weight range of the analysis. The
instrument was run in a linear-positive ion mode along with a
variable extraction delay. Non-accumulated spectra represented 100
shots of a "hot spot" per acquisition while accumulated spectra
were represented by 12 separate areas of each spot with 200 laser
shots per acquisition.
Data analysis: Data acquisition and analysis was performed using
Voyager's Data Explorer software package. Standard processing of
the mass spectra included smoothing of the spectrum and baseline
subtraction functions in addition to variations in the signal to
noise ratio.
ELISA for Ab quantification: Immunoprecipitated TBS soluble
fractions were analyzed for both "total" Abeta and Abeta oligomer
concentration using a modified sandwich ELISA technique. Briefly,
6E10 and 4G8 coated Nunc MaxiSorp 96-well plates were incubated
with Abeta containing samples and then probed with a Biotinylated
4G8 detection antibody. Incubation with Streptavidin-HRP (Rockland)
followed by development of a Tetramethyl benzidine (TMB) substrate
allowed for colorimetric detection (OD 450) of abeta on a BioTEk
Synergy HT plate reader. Monomeric Abeta 1-42 was used for
generation of a standard curve and along with GEN 5 software
allowed for quantification of Abeta levels in the
immuno-precipitated samples.
Example 4: Receptor Binding Assays
Certain compounds were tested for interaction with several
receptors by blocking the binding or action of their agonists or
antagonists. Some compounds were tested to see whether they
interact directly with known cellular receptor or signaling
proteins. Compounds can be tested for the ability to displace
binding of known agonists or antagonists of a given human receptor
that was overexpressed in cell lines or isolated from tissue.
Compounds can also be tested for the ability to block downstream
signaling induced by agonists or antagonists of a given human
receptor. Compounds can be tested for action at 100 known
receptors, and it is desirable that specific activity will occur at
only a small subset of CNS-relevant receptors.
Using the same protocol, some compounds for which membrane
trafficking data are given in Table 1 were tested for recognition
of sigma-2 receptor. Certain compounds preferentially bind to the
sigma-2 receptor.
Competitive Radioligand Binding Assay 1
For Sigma-1 binding, various concentrations of test compounds from
100 .mu.M to 1 nM were used to displace 8 nM [3H](+)pentazocine
from endogenous receptors on Jurkat cell membranes (Ganapathy M E
et al. 1991, J Pharmacol. Exp. Ther. 289:251-260). 10 .mu.M
Haloperidol was used to define non-specific binding. For Sigma-2
receptors various concentrations of test compounds from 100 .mu.M
to 1 nM were used to displace 5 nM [3H]1,3-Di-(2-tolyl)guanidine
from endogenous receptors on membranes from rat cerebral cortex in
the presence of 300 nM (+)pentazocine to mask Sigma-1 receptors.
(Bowen W D, et al. 1993, Mol. Neuropharmcol 3:117-126). 10 .mu.M
Haloperidol was used to define non-specific binding. Reactions were
terminated by rapid filtration through Whatman GF/C filters using a
Brandel 12R cell harvester followed by two washes with ice-cold
buffer. Radioactivity on the dried filter discs was measured using
a liquid scintillation analyzer (Tri-Carb 2900TR; PerkinElmer Life
and Analytical Sciences). The displacement curves were plotted and
the Ki values of the test compounds for the receptor subtypes were
determined using GraphPad Prism (GraphPad Software Inc., San Diego,
Calif.). The percentage specific binding was determined by dividing
the difference between total bound (disintegrations per minute) and
nonspecific bound (disintegrations per minute) by the total bound
(disintegrations per minute).
Affinities for Sigma-1 and Sigma-2 receptors are typically obtained
from published studies using cerebral tissue homogenates with
[3H](+)pentazocine to measure displacement from Sigma-1 receptors
and [3H] 1,3-Di-(2-tolyl)guanidine in the presence of 300 nM
(+)pentazocine to measure displacement from Sigma-2 receptors.
Competitive Radioligand Binding Assay 2
The affinity of test compounds at sigma-1 and sigma-2 receptors was
also determined by displacement of different known labeled sigma-2
or sigma-1 ligands. Filtration assays were conducted according the
previously published procedure (Xu, et al., 2005). Test compounds
were dissolved in N,N-Dimethylformamide (DMF), dimethyl sulfoxide
(DMSO) or ethanol and then diluted in 50 mM Tris-HCl pH 7.4 buffer
containing 150 mM NaCl and 100 mM EDTA. Membrane homogenates were
made from guinea pig brain for sigma-1 binding assay and rat liver
for sigma-2 binding assay. Membrane homogenates were diluted with
50 mM Tris-HCl buffer, pH 8.0 and incubated at 25.degree. C. in a
total volume of 150 uL in 96 well plates with the radioligand and
test compounds with concentrations ranging from 0.1 nM to 10 uM.
After incubation was completed, the reactions were terminated by
the addition of 150 uL of ice-cold wash buffer (10 mM Tris HCl, 150
mM NaCl, pH 7.4) using a 96 channel transfer pipette (Fisher
Scientific, Pittsburgh, Pa.) and the samples harvested and filtered
rapidly through 96 well fiber glass filter plate (Millipore,
Billerica, Mass.) that had been presoaked with 100 uL of 50 mM
Tris-HCl buffer. Each filter was washed four times with 200 uL of
ice-cold wash buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.4). A
Wallac 1450 MicroBeta liquid scintillation counter (Perkin Elmer,
Boston, Mass.) was used to quantitate the bound radioactivity.
The sigma-1 receptor binding assays were conducted using guinea pig
brain membrane homogenates (.about.300 ug protein) and .about.5 nM
[3H](+)-pentazocine (34.9 Ci/mmol, Perkin Elmer, Boston, Mass.),
incubation time was 90 min at room temperature. Nonspecific binding
was determined from samples that contained 10 .mu.M of cold
haloperidol.
The sigma-2 receptor binding assays were conducted using rat liver
membrane homogenates (.about.300 ug protein) and .about.2 nM
sigma-2 highly selective radioligand [3H]RHM-1 only (no other
blockers) (America Radiolabeled Chemicals Inc. St. Louis, Mo.),
.about.10 nM [3H]DTG (58.1 Ci/mmol, Perkin Elmer, Boston, Mass.) or
.about.10 nM [3H]Haloperidol (America Radiolabeled Chemicals Inc.,
St. Louis, Mo.) in the presence of 1 uM (+)-pentazocine to block
sigma-1 sites, incubation times were 6 minutes for [3H]RHM-1, 120
min for [3H]DTG and [3H]haloperidol at room temperature.
Nonspecific binding was determined from samples that contained 10
uM of cold haloperidol.
Data from the competitive inhibition experiments were modeled using
nonlinear regression analysis to determine the concentration of
inhibitor that inhibits 50% of the specific binding of the
radioligand (IC.sub.50 value). The binding affinity, Ki values was
calculated using the method of Cheng and Prusoff. The Kd value used
for [3H](+)-pentazocine in guinea pig brain was 7.89 nM, for
[3H]RHM-1 and [3H]DTG in rat liver were 0.66 nM and 30.73 nM
respectively. The standard compound haloperidol was used for
quality assurance. Affinity data at the sigma-2 receptor for
exemplary compounds are shown in Table 1.
In some embodiments, compounds according to according to any
embodiment herein, or pharmaceutically acceptable salts thereof,
exhibit sigma-2 receptor binding affinity Ki of not more than 1,000
nM, not more than 750 nM, not more than 500 nM, not more than 250
nM, not more than 100 nM, not more than 50 nM, not more than 25 nM,
or not more than 10 nM, when tested according to a sigma-2 receptor
binding assay protocol provided herein.
Example 5: Inhibition of Abeta Oligomer Effect on Neuronal Cells in
Membrane Trafficking Assay
Compounds according to any embodiment described herein, were tested
for their ability to inhibit an amyloid beta effect on the cells.
The compounds generally were able to inhibit the amyloid beta
effect as measured by a membrane trafficking/exocytosis assay (MTT
assay). The results are indicated in Table 1. The rationale for
this assay was as follows:
Since synaptic and memory deficits, and not widespread cell death,
predominate at the earliest stages of Alzheimer's disease, assays
that measure these changes are particularly well suited to
discovering small molecule inhibitors of oligomer activity. The MTT
assay is frequently used as a measure of toxicity in cultures.
Yellow tetrazolium salts are endocytosed by cells and reduced to
insoluble purple formazan in the endosomal pathway. The level of
purple formazan is a reflection of the number of actively
metabolizing cells in culture, and reduction in the amount of
formazan is taken as a measure of cell death or metabolic toxicity
in culture. When observed through a microscope, the purple formazan
is first visible in intracellular vesicles that fill the cell. Over
time, the vesicles are exocytosed and the formazan precipitates as
needle-shaped crystals on the outer surface of the plasma membrane
as the insoluble formazan is exposed to the aqueous media
environment. Liu and Schubert ('97) discovered that cells respond
to sublethal levels of Abeta oligomers by selectively accelerating
the exocytosis rate of reduced formazan, while leaving endocytosis
rate unaffected. The inventors have replicated these observations
in mature primary neurons in culture and quantified these
morphological shifts via automated microscopy and image processing.
Under these circumstances, there is no overall change in the total
amount of reduced formazan, simply a shift in its morphology
reflective of changes in rate of its formation and/or expulsion
from the cell. The inventors have confirmed previous findings that
this assay is sensitive to low levels of oligomers that do not
cause cell death (Liu and Schubert '04, Hong et al., '07). Indeed,
low amounts of oligomers that lead to inhibition of LTP do not lead
to cell death (Tong et al., '04) and are not expected to change
total amounts of formazan in culture (or in brain slices).
Evidence adduced by other investigators suggests that Abeta
oligomer-mediated reduction in neuronal surface receptor expression
mediated by membrane trafficking is the basis for oligomer
inhibition of electrophysiological measures of synaptic plasticity
(LTP) and thus learning and memory (Kamenetz et al., '03, Hseih et
al., '06). Measuring membrane trafficking rate changes induced by
oligomers via formazan morphological shifts has been used in cell
lines to discover Abeta oligomer-blocking drugs (Maezawa et al.,
'06, Liu and Schubert '97, '04, '06, Rana et al., '09, Hong et al.,
'08) that lower Abeta brain levels in rodents in vivo (Hong et al.,
'09). Similar procedures for exocytosis assays/MTT assays can be
found in the literature. See e.g., Liu Y, et. al., Detecting
bioactive amyloid beta peptide species in Alzheimer's disease. J
Neurochem. 2004 November; 91(3):648-56; Liu Y, and Schubert D.
"Cytotoxic amyloid peptides inhibit cellular
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
reduction by enhancing MTT formazan exocytosis." J Neurochem. 1997
December; 69(6):2285-93; and Liu Y, and Schubert D. "Treating
Alzheimer's disease by inactivating bioactive amyloid beta peptide"
Curr. Alzheimer Res. 2006 April; 3(2):129-35. Therefore the
approach is valid.
The present exocytosis assay was adapted for use with mature
primary neuronal cultures grown for 3 weeks in vitro. See WO
2011/106785, which is incorporated herein by reference in its
entirety. Abeta oligomers cause a dose-dependent decrease in the
amount of intracellular vesicles (puncta) filled with reduced
purple formazan as measured via image processing using a Cellomics
VTI automated microscopy system. Photomicrographs for a cultured
neuronal cell exposed to vehicle alone show vesicles filled with
formazan; wherein a photomicrograph of a neuronal cell exposed to
vehicle plus Abeta oligomer shows considerably fewer vesicles
filled with formazan and instead shows exocytosed formazan which,
when encountering the extracellular environment, precipitates into
crystals. Increasing the amount of Abeta oligomers eventually
results in overt toxicity. Thus, the concentration of neuroactive
Abeta oligomers used in the assay is much lower than that causing
cell death. The inventors confirmed that the assay is operative by
showing that the effects of Abeta oligomer are blocked upon
addition of anti-Abeta antibody but antibody alone has no effect on
its own (data not shown). When configured in this manner, the assay
is able to detect compounds that inhibit nonlethal effects of Abeta
oligomer whether these compounds act via disruption of oligomers,
inhibition of oligomer binding to neurons, or counteraction of
signal transduction mechanisms of action initiated by oligomer
binding.
The methods used to generate the results were as follows in the
Membrane Trafficking/Exocytosis (MTT) assay.
Primary hippocampal neurons from E18 Sprague-Dawley rat embryos
were plated at optimized concentrations in 384 well plates in NB
media (Invitrogen). Neurons were maintained in cultures for 3
weeks, with twice weekly feeding of NB media with N2 supplement
(Invitrogen). These neurons express the full complement of synaptic
proteins characteristic of neurons in the mature brain, and exhibit
a complex network of activity-dependent electrical signaling.
Neurons and glia in such cultures have molecular signaling networks
exhibiting excellent registration with intact brain circuitry, and
for this reason have been used for over two decades as a model
system for learning and memory (See e.g. Kaech S, Banker G.
Culturing hippocampal neurons. Nat Protoc. 2006; 1(5):2406-15. Epub
2007 Jan. 11; See also Craig A M, Graf E R, Linhoff M W. How to
build a central synapse: clues from cell culture. Trends Neurosci.
2006 January; 29(1):8-20. Epub 2005 Dec. 7. Review).
A test compound was added to cells at concentrations ranging from
100 uM to 0.001 nM followed by addition of vehicle or Abeta
oligomer preparations (3 .mu.M total Abeta protein concentration),
and incubated for 1 to 24 hr at 37.degree. C. in 5% CO.sub.2. MTT
reagent (3-(4,5-dimethylthizaol-2yl)-2,5diphenyl tetrazolium
bromide) (Roche Molecular Biochemicals) was reconstituted in
phosphate buffered saline to 5 mg/mL. 10 .mu.L of MTT labeling
reagent is added to each well and incubated at 37.degree. C. for 1
h, then imaged. Exocytosis was assessed by automated microscopy and
image processing to quantify the amount of endocytosed and
exocytosed formazan.
Each assay plate was formatted so that compounds are tested with
and without Abeta oligomer on each plate. This design eliminates
toxic or metabolically active compounds early on in the screening
cascade (at the level of the primary screen). Reduced formazan was
first visible in intracellular vesicles. Eventual formazan
exocytosis was accelerated via Abeta oligomers.
In the presence of an effective concentration of active test
compound, the membrane traffic changes are blocked and the cell is
indistinguishable from a vehicle-treated neuron. Furthermore, in
some cases this effect of test compound appears to be independent
of whether test compound is added before or after exposure of the
cells to Abeta oligomer, which indicates a therapeutic as well as a
prophylactic effect. Adequate concentration of active test compound
blocks membrane trafficking effects of Abeta oligomer seen in this
assay. Ascending doses of compounds according to any embodiment
described herein, that are selective, high affinity agonists of the
sigma-2 receptor, stop oligomer effects and make the cultures look
more like vehicle-treated cultures.
Compounds according to any embodiment described herein, that are
selective, high affinity agonists of the sigma-2 receptor that are
effective for inhibiting Abeta oligomer toxicity are promising as
therapeutic and prophylactic modalities for amyloid beta oligomer
toxicity related cognitive decline such as that seen in Alzheimer's
disease.
Synthetic Abeta oligomers were dosed in the membrane trafficking
assay, where it exhibited an EC.sub.50 of 820 nM. Each
concentration of Abeta was tested against several concentrations of
each test compound. Active compounds caused a rightward shift in
the EC.sub.50 by almost two orders of magnitude. When the data were
fitted to classical linear and non linear models, the data were
linear with a Schild analysis (Hill slope nH of 1), which indicates
that the compounds exhibit true pharmacological competition between
oligomers and compound for targets that mediate membrane
trafficking.
Abeta oligomers derived from Alzheimer's patient's brains can be
dosed against test compounds, and a rightward shift is also
expected to be exhibited by compound exposure. Specifically, at
effective doses, the active test compounds exhibit pharmacological
competition with both synthetic and human Alzheimer's
patient-derived oligomers.
Experimental Controls
Abeta 1-42 oligomers made according to published methods were used
as positive controls. [See e.g. Dahlgren et al., "Oligomeric and
fibrillar species of amyloid-beta peptides differentially affect
neuronal viability" J Biol Chem. 2002 Aug. 30; 277(35):32046-53.
Epub 2002 Jun. 10; LeVine H 3rd. "Alzheimer's beta-peptide oligomer
formation at physiologic concentrations" Anal Biochem. 2004 Dec. 1;
335(1):81-90; Shrestha et. al, "Amyloid beta peptide adversely
affects spine number and motility in hippocampal neurons" Mol Cell
Neurosci. 2006 November; 33(3):274-82. Epub 2006 Sep. 8; Puzzo et
al., "Amyloid-beta peptide inhibits activation of the nitric
oxide/cGMP/cAMP-responsive element-binding protein pathway during
hippocampal synaptic plasticity" J Neurosci. 2005 Jul. 20;
25(29):6887-97; Barghorn et al., "Globular amyloid beta-peptide
oligomer--a homogenous and stable neuropathological protein in
Alzheimer's disease" J Neurochem. 2005 November; 95(3):834-47. Epub
2005 Aug. 31; Johansson et al., Physiochemical characterization of
the Alzheimer's disease-related peptides A beta 1-42 Arctic and A
beta 1-42 wt. FEBS J. 2006 June; 2 73(12):2618-30] as well as
brain-derived Abeta oligomers (See e.g. Walsh et al., Naturally
secreted oligomers of amyloid beta protein potently inhibit
hippocampal long-term potentiation in vivo. Nature (2002). 416,
535-539; Lesne et al., A specific amyloid-beta protein assembly in
the brain impairs memory. Nature. 2006 Mar. 16; 440(7082):352-7;
Shankar et al, Amyloid-beta protein dimers isolated directly from
Alzheimer's brains impair synaptic plasticity and memory. Nat Med.
2008 August; 14(8):837-42. Epub 2008 Jun. 22). It should be noted
that any Abeta oligomer preparation can be used in this assay or as
a control, including preparations described in the patent
literature, cited above and incorporated by reference in their
entirety.
Various different Abeta oligomer preparations were demonstrated to
cause an Abeta effect in the membrane trafficking assay, including
notably oligomer preparations isolated from the brain of
Alzheimer's disease patients.
Oligomers were isolated from postmortem human hippocampus or
prefrontal cortex without the use of detergents and inhibited
membrane trafficking in a dose-dependent manner with a Kd of 6
pMolar. Human Alzheimer's disease patient-derived Abeta oligomers
(137 pM) produce a statistically significant inhibition of membrane
trafficking compared to vehicle. Compound
4-(3-(4-(trifluoromethyl)benzylamino)butyl)-2-methoxyphenol
eliminates the membrane trafficking deficits induced by AD
brain-derived Abeta oligomers, but does not affect trafficking when
dosed in the absence of Abeta.
Although potencies of various Abeta oligomer preparations differ
(for example native Alzheimer's isolates are more potent than any
of the synthetic preparations tested-data not shown), the results
are qualitatively the same: pathologies mediated by oligomers are
countered by compounds according to any embodiment herein that act
as sigma-2 functional antagonists.
Primary Neuronal Cultures
Optimal cell density is determined based on cellular response to
Abeta oligomers using the exocytosis assay as a readout, and
immunohistochemical analysis of the relative proportion of glia to
neurons in the cultures. Cultures are monitored on a weekly basis
with immunohistochemistry and image processing-based quantification
to monitor the percentage of the cultures that are neurons vs. glia
(Glial cells). Cultures containing more than 20% glia (positive for
GFAP) vs. neurons (staining positively with (chicken polyclonal)
antibodies (Millipore) directed against MAP2 at 1:5000
(concentration variable)) at the screening age of 21 days in vitro
(21 DIV) are rejected.
Abeta Oligomer Preparations
Human amyloid peptide 1-42 was obtained from a number of commercial
vendors such as California Peptide, with lot-choice contingent upon
quality control analysis. Quality controls of oligomer preparations
consist of Westerns to determine oligomer size ranges and relative
concentrations, and the MTT assay to confirm exocytosis
acceleration without toxicity. Toxicity was monitored in each
image-based assay via quantification of nuclear morphology
visualized with the DNA binding blue dye DAPI (Invitrogen). Nuclei
that are fragmented are considered to be in late stage apoptosis
(Majno and Joris '95) and the test would be rejected. Peptide lots
producing unusual peptide size ranges or significant toxicity at a
standard 1.5 .mu.M concentration on neurons would also be
rejected.
Plate-based controls--The assay optimization was considered
complete when reformatted plates achieve a minimum of statistically
significant two-fold separation between vehicle and Abeta
oligomer-treated neurons (p<0.01, Student's t-test, unequal
variance) on a routine basis, with no more than 10% CV between
plates.
Statistical Software and Analysis
Data handling and analysis were accomplished by Cellomics VTI image
analysis software and STORE automated database software. Because of
the low dynamic range and neuronal well-to-well variability after
three weeks in culture, statistical comparisons are made via
pairwise Tukey-Kramer analysis to determine the significance of the
separation between compound+Abeta oligomers from Abeta alone, and
between compound alone from vehicle. The ability of mature primary
neurons to more closely approximate the electrophysiologically
mediated signal transduction network of the adult brain justifies
this screening strategy. Power analysis was set for a number of
replicate screening wells that minimized false negatives (e.g.
N=4). Test compounds of the disclosure significantly reverse the
effects of Abeta oligomers on membrane trafficking but do not
affect neuronal metabolism themselves.
Selected compounds according to any embodiment described herein,
were dosed in the MTT assay described herein, prior to Abeta
oligomer addition and were shown to block the Abeta
oligomer-induced membrane trafficking deficits with the indicated
EC.sub.50. Specifically, these results indicate that compounds
block/abate the activity/effect of Abeta oligomer on membrane
trafficking of neuron cells at micromolar concentrations. Certain
compounds in Table 1 were shown to block the Abeta oligomer-induced
acceleration of exocytosis with the indicated EC.sub.50.
Accordingly, the compounds in Table 1 significantly blocked Abeta
oligomer-mediated changes in membrane trafficking. These results
indicate that compounds block/abate the activity/effect of Abeta
oligomer on neuron cells and that compounds according to any
embodiment described herein, can be used to block the Abeta
oligomer induced membrane trafficking abnormalities.
In some embodiments, compounds according to any embodiment
described herein, inhibit Abeta oligomer-induced membrane
trafficking deficits, with an EC.sub.50 of not more than 20 uM, not
more than 15 uM, not more than 10 uM, not more than 5 uM, not more
than 1 uM, not more than 0.5 uM, when tested according to the
membrane trafficking assay protocol provided herein.
Example 6: Pharmacokinetic and Metabolic Stability Studies
A first pharmacokinetic study was performed in microsomes of mice
mouse liver microsomes, MLM). The studies were performed according
to Obach, R. S et al. (1997) J. Pharmacol. Exp. Ther., 283: 46-58,
which is incorporated herein by reference. The half-life
(t.sub.1/2) of the compounds in MLM assay is shown in Table 1.
In some embodiments, a compound according to any embodiment
described herein, or pharmaceutically acceptable salts thereof,
exhibits a half-life (t1/2) in a mouse liver microsome (MLM) assay,
as provided herein, of at least 5 minutes, at least 10 minutes, at
least 25 minutes, at least 50 minutes, at least 100 minutes, or at
least 200 minutes.
The results indicate that several of the compounds tested had a
substantially longer half-life in mouse liver microsomes. This
result portends greater bioavalability after oral administration
for these compounds. The same compounds have been tested by the
membrane trafficking assay described above and their activity as
referred to herein.
If the rate of intrinsic clearance of test compound was rapid, it
is suggestive of substantial first pass metabolism. In order to
improve pharmacokinetic properties, compounds were designed to
enhance metabolic stability and improve drug-like properties.
Microsomal stability experiments and plasma stability experiments
were performed to determine metabolic and hepatic stability of
candidate compounds. In some embodiments, in vitro microsomal
stability was normalized to standard compound,
4-(3-(4-(trifluoromethyl)benzylamino)butyl)-2-methoxyphenol, an
early lead compound that had a mouse liver microsome t1/2 (min) of
16. Compounds of the invention are superior to the this early lead
compound.
A second PK study can be conducted in vivo and involves measuring
plasma levels and brain levels for test compounds administered by
various routes and in an acute or chronic manner, as follows:
HPLC-MS Optimization
A solution of each test compound is prepared and infused into the
TSQ Quantum spectrometer (Fisher Thermo Scientific) source via
syringe pump at a constant rate. Full scan MS (mass spectroscopy)
analysis is conducted and total ion current chromatograms and
corresponding mass spectra are generated for each test compound in
both positive and negative ionization modes. The precursor ions for
MS/MS are selected from either the positive or the negative mass
spectrum, as a function of the respective ion abundance. In
addition, product ion MS/MS analysis is performed in order to
determine the appropriate selected fragmentation reaction for use
in quantitative analysis. The final reaction monitoring parameters
are chosen to maximize the ability to quantify the test compound
when present within a complex mixture of components. Following
identification of the specific SRM transition to be used for each
test compound, the detection parameters are optimized using the
automated protocol in the TSQ Quantum Compound Optimization
workspace. Finally, the chromatographic conditions to be used for
LC-MS analysis are identified by injection and separation of the
analyte on a suitable LC column and adjustment of the gradient
conditions is performed as necessary.
Formulation for IV Dosing:
The solubility of the test compound in phosphate-buffered saline,
pH 7.4 (PBS) is first evaluated by visual inspection. PBS is used
as the vehicle if the compound is soluble at the target
concentration. (Other vehicles that are compatible with IV dosing
may be evaluated if the compound is not completely soluble in PBS.
Such vehicles include DMSO, polyethylene glycol (PEG 400), Solutol
HS 15, and Cremophor EL among others.) In the experiments reported
here a single bolus, 10 mg/kg, of test compound is administered
IV.
Formulation for PO dosing: The solubility of the test compound in
PBS is first evaluated. PBS is used as the vehicle if the compound
is soluble at the target concentration. (DMSO/Solutol HS 15/PBS
(5/5/90, v/v/v), or DMSO/1% methylcellulose (5/95, v/v) may be used
if the test compound is not completely soluble in PBS at the
respective concentration.)
Linearity in Plasma
Aliquots of plasma are spiked with the test compounds at the
specified concentrations. The spiked samples are processed using
acetonitrile precipitation and analyzed by HPLC-MS or HPLC-MS/MS. A
calibration curve of peak area versus concentration is constructed.
The reportable linear range of the assay is determined, along with
the lower limit of quantitation (LLQ).
Quantitative Bioanalysis of Plasma Samples
The plasma samples are processed using acetonitrile precipitation
and analyzed by HPLC-MS or HPLC-MS/MS. A plasma calibration curve
was generated. Aliquots of drug-free plasma are spiked with the
test compound at the specified concentration levels. The spiked
plasma samples are processed together with the unknown plasma
samples using the same procedure. The processed plasma samples
(dried extracts) are typically stored frozen (-20.degree. C.) until
the HPLC-MS or HPLC-MS/MS analysis. The dried extracts are
reconstituted into a suitable solvent and after centrifugation were
analyzed by HPLC-MS or HPLC-MS/MS. Peak areas are recorded, and the
concentrations of the test compound in the unknown plasma samples
are determined using the respective calibration curve. The
reportable linear range of the assay is determined, along with the
lower limit of quantitation (LLQ).
Animals used in the study are typically male C57BL/6 mice weighing
20-30 g each or male Sprague-Dawley rats weighing 180-250 g. Three
animals are treated for each administration condition and each time
point, so that each animal is subjected to only one blood draw.
Subcutaneous compound administration was accomplished by
intraperitoneal injection. Per oral administration is accomplished
by gastric gavage. Intravenous administration is accomplished via
jugular catheter.
Following compound administration at various concentrations, plasma
samples are collected at, e.g., 10, 30, 60, 120, 240, 360, 480 and
1440 min.
Plasma Sample Collection from Mice and Rats
Animals are sedated under general inhalant anesthesia (3%
isoflurane) for blood collection by cardiac puncture (mice) or
jugular catheter (rats). Blood aliquots (300-400 .mu.L) are
collected in tubes coated with lithium heparin, mixed gently, and
are kept on ice and centrifuged at 2,500.times.g for 15 minutes at
4.degree. C., within 1 hour of collection. The plasma is then
harvested and kept frozen at -20.degree. C. until further
processing.
Animal Dosing Design--In Vivo PK--Non Cannulated, Nonfasted
Animals
Group 1: SC, n=3 animals per time point (24 animals total) or
IV, n=3 animals per time point (24 animals total)
Group 2: PO, n=3 animals per time point (24 animals total)
Group 3: Control animals (for drug-free blood), n=5 mice
Each animal is subject to one blood draw and one brain
collection.
Brain Sample Collection from Animals
Immediately after blood sampling, animals are decapitated and the
whole brains are quickly removed, rinsed with cold saline (0.9%
NaCl, g/mL), surface vasculature ruptured, blotted dry with gauze,
weighted, kept on ice until further processing within one hour of
collection. Each brain is homogenized in 1.5 mL cold phosphate
buffered saline, pH 7.4 (mice=1.5 mL, rats=), for 10 seconds on ice
using the Power Gen 125. The brain homogenate from each brain is
then stored at -20.degree. C. until further processing.
Linearity in Brain Samples
Aliquots of brain homogenate are spiked with the test compound at
the specified concentrations. To each brain aliquot an equal volume
of chilled 26% (g/mL) neutral Dextran (average molecular Weight
65,000-85,000 from Sigma, catalog number D-1390) solution is added
to obtain a final Dextran concentration of 13%. The homogenate is
centrifuged at 54000.times.g for 15 minutes at 4.degree. C. The
supernatants are subsequently processed using acetonitrile
precipitation and analyzed by HPLC-MS/MS. A calibration curve of
peak versus concentration i constructed. The reportable linear
range of the assay is determined, along with the lower limit of
quantitation (LLQ).
Quantitative Analysis of Brain Samples
To each brain homogenate aliquot an equal volume of chilled 26%
(g/mL) neutral Dextran (average molecular Weight 65,000-85,000 from
Sigma, catalog number D-1390) solution is added to obtain a final
Dextran concentration of 13%. The homogenate is centrifuged at
54000.times.g for 15 minutes at 4.degree. C. The supernatants are
subsequently processed using acetonitrile precipitation and
analyzed by HPLC-MS/MS. A brain calibration curve is generated.
Aliquots of drug-free brain homogenate are spiked with the test
compound at specified concentration levels. The spiked brain
homogenate samples are processed together with the unknown brain
homogenate samples using the same procedure. The processed brain
samples are stored at -20.degree. C. until the LC-MS/MS analysis,
at which time peak areas were recorded, and the concentrations of
test compound in the unknown brain samples were determined using
the respective calibration curve. The reportable linear range of
the assay was determined along with the lower limit of quantitation
(LLQ).
Brain Penetratrability
The concentrations of test compound in brain (ng/g tissue) and in
plasma (ng/mL) as well as the ratio of the brain concentration and
the plasma concentration at each time point are determined by
LC-MS/MS and reported as described above.
Pharmacokinetics
Plots of plasma concentration of compound versus time are
constructed. The fundamental pharmacokinetic parameters of compound
after oral and SC dosing (AUClast, AUCINF, T1/2, Tmax, and Cmax)
are obtained from the non-compartmental analysis (NCA) of the
plasma data using WinNonlin (Pharsight). Noncompartmental analysis
does not require the assumption of a specific compartmental model
for either drug or metabolite. NCA allows the application of the
trapezoidal rule for measurements of the area under a plasma
concentration-time curve (Gabrielsson, J. and Weiner, D.
Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and
Applications. Swedish Pharmaceutical Press. 1997).
Definitions of Terms Reported
Area Under the Curve (AUC)--Measure of the total amount of
unchanged drug that reaches the systemic circulation. The area
under the curve is a geometric measurement that was calculated by
plotting concentration versus time and summing the incremental
areas of each trapezoid.
WinNonlin has two computational methods for calculation of the
area: the linear trapezoidal method and the linear-log trapezoidal
method. Because the linear trapezoidal method may give biased
results on the descending part of the concentration-time curve and
overestimate the AUC, WinNonlin provides the linear-log option for
calculation of AUC. By default, the log-linear trapezoidal method
is used to measure the post-Tmax area for the remainder of the
plasma concentration-time curve.
AUC.sub.last: area under the curve from the time of dosing to the
time of last observation that was greater than the limit of
quantitation.
AUC.sub.INF: Area under the curve from the time of dosing
extrapolated to infinity.
C.sub.max--Maximum plasma drug concentration obtained after oral or
non-IV administration of a drug between the time of doing and the
final observed time point.
T.sub.max--Time at maximum observed plasma concentration (Cmax)
noted in minutes after administration of drug.
T.sub.1/2--Terminal elimination half-life from both IV and non-IV
dosing.
where lambda Z (z) is the first order rate constant associated with
the terminal (log-linear) portion of the plasma concentration-time
curve. z is estimated by linear regression of time versus log
concentration.
The results are expected to show that certain test compounds
exhibit good bioavailability and good brain penetrability when
administered at doses ranging from 0.1 to 0.5 mg/kg acutely or
chronically (daily over 5 days). Selected test compounds are
evaluated for oral bioavailability in this manner.
Example 8: In Vitro Testing for hERG Inhibition
In vitro testing for hERG inhibition was performed in a standard
assay (See: Haverkamp W, Breithardt G, Carnm A J, Janse M J, Rosen
M R, Antzelevitch C, Escande D, Franz M, Malik M, Moss A and Shah
R. (2000) Eur Heat J 21 (15); 1216-31). Results for test compounds
for hERG inhibition (IC.sub.50, nM) is shown in Table 1. In some
embodiments, compounds according to any embodiment described
herein, or pharmaceutically acceptable salts thereof, exhibit
minimal hERG inhibition, with an IC.sub.50 of greater than 300 nM,
greater than 500 nM, greater than 1,000 nM, greater than 3,000 nM,
greater than 5,000 nM, greater than 10,000, or greater than 20,000
nM. In particular embodiments, compounds according to any
embodiment described herein, or pharmaceutically acceptable salts
thereof, exhibit minimal hERG inhibition, and exhibit an IC.sub.50
of greater than 5,000 nM, greater than 10,000, or greater than
20,000 nM.
Combined Results for particular compounds described herein, with
respect to log P, membrane trafficking (uM), sigma-2 receptor
affinity, sigma-1 receptor affinity microsomal stability in mouse
liver microsomes (MLM) (t.sub.1/2, min), t.sub.1/2 normalized to
CT)10914 and in vitro toxicity potassium channel hERG (IC.sub.50,
nM) are provided in Table 1:
TABLE-US-00001 EC.sub.50 MLM hERG Example MW LC-MS Abeta S1 K.sub.i
S2 K.sub.i T.sub.1/2 IC.sub.50 Compound g/mol [MH].sup.+ log P (uM)
(nM) (nM) (min.) T.sub.1/2* (nM) 1 383.5 384.4 5.16 0.7 0.2 740 2
357.5 358.5 4.67 >15 0.9 0.6 9200 3 383.6 384.5 6.22 0.25 0.76 4
371.5 372.2 5.35 0.5 0.8 2200 5 323.9 324.7 4.4 >15 0.8 75 6
343.4 344.4 4.49 >15 0.3 1 750 7 343.4 344.6 4.31 >15 0.7 1.5
1500 8 281.8 282.9 3.16 0.25 0.4 1.6 14000 9 437.6 438.5 6.58 0.5
13 1.8 114 166 1000 10 295.8 296.9 3.8 1.26 0.7 2.1 11000 11 404.0
405.2 6.31 3 14, 69 2.2 26, 87 1500 12 343.4 344.1 4.13 1 2.7 970
13 329.4 330.4 3.85 1 2.9 2500 14 329.4 330.2 3.71 3.7 1.9 3 18000
15 387.6 388.7 5.85 1.6 40 4.5 14 20 2200 16 309.9 310.9 4.03 0.8
4.5 840 17 315.4 316.4 3.43 2.24 1.3 5.1 11000 18 293.4 294.4 2.72
0.25 2.6 5.6 29000 19 293.4 294.5 3.57 <0.25 2.2 6 37000 20
295.8 296.9 3.57 1 6.1 1700 21 359.5 360.4 5.26 20 8 6.2 11 37 830
22 309.9 310.8 3.85 1 7 1700 23 392.0 393.2 6.49 0.95 140 9.2 8.2
25 2200 24 397.0 398.1 6.31 20 10 25 279.4 280.5 3.11 2.3 10 4000
26 403.5 404.6 3.35 20 11 27 376.6 377.7 6.22 0.4 15 28 397.5 398.2
5.68 4 6.1 18 60 60 10200 29 392.6 393.7 5.55 20 19 30 381.5 382.7
6.97 2.2 4.1 19 83 78 6500 31 348.0 349.2 6.7 0.7 41 28 21 20 10900
32 474.1 475.3 6.37 6.9 32 33 341.6 342.6 7.04 1.92 33 34 423.6
424.7 6.15 20 5.3 39 60 60 23000 35 383.5 384.5 5.31 20 56 39 60 60
13400 36 373.5 374.6 5.41 20 12 40 25 129 10000 37 466.6 467.8 6.18
0.2 8.8 40 38 36 26200 38 369.5 370.5 4.85 4.5 190 42 84 79 16200
39 383.5 384.6 5.49 0.6 25 43 8200 40 455.6 456.9 6.28 0.83 170 44
9600 41 390.0 391.2 5.87 1.6 16 67 35 60 4000 42 349.9 350.7 5.04
20 150 71 88 83 6900 43 417.1 418.3 6.37 0.3 61 74 29 88 4900 44
411.5 412.3 6.27 1.4 260 79 9200 45 356.6 357.7 6.26 2.6 85 46
474.1 475.6 6.37 4.8 86 47 404.6 405.4 5.55 1913 90 14000 48 349.9
350.7 5.3 1.8 93 49 404.6 405.7 5.74 575 94 2400 50 313.5 314.7
6.31 1.7 96 51 440.6 441.4 4.55 20 100 52 327.5 328.6 6.9 4.8 110
53 364.0 365.2 5.41 20 74 110 28 26 13300 54 335.5 336.3 7.02 3.2
120 55 337.9 338.9 5.47 2.5 25 120 3.6 11 7200 56 362.5 362.8 4.49
571 139 1900 57 329.5 330.4 5.21 0.73 150 58 347.5 348.6 4.94 0.5
64 160 39 79 14000 59 347.5 348.5 5.12 0.25 600 160 73000 60 376.6
377.8 6.91 1.0 210 61 353.5 354.2 6.38 4.7 160 230 53 77 7300 62
333.5 334.2 4.4 0.8 130 230 60 122 41000 63 466.1 467.2 7.42 1.5
240 64 318.4 319.6 3.52 535 268 11000 65 335.5 336.7 4.13 1200 270
2300 66 333.5 334.7 4.84 20 39 290 8.8 45 16000 67 482.1 483.2 6.8
13 300 68 303.5 304.4 5.65 20 500 300 11 57 27000 69 335.5 336.7
6.93 4.2 320 70 421.5 422.4 6.95 20 33 340 14 13 16300 71 396.5
397.8 4.61 62 340 17000 72 355.4 356.6 5.32 20 770 400 2.1 11 80000
73 349.9 350.4 4.86 0.7 29 410 87 176 24000 74 345.5 346.5 4.54
12.9 430 75 362.9 363.8 4.33 0.25 690 690 15000 76 371.5 371.7 6.21
0.3 370 790 3.5 7 18000 77 335.9 336.8 4.58 20 540 800 44 41 15200
78 335.5 336.7 6.93 0.56 940 79 319.5 320.2 4.12 1.9 1200 940 74
150 29000 80 335.5 336.5 6.93 0.64 1300 81 346.5 347.6 3.87 160
2500 32000 82 433.6 434.6 4.11 20 380 2800 60 60 100000 83 369.5
370.4 5.31 3.8 1000 1000 14000 84 309.9 310.5 4.67 0.25 1000 1000
3900 85 343.4 344.6 4.95 0.98 1000 1000 11000 86 357.6 358.6 6.37
0.22 87 362.0 363.3 7.13 20 88 393.6 394.5 3.54 89 405.6 406.6 5.37
90 440.1 441.3 7.02 20 91 277.4 278.7 3.99 20 92 275.4 276.4 5.06
20 93 273.4 274.5 4.36 20 3.4 9 94 271.4 272.6 5.43 20 1.8 5 95
293.8 294.6 4.45 20 1.5 4 96 291.9 292.3 5.52 1.6 6.2 16 97 369.6
370.7 5.78 10 8.7 15 98 385.6 386.4 5.11 20 1.7 4 99 331.5 332.3
4.08 20 7.4 19 100 315.5 316.9 4.75 13.6 4.5 12 101 343.5 344.7
5.57 9.6 1.8 5 102 359.5 360.5 4.9 20 1.5 4 103 287.4 288.3 4.76 20
1.1 2 104 289.4 290.4 3.69 20 1.3 2 105 376.0 377.3 5.72 20 1.3 2
106 373.6 374.7 5.35 20 3.9 7 107 341.5 342.4 5.21 20 3.5 6 108
345.5 344.5 4.46 20 7.3 12 109 329.5 330.8 5.13 20 5.4 9 110 387.6
388.5 5.73 20 2.6 4 111 364.0 365.2 5.68 20 6.8 23 112 343.5 344.4
5.59 4.9 16 113 359.5 360.7 4.92 20 8.2 27 114 355.6 356.8 5.63 1.8
6 115 367.5 368.4 4.9 20 116 337.5 338.7 5.71 117 341.9 342.6 6.47
118 339.5 340.9 4.64 119 426.0 427.0 6.67 120 343.9 344.6 5.4 121
371.9 372.9 5.66 122 421.6 422.4 5.91 123 387.9 388.8 6.67 0.3 124
395.6 396.7 6.45 0.2 125 372.6 373.4 5.23 0.25 126 388.6 389.9 4.61
0.3 7400 127 436.6 437.7 6.41 0.3 3300 128 445.6 446.7 7.19 20 129
383.5 384.4 5.13 1.3 24000 130 422.6 423.6 5.97 0.3 131 331.5 332.8
6.24 20 132 412.0 413.2 6.91 20 133 386.6 387.6 5.68 2.2 134 321.4
322.2 5.01 20 135 389.0 390.2 5.69 20 136 364.0 365.0 5.58 1.5 2100
137 438.6 439.8 5.34 0.15 138 405.0 406.1 5.07 0.45 139 375.6 376.9
6.03 20 140 442.7 443.9 5.78 20 141 371.5 372.5 5.74 1.6 142 349.9
350.7 5.22 20 143 438.6 439.6 5.96 20 144 414.6 415.4 4.69 20 145
333.5 334.9 4.76 20 146 403.0 404.1 6.14 0.025 147 440.7 441.8 5.16
148 400.6 401.7 4.14 149 454.7 455.8 5.59 20 150 386.6 387.8 3.86
20 151 372.5 373.3 4.65 20 152 389.0 390.2 5.11 0.26 153 408.6
409.7 5.73 0.5 154 382.5 383.2 3.37 155 458.6 459.6 6.46 156 399.0
400.0 3.83 0.34 157 425.0 426.3 6.19 158 378.0 379.1 5.99 2.88 159
389.6 390.4 6.36 10 160 406.0 407.2 6.82 15 161 432.5 433.5 4.1
0.27 162 422.0 423.2 6 15 163 405.6 406.3 5.54 15 164 439.6 440.3
7.1 165 351.9 352.9 4.6 166 317.5 318.7 3.99 167 321.9 322.9 5.1
168 427.7 428.8 6.17 169 387.6 388.3 5.15 170 373.6 374.3 4.87 171
415.7 416.5 6.5 172 277.4 278.4 3.52 173 275.4 276.4 4.81 174 295.4
296.3 3.67 175 311.8 312.8 4.13 176 293.4 294.2 4.96 177 309.9
310.7 5.42 178 359.5 360.5 4.59 179 417.6 418.6 5.49 430 4000 180
373.6 374.2 4.87 20000 181 434.1 435.6 5.95 1800 182 467.6 468.6
6.22 160 2600 183 429.7 430.7 6.79 2100 184 275.4 276.2 2.57 220
62000 185 407.6 408.4 6.16 3000 186 309.8 310.9 3.18 42 2300 187
424.0 425.2 6.62 1000 188 337.9 338.9 4 400 189 457.6 458.5 6.89 37
5700 190 349.5 350.6 4.63 191 329.4 330.2 4.07 192 295.8 296.8 3.44
19000 193 349.9 350.7 4.89 194 421.0 422.1 6.01 195 411.6 412.7
3.36 196 376.5 377.4 4.85 197 378.9 379.7 4.95 198 421.0 422.0 6.2
4800 199 309.9 310.8 4.22 1200 200 454.6 455.4 6.28 83000 201 301.5
302.5 3.97 15 15000 202 315.5 316.6 4.62 203 332.5 333.6 3.75 204
369.6 370.5 5.7 205 445.6 446.7 6.5 0.59 3900 206 368.4 369.5 4.26
207 461.6 462.7 4.09 208 426.5 427.3 5.58 209 454.6 455.8 6.47 210
427.5 428.6 4.79 0.42 4400 211 412.0 413.0 6.23 212 425.6 426.8
6.54 1.8 27000 213 315.5 316.7 4.25 6.6 6400 214 392.0 393.1 6.27
215 418.6 419.6 5.5 216 510.7 511.9 7.65 217 394.0 395.0 4.51 4.6
7700 218 377.5 378.7 4.05 13000 219 359.5 360.3 3.91 220 377.6
378.2 5.62 221 395.6 396.7 5.76 222 375.6 376.5 5.81 223 357.6
357.9 5.67 224 334.9 335.6 3.98 225 477.1 478.1 7.37 226 460.7
461.6 6.91 1.25 227 300.4 301.3 3.38 228 468.6 469.8 6.24 229 295.8
296.8 4.03 15 21000 230 321.9 323.0 4.52 10 16000 231 295.8 296.6
4.03 11000 232 355.4 356.4 4.79 15 29000 233 315.4 316.9 3.79 0.26
24000 234 349.9 350.7 5.68 235 349.9 350.9 5.68 236 369.5 370.5
5.31 15 20000 237 335.9 336.7 5.04 238 309.9 310.7 4.67 15 13000
239 335.9 336.5 5.04 4600 240 335.9 336.9 5.04 241 319.5 320.7 4.57
242 319.5 320.3 4.57 14000 243 369.5 370.7 5.31 244 333.5 334.6
5.22 8.5 4800
245 333.5 334.5 5.22 >15 14000 246 349.9 350.9 5.68 247 383.5
384.3 5.95 248 392.0 393.0 5.84 249 315.5 316.7 5.07 15 9400 250
281.8 282.3 3.51 15 28000 251 333.5 334.6 5.22 252 315.5 316.7 5.07
15 7000 253 309.9 310.9 4.67 0.25 254 343.4 344.4 4.95 5000 255
281.8 282.9 3.51 15 256 543.7 544.3 5.01 15 257 507.6 508.7 4.08
258 508.7 509.6 2.62 259 570.7 571.5 4.03 260 520.7 521.7 2.46 261
437.6 438.9 6.58 0.73 262 437.6 438.7 6.58 1.85 263 455.6 456.9
6.28 264 455.6 456.4 6.28 265 383.5 384.7 5.13 266 383.5 384.6 5.13
267 375.5 376.5 5.37 268 351.9 352.9 4.83 269 494.6 495.4 2.2 270
480.6 481.5 1.81 271 598.8 599.7 4.85 272 481.6 482.6 3.35 273
522.7 523.7 3.19 274 534.7 535.9 3.24 275 383.5 384.1 5.95 276
343.4 344.6 4.95 277 385.5 386.5 5.11 278 357.5 358.5 5.23 279
522.6 523.6 1.63 280 612.8 613.9 3.85 281 495.6 496.4 2.48 282
562.7 563.9 2.47 283 295.8 296.4 3.62 284 309.9 310.7 3.98 285
357.9 358.9 4.81 286 425.5 426.5 6.11 287 337.9 338.7 4.41 288
267.8 267.9 3.1 289 295.8 296.8 4.26 290 309.8 310.6 4.08 291 323.9
324.9 4.06 292 392.0 393.2 6.49 1.6 293 275.4 276.5 3.48 294 275.4
276.7 3.48 295 289.4 290.5 3.45 296 261.4 262.7 2.83 297 321.5
322.4 5.81 298 295.8 296.8 4.26 299 303.4 304.4 3.81 300 261.4
262.7 3.65 301 233.3 234.5 2.49 302 261.4 262.4 3.65 303 368.0
369.0 4.58 304 275.4 276.5 3.38 305 553.6 554.6 3.1 306 329.4 330.3
3.89 307 391.5 392.6 5.08 308 261.4 262.4 3.01 309 579.6 579.6 3.96
310 261.4 262.5 3.2 311 371.4 372.3 4.69 312 329.4 330.5 4.53 313
315.5 316.4 4.28 314 401.5 402.7 4.85 315 301.3 302.3 3.37 316
341.5 342.5 4.34 317 329.4 330.6 4.53 318 279.4 280.3 3.8 319 279.4
280.6 3.8 320 293.4 294.4 3.62 321 321.5 322.7 4.61 322 321.4 322.4
3.95 323 249.4 250.4 4.15 324 337.9 338.7 5.07 325 303.5 304.6 4.47
326 307.4 308.4 3.6 *normalized to
4-(3-(4-(trifluoromethyl)benzylamino)butyl)-2-methoxyphenol
SYNTHETIC EXAMPLES
Example Syn 1: Preparation of Example Compound 9
##STR00137##
Example 9
##STR00138## ##STR00139##
General Procedure for the Preparation of Compound S1-2
##STR00140##
In three-neck flask, was placed magnesium (9.39 g, 391.09 mmol, 1.1
eq) and a grain of iodine. Then 15 percent volume of compound S1-1
(80 g, 355.54 mmol, 1.0 eq) in THF (800 mL) was added into the
mixture under nitrogen atmosphere, and the stirred mixture was
heated to 70.degree. C. until yellow brown disappeared and then
stirred at that temperature for another 6 h, to give a solution of
compound S1-2 (0.44 M) in THF, which was used directly in next
step.
General Procedure for the Preparation of Compound S1-4
##STR00141##
To a solution of compound S1-2 (320 mmol, 1.0 eq) in THF (500 mL)
was added CuCl (3.17 g, 32 mmol, 0.1 eq). When the solution was
cooled to 0.degree. C. the compound S1-3 (64 g, 320 mmol, 1.0 eq)
was added dropwise. The reaction mixture was stirred at rt for 3 h,
quenched with saturated NH.sub.4Cl solution, extracted with ethyl
acetate. The organic layer was dried over Na.sub.2SO.sub.4,
concentrated under vacuum. The residue was purified by column
chromatography (PE/EA, 50:1-10:1) to afford the title compound S1-4
(51 g, 46%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.57-7.49
(m, 4H), 4.08-4.03 (m, 4H), 3.80 (d, J=2.4 Hz, 1H), 1.62-1.58 (m,
6H), 1.13-1.09 (m, 6H)
TLC: PE/EA=10:1, UV 254 nm
R.sub.f (Compound S1-4)=0.5
General Procedure for the Preparation of Compound S1-5
##STR00142##
To a solution of compound S1-4 (51 g, 147.25 mmol, 1.0 eq) in MeOH
(300 mL) was added 1N aqueous solution of NaOH (736 mL, 736.25
mmol, 5.0 eq). The reaction mixture was stirred at 90.degree. C.
for 3 h, and then cooled to rt. The mixture was acidified with 1N
HCl solution until pH 4-5 and extracted with ethyl acetate. The
organic layer was dried over Na.sub.2SO.sub.4 and concentrated
under vacuum to give a compound S1-5 (40 g, 94%), which was used
directly in next step without further purification. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 7.57-7.55 (m, 2H), 7.50-7.48 (m, 2H),
3.86 (s, 1H), 1.59 (s, 6H);
TLC: DCM/MeOH=10:1, UV 254 nm
R.sub.f (Compound S1-5)=0.5
General Procedure for the Preparation of Compound S1-6
##STR00143##
A solution of compound S1-5 (40 g, 137.82 mmol, 1.0 eq) in DMSO
(200 mL) was stirred at 150.degree. C. for 2 h, diluted with ethyl
acetate, washed with water, brine. Then the organic phase was dried
over Na.sub.2SO.sub.4 and concentrated under vacuum to afford the
title compound S1-6 (30 g, 88%), which was used directly without
further purification. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.57-7.55 (m, 2H), 7.48-7.45 (m, 2H), 2.67 (s, 2H), 1.49-1.46 (m,
6H);
TLC: DCM/MeOH=10:1, UV 254 nm
R.sub.f (Compound S1-5)=0.4
R.sub.f (Compound S1-6)=0.8
General Procedure for the Preparation of Compound S1-8
##STR00144##
To a solution of compound S1-6 (30 g, 121.84 mmol, 1.0 eq) in THF
(500 mL) was added HOBt (19.8 g, 146.2 mmol, 1.2 eq), EDCI (28 g,
146.21 mmol, 1.2 eq), TEA (37 g, 365.52 mmol, 3.0 eq) and compound
S1-7 (23.77 g, 243.68 mmol, 2.0 eq). The reaction was stirred at rt
overnight and then quenched with water, extracted with ethyl
acetate. The organic layer was dried over Na.sub.2SO.sub.4 and
concentrated to give the crude product, which was purified by
column chromatography on a silica gel (PE/EA, 10:1.about.3:1) to
give compound S1-8 (31 g, 88%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.56-7.54 (m, 2H), 7.50-7.47 (m, 2H), 3.59 (s, 3H), 3.06
(s, 3H), 2.78 (s, 2H), 1.49 (s, 6H);
TLC: PE/EA=3:1, UV 254 nm
R.sub.f (Compound S1-6)=0.4
R.sub.f (Compound S1-8)=0.8
General Procedure for the Preparation of Compound S1-10
##STR00145##
In three-neck flask, was placed magnesium (8.0 g, 331.39 mmol, 1.1
eq) and a grain of iodine. Then 15 percent volume of compound S1-9
(40.67 g, 301.26 mmol, 1.0 eq) in THF(300 mL) was added into the
mixture under nitrogen atmosphere, and the stirred mixture was
heated to 70.degree. C. until yellow brown disappeared and then the
solution was stirred at that temperature for another 6 h, to give a
solution of compound S1-10 (1.0 M) in THF, which was used directly
in next step.
General Procedure for the Preparation of Compound S-11
##STR00146##
To a solution of compound S1-8 (31 g, 107.16 mmol, 1.0 eq) in THF
(200 mL) was added compound S1-10 (1.0 M, 215 mL, 214.32 mmol, 2.0
eq) at 0.degree. C. The reaction was stirred at rt for 3 h. Then
the mixture was quenched with saturated NH.sub.4Cl solution,
extracted with ether, and the organic layer was dried over
Na.sub.2SO.sub.4, concentrated in vacuum to give crude product,
which was purified by column chromatography on a silica gel (PE) to
give crude compound S-11 (28.9 g, 95%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.56-7.54 (m, 2H), 7.47-7.45 (m, 2H), 7.75 (m,
1H), 2.75 (s, 2H), 2.01-1.99 (m, 3H), 1.74-1.73 (m, 3H), 1.44-1.42
(m, 6H);
TLC: PE/EA=10:1, UV 254 nm
R.sub.f (Compound S1-8)=0.5
R.sub.f (Compound S1-11)=0.9
General Procedure for the Preparation of Example 9
##STR00147##
A mixture of compound S1-11 (2.4 g, 8.44 mmol, 1.0 eq), compound
S1-12 (1.43 g, 8.44 mmol, 1.0 eq) and Ti(EtO).sub.4 (7.7 g, 33.76
mmol, 4.0 eq) in THF (100 mL) was stirred at 70.degree. C.
overnight under nitrogen atmosphere. Then the mixture was allowed
to cool to rt, NaBH.sub.4 (1.23 g, 33.76 mmol, 4.0 eq) was added.
After complete addition, the mixture was stirred at rt for 3 h.
Then water was added and extracted with ethyl acetate, filtered.
The organic phase was dried over Na.sub.2SO.sub.4, concentrated in
vacuum. The residue was purified by column chromatography on a
silica gel (PE/EA, 10:1.about.1:1) to give compound Example 9,
which was dissolved in HCl/EA (2.0 M, 10 mL). The mixture was
stirred at rt for 2 h, concentrated to give Example 9 HCl (600 mg,
15%) as oil. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.60-7.52
(m, 4H), 4.70-4.67 (m, 1H), 3.95-3.92 (m, 2H), 3.79-3.73 (m, 1H),
3.61-3.59 (m, 1H), 2.81-2.73 (m, 2H), 2.38-2.22 (m, 2H), 1.98 (s,
6H), 1.64-1.61 (m, 2H), 1.46-1.43 (m, 12H), 1.31-1.28 (m, 6H);
MS: [M+H]+=438.5
Example Syn 2: Preparation of Example Compound 262
##STR00148##
General Procedure for the Preparation of Compound S2-7
##STR00149##
To a solution of compound S2-6 (450 g, 1.83 mol, 1.0 eq) in
anhydrous THF (4.5 L) cooled to 0.degree. C., a solution of 1 M
BH.sub.3 (2.75 L, 2.745 mol, 1.5 eq) was added dropwise. The
mixture was stirred at rt for 16 h. The reaction was monitored by
TLC. The colorless homogeneous reaction mixture was cooled to
0.degree. C., and MeOH (2 L) was carefully added followed by water
(1 L). MeOH and THF were then removed under vacuum. The mixture was
extracted with DCM (3.times.1 L), the combined organic extracts
were washed with brine (1 L), dried over MgSO4, filtered, and
concentrated to dryness under reduced pressure to give crude
compound S2-7 (340 g, 80%) as a colorless oil. .sup.1H NMR (400
MHz, CDCl.sub.3): .delta. 7.57 (d, J=8.0 Hz, 2H), 7.47 (d, J=8.4
Hz, 2H), 3.47 (t, J=7.2 Hz, 2H), 1.98 (t, J=7.2 Hz, 2H), 1.29 (s,
6H).
General Procedure for the Preparation of Compound S2-9
##STR00150##
A solution of compound S2-7 (296 g, 1.27 mol, 1.0 eq) was dissolved
in CH.sub.3CN (3.6 L), NMI (10.3 g, 127 mmol, 0.1 eq), TEMPO (9.8
g, 63 mmol, 0.05 eq) and BPy (9.7 g, 63 mmol, 0.05 eq) were added,
then Cu(PF.sub.6)(MeCN).sub.4 (23.5 g, 63 mmol, 0.05 eq) was added.
The mixture was stirred under oxygen atmosphere for 4 h. The
reaction was monitored by TLC. The mixture was poured into water (2
L), extracted with DCM (3.times.2 L). The combined extracts were
washed with water, dried over Na.sub.2SO.sub.4 and concentrated to
give compound S2-9 (281 g, 96%) as a dark green oil. .sup.1HNMR
(400 MHz, CDCl.sub.3): .delta. 9.54 (s, 1H), 7.61 (d, J=7.6 Hz,
2H), 7.51 (d, J=7.6 Hz, 2H), 2.66 (s, 2H), 1.49 (s, 6H).
TLC: PE/EA=20:1, UV 254 nm
R.sub.f (compound S2-7)=0.1
R.sub.f(S2-9)=0.8
General Procedure for the Preparation of Compound S2-11R
##STR00151##
To a solution of compound S2-9 (150 g, 652.5 mmol, 1.0 eq) in THF
(750 mL), compound S2-10R (118.96 g, 978.77 mmol, 1.5 eq) and
Ti(OEt).sub.4 (74.4 g, 326.2 mmol, 0.5 eq) were added. The mixture
was stirred at rt overnight, and then quenched with water (24 g,
1.3 mol), filtered by celite pad and diluted with ethyl acetate,
washed with brine, water. The organic layer was dried over
Na.sub.2SO.sub.4 and concentrated to give crude product, which was
purified by column chromatography on a silica gel (PE/EA, 5:1) to
give compound S2-11R (165 g, 75.9%).
TLC: PE/EA=3:1, UV 254 nm
R.sub.f (Compound S2-9)=0.6
R.sub.f (Compound S2-11R)=0.5
General Procedure for the Preparation of Compound S2-12
##STR00152##
In three-neck flask, was placed magnesium (31.9 g, 1.3 mol, 1.1 eq)
and a grain of iodine. Then 15 percent volume of compound S2-31
(149 g, 1.2 mol, 1.0 eq) in THF (1.5 L) was added into the mixture
under nitrogen atmosphere, and the stirred mixture was heated to
70.degree. C. until yellow brown disappeared. Then the remaining
solution was added dropwise and stirred for another 6 h to give a
solution of compound S2-12 (1.0 M) in THF, which was used directly
in next step.
General Procedure for the Preparation of Compound S2-13R
##STR00153##
To a solution of compound S2-11R (120 g, 359.9 mmol, 1.0 eq) in THF
(80 mL) was added the compound S2-12 (1080 mL, 539.9 mmol, 1.50 eq,
0.5 M) at 0-5.degree. C. After stirring at rt for overnight, the
reaction was quenched by NH.sub.4Cl, extracted with ethyl acetate.
The organic layer was dried over Na.sub.2SO.sub.4 and concentrated
to give crude product, which was purified by column chromatography
on a silica gel (PE/EA, 10:1.about.3:1) to give compound S2-13R
(69.1 g, 49.3%).
The compound S2-13R (69.1 g) was recrystallized with ether/hexane
(1/1) (30 mL) at 4-8.degree. C. for up to two days, to give white
solid (25.6 g, 37%), which was used to produce Example 262 in 99%
ee. The mother liquor was recrystallized with ether/hexane (1/1)
(20 mL) to give white solid (15.1 g).
TLC: PE/EA=3:1, UV 254 nm
R.sub.f (Compound S2-11R)=0.5
R.sub.f (Compound S2-13R)=0.3
General Procedure for the Preparation of Compound S2-14R
##STR00154##
Compound S2-13R (34.6 g, 88.8 mmol, 1.0 eq) was added in the round
bottom flask. HCl in EtOAc (90 mL, 2N, 2 eq) was then added. After
stirring for two hours, about 80 mL of solvent was removed under
vacuous. The mixture diluted with ether (20 mL), the white solid
was filtered out as compound S2-14R hydrochloride. The
hydrochloride was dissolved in H.sub.2O (30 mL), alkalinized with
saturated aqueous of Na.sub.2CO.sub.3 to pH 10. Then extracted with
ether (30 mL.times.3), dried over (Na.sub.2SO.sub.4), concentrate
to give colorless oil (20.2 g 79.7%).
TLC: PE/EA=3:1, UV 254 nm
R.sub.f (Compound S2-13R)=0.3
R.sub.f (Compound S2-14R)=0.1
General Procedure for the Preparation of Example Compound 262
##STR00155##
To a solution of compound S2-14R (4.8 g, 16.8 mmol, 1.0 eq) in ACN
(48 mL) was added the compound S2-15 (8.35 g, 16.8 mmol, 1.0 eq)
and K.sub.2CO.sub.3 (4.46 g, 33.6 mmol, 2.0 eq). After stirring at
85.degree. C. overnight, the reaction was quenched by H.sub.2O (50
mL) and extracted with ethyl acetate (40 mL.times.3). The organic
layer was dried over Na.sub.2SO.sub.4 and concentrated to give
crude product, which was purified by column chromatography on a
silica gel (PE/EA, 10:1.about.3:1) to give compound Example 262
(5.1 g 69%) as the free base. The ee % was determined to be 99% on
chiral HPLC. The free base was dissolved in HCl/EA (1.3 M, 50 mL).
The mixture was stirred at rt for 2 h, concentrated to give Example
262 HCl (5.5 g, 69%) as a white solid. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 7.60-7.52 (m, 4H), 4.70-4.67 (m, 1H), 3.95-3.92
(m, 2H), 3.79-3.73 (m, 1H), 3.61-3.59 (m, 1H), 2.81-2.73 (m, 2H),
2.38-2.22 (m, 2H), 1.98 (s, 6H), 1.64-1.61 (m, 2H), 1.46-1.43 (m,
12H), 1.31-1.28 (m, 6H);
MS: [M+H]+=438.5
General Procedure for the Preparation of Compound 2-15
##STR00156##
To a solution of compound S2-16 (5.0 g, 26.6 mmol, 1.0 eq) in DCM
(50 mL) was added the compound TsCl (20.2 g, 106.2 mmol, 4.0 eq)
and pyridine (8.4 g, 106.2 mmol, 4.0 eq). After stirring at rt
overnight, the reaction was quenched by H.sub.2O (100 mL) and
extracted with ethyl acetate (40 mL.times.3). The organic layer was
dried over Na.sub.2SO.sub.4 and concentrated to give crude product,
which was purified by column chromatography on a silica gel (PE/EA,
10:1.about.3:1) to give compound S2-15 (5.4 g 40.9%).
Example Syn 3: Preparation of Example Compound 14
##STR00157##
Example 14
##STR00158##
To a mixture of compound S3-9 (60.0 g, 0.26 mol, 1.0 eq) and
compound S3-10 (30.0 g, 0.26 mol, 1.0 eq) in MeOH (600 mL) was
added NaBH.sub.4 (39.6 g, 1.04 mol, 4.0 eq). The mixture was
stirred at rt for 3 h under nitrogen atmosphere. Then brine was
added and the solution was extracted with ethyl acetate. The
organic phase was combined, dried over Na.sub.2SO.sub.4,
concentrated in vacuum. The residue was purified by column
chromatography to give compound Example 14 (45.1 g, 52%).
TLC: DCM:MeOH=10:1
R.sub.f (Example 14)=0.2
General Procedure for the Preparation of Example Compound 14
HCl
##STR00159##
A mixture of Example 14 (65 g, 0.2 mol) in HCl/EA (2.5 M, 160 mL).
was stirred at rt for 2 h. The cloudy mixture was concentrated to
give Example 14 HCl (68 g, 94%) as white solid. .sup.1H NMR (400
MHz, CD.sub.3OD): .delta. ppm 7.67-7.61 (m, 4H), 3.31-3.3 (m, 3H),
3.15-3.11 (m, 2H), 2.85-2.79 (m, 2H), 2.17-2.12 (m, 2H), 1.82-1.76
(m, 2H), 1.43 (s, 6H), 1.27 (s, 3H).
MS: [M+H]+=330.20
Example Syn 4: Preparation of Example Compound 17
##STR00160##
Example 17
##STR00161##
A mixture of compound S4-11 (300 mg, 1.3 mmol, 1.0 eq), compound
S4-12 (150 mg, 1.3 mmol, 1.0 eq) and NaBH.sub.4 (197 mg, 5.2 mmol,
4.0 eq) in MeOH (10 mL) was stirred at rt for 3 h under nitrogen
atmosphere. Then aq. NaCl was added and extracted with ethyl
acetate, filtered. The organic phase was dried over
Na.sub.2SO.sub.4, concentrated in vacuum. The residue was purified
by pre-TLC to give compound Example 17, which was dissolved in
HCl/EA (1.3 M, 10 mL). The mixture was stirred at rt for 2 h,
concentrated to give Example 17 HCl (144.1 mg, 31.4%) as white
solid. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.75-7.60 (m, 4H),
4.07-4.03 (m, 1H), 3.63-3.57 (m, 1H), 3.34-3.30 (m, 6H), 3.16-3.09
(m, 2H), 2.87-2.83 (m, 2H), 2.19-2.14 (m, 2H), 1.43 (s, 6H);
MS: [M+H]+=316.4
Example Syn 5: Preparation of Example Compound 307
##STR00162##
Example 307
##STR00163##
To a solution of compound S5-9 (3.54 g, 15.38 mmol, 1.0 eq) in MeOH
(60 mL) was added compound S5-10 (3.0 g, 16.9 mmol, 1.1 eq) and 2
drops of AcOH. The reaction mixture was stirred at rt for 2 h.
NaBH.sub.4 (2.33 g, 61.55 mmol, 4.0 eq) was added and then the
reaction mixture was stirred at rt for 2 h. The reaction was
quenched with H.sub.2O (20 mL), filtered, extracted with EA (20
mL.times.3) and concentrated to get a residue, which was purified
by column chromatography (PE:EA=1:1) to give compound Example 307
(1.3 g, 21.6%).
TLC: DCM:EA:MeOH=1:1:0.1
R.sub.f (compound S5-9)=0.9
R.sub.f (compound Example 307)=0.3
General Procedure for the Preparation of Example 307 HCl
##STR00164##
To a solution of compound Example 307 (1.9 g, 4.85 mmol, 1.0 eq) in
EA (5 mL) was added EA/HCl (2.5 M, 6 mL, 3.0 eq). The reaction
mixture was stirred at rt for 30 min. The reaction mixture was
concentrated to give Example 307 HCl (2.1 g, 100%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 7.62-7.60 (m, 2H), 7.50-7.47 (m, 4H),
7.46-7.31 (m, 2H), 7.28 (m, 2H), 3.32 (m, 2H), 3.13 (m, 2H), 2.64
(m, 2H), 2.32 (m, 2H), 1.67 (m, 3H), 1.39 (m, 6H);
MS: [M+H]+=392.6
Example Syn 6: Preparation of Example Compound 191
##STR00165##
Example 191
##STR00166##
To a solution of compound S6-9 (5.4 g, 23.68 mmol, 1.0 eq) in MeOH
(100 mL) was added compound S6-12 (3.0 g, 26 mmol, 1.1 eq) and 2
drops of AcOH. The reaction mixture was stirred at rt for 2 h.
NaBH.sub.4 (3.58 g, 94.71 mmol, 4.0 eq) was added and then the
reaction mixture was stirred at rt for 2 h. The reaction was
quenched with H.sub.2O (30 mL), filtered, extracted with EA (30
mL.times.3) and concentrated to get a residue, which was purified
by column chromatography (PE:EA=1:1) to give Example 191 (3.4 g,
44%).
TLC: DCM:EA:MeOH=1:1:0.1
R.sub.f (compound S6-9)=0.9
R.sub.f(Example 191)=0.3
General Procedure for the Preparation of Example 191 HCl
##STR00167##
To a solution of Example 191 (3.4 g, 10.33 mmol, 1.0 eq) in EA (10
mL) was added EA/HCl (2.5 M, 8.9 mL, 2.0 eq). The reaction mixture
was stirred at rt for 30 min. The reaction mixture was concentrated
to give Example 191 HCl (3.5 g, 93%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.60-7.58 (m, 2H), 7.49-7.47 (m, 2H), 3.56 (s,
1H), 3.25 (s, 3H), 3.19 (m, 2H), 2.80 (m, 2H), 2.59 (m, 2H), 2.39
(m, 2H), 2.30 (m, 2H), 1.93 (m, 2H), 1.37 (s, 6H);
MS: [M+H]+=330.2
Example Syn 7: Preparation of Example Compound 317
##STR00168##
Example 317
##STR00169##
To a solution of compound S7-9 (5.46 g, 23.7 mmol, 1.0 eq) in MeOH
(100 mL) was added compound S7-14 (3.0 g, 26 mmol, 1.1 eq) and 2
drops of AcOH. The reaction mixture was stirred at rt for 2 h.
NaBH.sub.4 (3.58 g, 94.63 mmol, 4.0 eq) was added and then the
reaction mixture was stirred at rt for 2 h. The reaction was
quenched with H.sub.2O (30 mL), filtered, extracted with EA (30
mL.times.3) and concentrated to get a residue, which was purified
by column chromatography (PE:EA=1:1) to give Example 317 (2.1 g,
27%).
TLC: DCM:EA:MeOH=1:1:0.1
R.sub.f (compound S7-9)=0.9
R.sub.f (Example 317)=0.3
General Procedure for the Preparation of Example 317 HCl
##STR00170##
To a solution of Example 317 (2.1 g, 6.37 mmol, 1.0 eq) in EA (10
mL) was added EA/HCl (2.5 M, 6 mL, 2.0 eq). The reaction mixture
was stirred at rt for 30 min. The reaction mixture was concentrated
to give Example 317 HCl (2.1 g, 91%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 12.17 (m, 1H), 7.61-7.59 (m, 2H), 7.50-7.48 (m,
2H), 4.16-4.13 (m, 1H), 3.90-3.86 (m, 1H), 3.55-3.53 (m, 1H), 3.33
(m, 1H), 3.23 (s, 3H), 2.63-2.59 (m, 2H), 2.51 (m, 1H), 2.23 (m,
1H), 2.19-1.90 (m, 4H), 1.39-1.37 (m, 6H);
MS: [M+H]+=330.6
Example Syn 8: Preparation of Example Compound 306
##STR00171##
Example 306
##STR00172##
To a solution of compound S8-9 (3.08 g, 13.3 mmol, 1.0 eq) in MeOH
(80 mL) was added compound S8-16 (2.0 g, 17.36 mmol, 1.1 eq) and 2
drops of AcOH. The reaction mixture was stirred at rt for 2 h.
NaBH.sub.4 (2.02 g, 53.4 mmol, 4.0 eq) was added and then the
reaction mixture was stirred at rt for 2 h. The reaction was
quenched with H.sub.2O (30 mL), filtered, extracted with EA (30
mL.times.3) and concentrated to get a residue, which was purified
by column chromatography (PE:EA=1:1) to give Example 306 (1.2 g,
27%).
TLC: DCM:EA:MeOH=1:1:0.1
R.sub.f (compound S8-9)=0.9
R.sub.f (Example 306)=0.3
General Procedure for the Preparation of Example 306 HCl
##STR00173##
To a solution of Example 306 (2.0 g, 26.07 mmol, 1.0 eq) in EA (5
mL) was added EA/HCl (2.5 M, 5 mL, 2.0 eq). The reaction mixture
was stirred at rt for 30 min. The reaction mixture was concentrated
to give Example 306 HCl (2.28 g, 100%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 12.75 (m, 1H), 7.60-7.58 (m, 2H), 7.49-7.47 (m,
2H), 3.53-3.51 (m, 2H), 2.63-2.60 (m, 2H), 2.53-2.50 (m, 2H),
2.34-2.30 (m, 2H), 2.05 (m, 4H), 2.00 (m, 1H), 1.97-1.88 (m, 2H),
1.38 (s, 6H);
MS: [M+H]+=330.3
* * * * *
References